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ABSTRACT 
 
 
Current prostate cancer treatment remains ineffective primarily due to ineffectual 
therapeutic strategies and numerous tumor-associated physiological barriers which hinder 
efficacy of anticancer agents. Therefore, the focus of this study was to investigate a new 
combination therapy approach for treating prostate cancer and develop polymeric 
nanocarriers to facilitate anticancer drug and nucleic acid delivery. 
 
It was hypothesized that simultaneously targeting androgen-androgen receptor 
(AR) and X-linked inhibitor of apoptosis protein (XIAP) signaling pathways would be 
effective in treating prostate cancer. The effect of bicalutamide (antiandrogen) and 
embelin (XIAP inhibitor) on the growth of prostate cancer cells in vitro and in vivo was 
first examined. Embelin induced caspase 3 and 9 activation in LNCaP and C4-2 cells by 
decreasing XIAP expression and was more potent than bicalutamide in killing prostate 
tumor cells irrespective of their androgen status. Using a combination of MTT assay and 
isobologram analyses, combination of bicalutamide and embelin was observed to be cell 
line and schedule dependent. Since bicalutamide and embelin are extremely hydrophobic, 
polymeric micelles were fabricated using polyethylene glycol-b-polylactic acid  
(PEG-b-PLA) copolymer to improve drug solubility. Micellar formulations were found to 
result in at least 60-fold increase in the aqueous solubility of bicalutamide and embelin. 
Tumor growth was also effectively regressed upon treatment with bicalutamide, but the 
extent of tumor regression was significantly higher when bicalutamide was formulated in 
micelles.  
 
To further improve bicalutamide aqueous solubility, a series of novel 
biodegradable copolymers for the systematic micellar delivery of bicalutamide was 
designed and synthesized. Flory-Huggins interaction parameter (χFH) was used to assess 
compatibility between bicalutamide and poly (L-lactide) or poly (carbonate-co-lactide) 
polymer pairs. Polyethylene glycol-b-poly (carbonate-co-lactide) [PEG-b-P(CB-co-LA)] 
copolymers were synthesized and characterized by NMR and gel permeation 
chromatography.  Micelles formulated using these copolymers had average diameter of 
100 nm and distinct spherical shape. Drug loading studies revealed that adding the 
carbonate monomer could increase bicalutamide loading. Among the series, drug loading 
of micelles formulated with PEG-b-P(CB-co-LA) copolymer containing 20 mol% 
carbonate was about four-fold higher than PEG-b-PLLA and aqueous solubility of 
bicalutamide increased from 5 to 4000 µg/mL. CMC values for PEG-b-P(CB-co-LA) 
copolymers was up to 10-fold lower than those of PEG-b-PLLA. Bicalutamide-loaded 
PEG-b-P(CB-co-LA) micelles showed significant inhibition of LNCaP cell growth in  a 
dose dependent manner which was similar to the  methanol solution of free drug. 
 
 Bicalutamide tends to act as an agonist rather than an antagonist after prolonged 
treatment. Hence, a second generation antiandrogen ((S)-N-(4-cyano-3-(trifluoromethyl) 
phenyl)-3-((4-cyanophenyl)(methyl)amino)-2-hydroxy-2-methylpropanamide) 
(CBDIV17)) was synthesized and its effect in combination with XIAP inhibitors for 
treating advanced prostate cancer was determined. CBDIV17 was more potent than 
 vi 
bicalutamide and inhibited proliferation of C4-2 and LNCaP cells. CBDIV17-induced 
apoptosis more effectively compared to bicalutamide and significantly inhibited DNA 
replication. Combination of CBDIV17 and embelin resulted in supra-additive 
antiproliferative and apoptotic effects. Embelin downregulated AR expression and 
decreased androgen-mediated AR phosphorylation at Ser81. These hydrophobic drugs 
were solubilized using micelles prepared using polyethylene glycol-b-poly (carbonate-co-
lactide) (PEG-b-p(CB-co-PLA)) copolymer. Combination therapy inhibited prostate 
tumor growth more effectively compared to control or monotherapy in vivo.  
 
Polymeric micelles tend to be unstable in vivo. To address this, lactic acid- and 
carbonate-based biodegradable core- and core-corona crosslinkable copolymers for 
anticancer drug delivery were synthesized and evaluated. Methoxy poly (ethylene 
glycol)-b-poly (carbonate-co-lactide-co-5-methyl-5-allyloxycarbonyl-1,3-dioxane-2-one) 
[mPEG-b-P(CB-co-LA-co-MAC)] and methoxy poly (ethylene glycol)-b-poly(acryloyl 
carbonate)-b-poly (carbonate-co-lactide) [mPEG-b-PMAC-b-P(CB-co-LA)] copolymers 
were synthesized by ring opening polymerization of LA, CB and MAC using mPEG as 
an macroinitiator and 1,8-diazabicycloundec-7-ene (DBU) as a catalyst. These 
amphiphilic copolymers which exhibited low polydispersity (1.08) and CMC values  
(0.8-1 mg/L) were used to prepare micelles with or without drug and stabilized by 
crosslinking via radical polymerization of double bonds introduced in the core and 
interface to improve stability. 1H NMR and IR spectroscopy confirmed successful 
crosslinking (crosslinking efficiency of ~70%) while light scattering and transmission 
electron microscopy were used to determine micelle size and morphology. Crosslinked 
micelles demonstrated enhanced stability against extensive dilution with aqueous 
solvents and in the presence of physiological simulating serum concentration.  
 
Since nucleic acids are not susceptible to chemoresistance, it was determined 
whether simultaneous AR and XIAP gene silencing via RNA interference (RNAi) has the 
potential to treat hormone refractory prostate cancer. Small interfering RNAs (siRNAs) 
targeting three different regions of AR and XIAP were screened by transfecting LNCaP 
and C4-2 prostate cancer cells and their silencing effects determined at mRNA and 
protein levels by real time RT-PCR, Western blot and ELISA. The most potent siRNAs 
against AR and XIAP were selected and their combination was more effective in 
inducing apoptosis and inhibiting C4-2 cell proliferation. N-(2-hydroxypropyl) 
methacylamide (HPMA) based copolymer containing polycationic, lipid and pka 
modulator moieties was developed for delivering the most potent siRNA and bipartite 
plasmid encoding two different shRNAs targeting AR and XIAP. HPMA based 
copolymer showed efficient cellular uptake in prostate cancer cells. 
 
 The findings reported in this work demonstrate the potential benefit of 
combination therapy targeting AR and XIAP pathways for treating prostate cancer using 
polymeric nanocarriers. Systematic chemical tailoring of polymers for improving drug 
loading as well as efforts made to improve micelle stability through crosslinking also 
generated insights which can be applied to other drugs and cancer types. Results reported 
in this study therefore offer a new way of addressing the time old problem of treating 
cancer. 
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CHAPTER 1.    INTRODUCTION 
 
 
Prostate cancer is the most prevalent malignancy affecting men in the United 
States and the second most lethal cancer. Approximately, 241,740 new cases are expected 
to be diagnosed and 28,170 men are projected to die from the disease in the United States 
in 2012 [1]. Since most prostate cancer patients present with the disease already beyond 
the confines of the prostate, radical prostatectomy which is potentially curative is not 
possible. Instead, nonsurgical approaches such as androgen ablation remain the preferred 
therapy for patients with advanced prostate cancer. Although, androgen deprivation 
therapy is initially highly effective, approximately 70-80% of patients eventually relapse. 
The fatal nature of prostate cancer is partly due to chemoresistance and the inability to 
selectively deliver potent anticancer agents to cancer cells. 
 
Therefore, the focus of this research was to develop and investigate a novel 
holistic approach for treating chemoresistant prostate cancer tumors with the goal that 
insights obtained can be translated to treating other chemoresistant tumors. Consequently, 
three highly focused aims hinging on fundamental cancer biology, creation of 
biomaterials and application of nanobiotechnology for improving cancer therapy were 
stipulated and addressed. The aims specifically examined and their attendant objectives 
are as follows:  
 
 
Aim 1: To Establish a Novel Therapeutic Approach Simultaneously Targeting the 
Androgen Receptor (AR) and X-linked Inhibitor of Apoptosis Protein (XIAP) 
Pathways for Treating Prostate Cancer 
 
Objectives for Aim 1 are given below. 
 
(i) Examine growth inhibitory effect and apoptotic cell death following 
treatment with bicalutamide (AR antagonist) and embelin (XIAP 
inhibitor). 
(ii) Determine whether XIAP inhibitor (embelin and embelin-6g) exhibit 
synergy with second generation antiandrogen in inhibiting tumor growth 
in vitro and in vivo. 
(iii) Elucidate molecular mechanism of XIAP inhibitor on prostate cancer 
(iv) Utilize siRNA targeting AR and XIAP genes alone and in combinations 
for treating prostate cancer.  
(v) Construct a bipartite plasmid expressing shRNAs simultaneously targeting 
AR and XIAP genes for combination therapy for treating prostate cancer. 
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Aim 2: To Develop a Series of Biodegradable and Biocompatible Copolymers for 
Enhanced Drug and Nucleic Acid Delivery 
 
Objectives for Aim 2 are given below. 
 
(i) Design and develop tailor made biodegradable copolymers for 
antiandrogen delivery. 
(ii) Synthesize, characterize and evaluate lactic acid and carbonate-based 
copolymers and characterize drug loading, release profiles, and micellar 
stability. 
(iii) Synthesize, characterize and evaluate lactic acid and carbonate-based 
copolymers for core or core/corona interface crosslinked micelles for 
enhanced stability of micelles. 
(iv) Synthesize, characterize and asssess N-(2-hydroxypropyl) methacrylamide 
(HPMA) based copolymer composed of polycationic, lipid and pka 
modulator moieties for efficient delivery of nucleic acids. 
 
 
Aim 3: To Explore the Utility of Polymeric Micelles as Drug Delivery Vehicles for 
Treating Prostate Cancer 
 
Objectives for Aim 3 are given below. 
 
(i) Assess effect of polymeric micelles on drug solubilization and efficacy. 
(ii) Determine whether XIAP inhibitor and antiandrogen formulated 
polymeric micelle exhibits synergy in inhibiting prostate tumor growth in 
vitro and in vivo. 
 
The remainder of the dissertation is organized in the following manner. Review of 
the pertinent literature regarding tumor microenvironment, intrinsic barriers to therapy 
and the role of polymeric nanomedicines in overcoming these barriers are presented in 
Chapter 2. Results showing the potential of bicalutamide and embelin combination 
therapy for treating prostate cancer in vitro and in vivo are presented in Chapter 3. 
Chapter 4 covers the design, synthesis, characterization and in vitro evaluation of 
polyethylene glycol-b-poly (carbonate-co-lactide) [PEG-b-P(CB-co-LA)] copolymers for 
improved bicalutamide loading and micelle thermodynamic stability. Findings 
demonstrating superior anticancer activity of a newly synthesized antiandrogen ((S)-N-
(4-cyano-3-(trifluoromethyl) phenyl)-3-((4-cyanophenyl)(methyl)amino)-2-hydroxy-2-
methylpropanamide) (CBDIV17)) and supra additive effects observed in combination 
with XIAP inhibitor for treating prostate cancer is reported in Chapter 5. A possible 
additional mechanism of embelin as a modulator of the AR is also presented in Chapter 5. 
Chapter 6 describes the design, synthesis, characterization and in vitro assessment of 
lactic acid and carbonate-based copolymers for core and core-corona interface 
crosslinked micelles demonstrating improved micelle stability. The results of 
simultaneous silencing of AR and XIAP genes using RNA interference and their effect 
on prostate cancer cell growth and apoptosis is given in Chapter 7. Synthesis and 
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evaluation of N-(2-hydroxypropyl) methacrylamide (HPMA) based copolymer 
possessing polycationic, lipid and pka modulator moieties for nucleic acid delivery is also 
addressed in Chapter 7. Finally, the conclusions of this work are presented in Chapter 8. 
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CHAPTER 2.    EXTRAVASATION OF POLYMERIC NANOMEDICINES 
ACROSS TUMOR VASCULATURE* 
 
 
Introduction 
 
Tumors possess poorly differentiated, highly chaotic arrangement of vessels 
which have unsealed endothelial cell-cell junctions and discontinuous basement 
membrane. The “leaky” nature of tumor vessels is accompanied with functionally 
impaired tumor vasculature resulting in high permeability of macromolecules in tumors 
compared to normal tissue. Tumors also have functionally defective lymphatic vessels. 
The decreased lymphatic drainage associated with tumors results in retention of permeant 
macromolecules in tumors since the fluid that leaves the bloodstream inside the tumor 
can only escape from the tumor either by feeding back into postcapillary venules or by 
passage through the tumor interstitium. 
 
Delivery of anticancer agents to solid tumors remains a significant challenge. 
First, anticancer drugs have low tumor to normal cell selectivity making them potentially 
toxic to both normal and tumor cells. Moreover, normal tissues possess low intrinsic 
tolerance compared to tumors severely limiting the dose required for tumor regression [2, 
3]. Second, most anticancer agents are highly lipophilic, requiring the use of solubilizing 
agents or surfactants so that they can be used via systemic administration. Paclitaxel, for 
example, is a potent anticancer drug with aqueous solubility of only ~ 1µg/mL [4]. 
Docetaxel, its more water soluble derivative also has a low aqueous solubility of ~ 6-
7µg/mL [5]. Hence, solubilizing agents such as dimethyl sulfoxide (DMSO), 
Cremophor® EL or Tween 80 are typically used to bring these drugs into true solution for 
systemic administration. However, such agents are harmful to the liver and kidneys [6], 
cause dose-dependent hemolysis and lead to neurotoxicity [7] thus hindering their 
medical utility for intravenous applications. 
 
Biodegradable polymeric or lipid carriers are attractive candidates for anticancer 
drug delivery since they lead to high therapeutic concentrations of anticancer agents to 
tumors, with minimal systemic exposure. Examples include nanoparticles, liposomes [8], 
micelles [9-11], and polymer-drug conjugates [12]. These nanosized delivery platforms 
are capable of improving drug solubility and take advantage of the unique 
pathophysiology of tumor vasculature to ferry hydrophobic drugs with minimal adverse 
effects upon systemic administration. Typically this occurs by the enhanced permeability 
and retention (EPR) effect where macromolecular systems preferentially accumulate in 
tumors when administered systemically [13-15]. 
 
Successful treatment of cancer utilizing polymeric nanomedicines requires that 
once blood borne, they reach the site of action in optimal quantities. To achieve this, they 
 
 
*Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across 
tumor vasculature. Adv Drug Deliv Rev. 2011;63:623-39.  
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must arrive at the tumor through blood vessels, be transported across vascular walls 
(extravasation) and then move through the interstitium. Jain and others have shown 
tremendous heterogeneity in vessel permeability within tumors and between tumor types. 
Aberrant extravasation has been implicated in the heterogeneous distribution of drugs 
inside the tumors accounting for their moderate therapeutic effect in complete tumor 
eradication. Hence, overcoming this obstacle of nonuniform extravasation is crucial to 
improving the drug delivery potential of polymeric nanomedicines. This challenge 
demands an understanding of the mechanisms governing vascular permeability and the 
spatial and temporal regulation of transport pathways in tumors [16]. Insight from such 
understanding can be utilized in developing the next generation of drug delivery 
polymeric nanomedicines possessing tunable properties that facilitate their extravasation 
across tumor vasculature and discovering superior approaches for modulating tumor 
vasculature.  
 
In this review, we summarize current knowledge on the distinct tumor 
microenvironment and blood vessel structure, talk about barriers to drug delivery to 
tumors, mechanisms of barrier formation and finally appraise modalities for overcoming 
these barriers. 
 
 
Microenvironment of Solid Tumors 
 
To develop potent therapeutic approaches for site-specific delivery of drugs to 
tumors using polymeric nanomedicines, it is imperative to understand the 
microenvironment of the tumor. Solid tumors are organ-like entities arising from stem 
cell populations and consist of cancer cells, non-transformed stromal cells, blood vessels 
and the interstitium [17]. Cancer and stromal cells comprise the major portion of solid 
tumors accounting for greater than 50% of tumor volume. Blood vessels nourish both 
stromal and cancer cells in tumors and constitutes up to 10% of tumor volume, while the 
interstitium forms the remainder of the tumor and provides the nutritional and structural 
framework for it to grow.  
 
While the normal cellular microenvironment can inhibit malignant cell growth, 
the tumor microenvironment supports cell proliferation. Tumors shape their 
microenvironment and support the tumor and non-malignant cells. Tumor 
microenvironment greatly influences its development and generates barriers (Figure 2-1) 
that prevent therapeutic agents from accessing and killing cancerous cells in the tumor, 
thereby limiting the efficacy of current chemotherapy [18]. Below, we discuss interstitial 
hypertension, low extracellular pH, hypoxia, angiogenesis, tumor-stromal cell interaction, 
cancer stem cells, and abnormal lymphatics. These key microenvironmental features of 
solid tumors greatly impact the extravasation of polymeric nanomedicines. 
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Figure 2-1. Schematic portraying complex microenvironment of tumors. 
 
Cancer cells are surrounded by cancer stem cells and embedded within the stroma 
composed of lymphocytes,monocytes, fibroblasts, macrophages and extracellular matrix. 
Tumor–stroma interaction is bidirectional and may lead to tumor rejection or facilitate 
tumor growth. Key tumor microenvironmental features: hypoxia, interstitial fluid 
pressure (IFP) and acidity increase with distance from blood vessels resulting in 
increasing drug resistance from the tumor periphery to the avascular core. 
 
  
Cancer cell FibroblastMonocyte
Extracellular matrix
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MacrophageStem cell
avascular core
Blood Vessel
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Interstitial hypertension 
 
The interstitium is a collagen rich matrix and serves as a biological scaffold for 
tissues. It occupies the space between cells and tissues and is bordered by cell membranes 
and blood vessel walls. Within this matrix is a hydrophilic gel composed of interstitial 
fluid and macromolecular constituents such as proteoglycans and hyaluronate. Tumor 
interstitium differs greatly from that of normal tissues. Important distinctions include an  
interstitial space three to five times larger than that of normal tissues, high interstitial 
hydraulic conductivity and diffusivity, comparatively larger amounts of mobile fluid and 
faster spread of hydrophilic agents resulting from significant extravascular convection 
[19]. 
 
Leaky tumor vasculature and dysfunctional lymphatics in tumor interstitium result 
in undesirable accumulation of vascular contents in the tumor leading to interstitial 
hypertension [20, 21]. Physico-chemical properties of the interstitium influence the 
movement of molecules between blood vessels and the cells. The interstitial pressure in 
normal tissues is approximately 0 mm Hg while normal capillary pressure is around 1 -3 
mm Hg. This pressure gradient facilitates convective transport of macromolecules from 
the vascular compartment to the interstitium. To the contrary, tumors display pressure 
gradients opposite to that of normal tissues. The presence of osmotic forces drawing 
solutes into tissue combined with functionally deficient tumor blood vessels and 
lymphatics as well as the ability of tumor stroma to contract all contribute to the higher 
interstitial fluid pressure within the tumor compared to blood vessels [21, 22]. Several 
studies have shown IFP of up to 100 mm Hg in the tumor core while the periphery 
exhibits atmospheric like or slightly negative pressures [23-26]. Consequently, interstitial 
hypertension results in reduced convection across the walls of tumor blood vessels. 
Additionally, higher IFP in tumors favor the movement of interstitial fluid into 
surrounding tissues, flushing out therapeutic agents from the tumor. The combination of 
these two factors potentially hampers the potency of systemic therapies to tumors, 
especially delivery of macromolecules, since they depend on convective transvascular 
transport to cross the endothelial barrier and migrate through the interstitium [27]. 
 
 
Low extracellular pH 
 
For several decades tumors were generally believed to be acidic since cells 
actively convert glucose to lactic acid [28-31]. Using techniques that specifically measure 
intra- or extracellular pH in malignant tumors, it has now been shown that intracellular 
pH in tumor cells is neutral to alkaline while the extracellular pH is acidic [32-34]. This 
resulting pH gradient established across tumor cell membranes is preserved by a number 
of ion pumps which export protons into the extracellular compartment [35]. Aside 
aerobic and anaerobic glycolysis, other mechanisms have also been implicated in the 
tumor acidosis. Some of these pathogenetic mechanisms include ATP hydrolysis, 
glutaminolysis, ketogenesis and CO2/ carbonic acid production [36-38]. The pH gradient 
peculiar to tumors facilitates the accumulation of weakly acidic drugs (e.g., mitomycin C) 
within tumors and may be utilized as a strategy for treating cancer [39, 40]. 
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One such approach involves polymeric micelle delivery systems designed to 
release drugs when they encounter the acidic environment in tumors. These systems are 
stable at neutral pH but destabilize under mild acidic conditions (pH 4.5-6.0) and 
facilitate release of anticancer drugs. pH sensitive drug carriers are typically designed by 
introducing acid labile chemical bonds between drug and carriers (Figure 2-2) [41, 42]. 
For instance, Bae and coworkers have utilized pH-sensitive polymers such as poly (l-
histidine) as components in amphiphilic copolymers for micellar delivery [43-45]. Poly(l-
histidine) (pKb ~ 7.0) has an imidazole ring with lone electron pairs associated with the 
unsaturated nitrogen that confer it with pH-dependent amphoteric properties . In one 
study, Bae et al., developed a pH-sensitive mixed micelles system using poly(l-histidine) 
(polyHis) (Mw 5000)-b-poly(ethylene glycol) (PEG) (Mw 2000) and poly(l-lactic acid) 
(PLLA) (Mw 3000)-b-PEG (Mw 2000)-folate (0–25 wt.%). At pH lower than 7.0, the 
poly(l-histidine) block ionized leading to a gradual disintegration of the system . When 
doxorubicin was incorporated, their studies showed 32 wt.% of doxorubicin (DOX) was 
released at pH 7.0, 70 wt.% of DOX at pH 6.8, and 82 wt.% at pH 5.0 in 24 hours [43]. 
Furthermore, it has been demonstrated that pH-triggered micelle dissociation may 
enhance extravasation of subsequent micelles by creating space for the newly arriving 
micelles [46]. 
 
 
Hypoxia 
 
From a pathophysiological standpoint, hypoxia refers to the condition in which 
tissues are deprived of oxygen or the partial pressures of oxygen falls below critical 
levels leading to hindered clinical and biological functioning of cells or organs [47]. For 
normal tissues, consumption of O2 for metabolic requirements is equaled by supply. In 
contrast, O2 demand far exceeds supply in tumors as they grow. High cell density caused 
by excessive rates of cell proliferation in tumors places a huge demand on local supply of 
oxygen. Furthermore, abnormal tumor vasculature (characteristic of tumors) reduces 
blood flow and limits delivery of oxygen to throughout the tumor resulting in regions of 
hypoxia. A major consequence of tumor hypoxia is resistance to chemotherapy [48]. 
 
Several factors contribute to hypoxia in tumors (Figure 2-3) and the different 
types of hypoxia are characterized accordingly. These include: inadequate perfusion 
(ischemic or acute hypoxia), increased diffusion distances (chronic hypoxia), anemia 
(anemic hypoxia) and hypoxemia (hypoxemic hypoxia). Generally, 50 – 60% of solid 
tumors display heterogeneous distribution of hypoxic regions within the tumor. However, 
despite the type of hypoxia, controlling oxygen consumption within tumor cells is equally 
important as reduced oxygen delivery in determining tumor hypoxia. Hypoxia inducible 
factor-1 (HIF-1) plays a key role in tumor progression under hypoxia. 
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Figure 2-2. Schematic depicting pH triggered cleavage and drug release of poly (ethylene glycol)-poly(aspartate-hydrazone-
drug) delivery system in acidic endosomal compartment. 
 
Modified with permission from Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with 
folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst. 
2005;1:242-50. 
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Figure 2-3. Crucial factors contributing to hypoxia in tumors. 
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Angiogenesis 
 
Tumor growth and metastasis requires the formation of new blood vessels from 
pre-existing vessels. This process is known as angiogenesis. Tumor microenvironment is 
replete with pro-angiogenic factors originating from neoplastic, stromal and infiltrating 
cells which affect angiogenesis. Tumor angiogenesis is characterized by an abundance of 
functionally defective and structurally abnormal blood vessels and occurs due to a 
disparity between the pro-angiogenic and anti-angiogenic factors. A consequence of these 
defective vessels is an inflamed tumor environment which encourages thrombosis and 
impaired blood supply resulting in hindered drug delivery to the tumor. Vascular 
endothelial growth factor (VEGF)/vascular permeability factor (VPF) is one of the most 
important angiogenic factors responsible for inducing proliferation and migration of 
endothelial cells and increasing vascular permeability [49]. Recently, VEGF was found to 
negatively regulate the maturation of blood vessel and the function of pericytes [50]. 
Other pro-angiogenic factors such as transforming growth factor-β (TGF-β), interleukin 
(IL)-8 and basic fibroblast growth factor (bFGF) are produced as tumors begin to grow 
[51]. The key role blood vessels play in tumor growth and metastasis makes tumor 
angiogenesis a rational and well studied target for cancer therapy. 
 
 
Tumor-stromal cell interaction 
 
Tumor microenvironment consists of tumor cells embedded within the stroma. 
The tumor stroma is composed of a variety of normal cell types actively recruited by the 
tumor to provide the blood supply through the production and secretion of cytokines and 
stimulatory growth factors. A large number of T cells and macrophages are part of the 
tumor stroma. Tumor rejection partly depends on T cell activation. Tumor-infiltrating 
macrophages secrete angiogenic factors useful for tumor growth and inhibition of 
macrophage infiltration resulting in tumor regression. A thorough understanding of 
interactions between different stroma cell components that either support tumor growth 
or tumor rejection is important since this interaction is crucial to cancer development at 
the primary site and metastasis. 
 
 
Cancer stem cells 
 
Like normal adult tissues, solid tumors contain a population of cells that self-
renew and resupply the tumor with the various cell lineages of which it is composed of. 
These cells known as cancer stem cells (CSCs) are associated with tumor stromal 
components such as fibroblasts and blood vessels. They compose the cancer stem cell 
niche from which factors that support CSC renewal are released. CSCs form 
approximately 1% of the tumor. However, since they are the only cells that can maintain 
tumor growth indefinitely due to their self-renewal properties, they are the actual driving 
force behind tumor growth. The rest of the cells in the tumor microenvironment 
vigorously proliferate, differentiate and eventually die. 
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It is known that CSCs exhibit similar properties to normal stem cells. Among 
these, CSCs are hypothesized to be relatively quiescent and have protracted life span, are 
refractory to apoptosis and resistant to toxins and drugs since they express at least one 
ATP-binding cassette (ABC) efflux transporter [52-55]. Since these drug efflux pumps 
occur naturally in CSCs, this hypothesis offers an additional mechanism by which tumors 
acquire multidrug resistance. A number of studies confirm this hypothesis. Recently, Hu 
et al. have shown a side population of ovarian cancer cells to possess ABC transporters 
and be drug resistant [56]. These cancer stem-like cell side populations were found to be 
responsible for tumorigenesis and grew more rapidly in xenogeneic transplant mice 
compared to ovarian cancer cells without these side population cells. Furthermore, drug 
efflux transporters have also been shown to be present in leukemic stem cells making 
them resistant to chemotherapeutic agents such as daunorubicin [57, 58]. The purported 
role of CSCs in tumorigenesis and metastasis suggests targeting CSCs to be a potential 
therapeutic strategy for chemoprevention and cancer therapy. 
  
  
Abnormal lymphatics 
 
The lymphatic network transports interstitial fluid and immune cells out of normal 
tissue and is essential for immune function and maintenance of fluid balance in tissue 
interstitium. In contrast to normal tissues, the lymph vessels in tumors are compressed by 
solid stresses induced by tumor cells within the microenvironment [59]. Therefore, the 
functional performance of lymphatic vessels within the tumor microenvironment depends 
on their location. Lymphatic vessels situated at the periphery of the tumor or the stroma-
tumor interface possess functionality while those within the tumor are functionally 
defective [60, 61]. Lymphangiogenesis is facilitated by similar factors responsible for 
angiogenesis such as VEGF, angiopoietins and platelet-derived growth factor (PDGF). 
For instance, lymphangiogenesis and angiogenesis can be triggered by VEGF-C and -D 
and have been implicated in increased lymphatic metastases in numerous tumors [62, 63]. 
Abnormal lymphatics encourage retrograde flow in lymphatic vessels, allow tumor cells 
to invade the periphery of lymphatic vessels and promote metastases within the lymphatic 
system [64, 65].  
 
 
Anatomical Pathways of Macromolecular Extravasation 
 
The efficacy of blood borne therapeutic agents in cancer therapy depends on their 
extravasation across tumor blood vessels. Significant differences exist between the 
mechanism of extravasation of small molecules and macromolecules. However, the 
extent of extravasation in both cases is influenced by the macroscopic arrangement and 
wall structure of tumor microvessels. Also, the endothelial cell lining of microvessels 
function as a rate-limiting barrier for extravasation of plasma components. In normal 
tissues, transvascular transport of plasma water and small solutes (less than 2 nm) occurs 
through gaps between adjacent cells [66]. However, since macromolecules have 
comparatively larger sizes they are unable to pass through these gaps. Although 
microvessels are more permeable than normal vessels, it has been shown that additional 
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anatomical pathways are responsible for movement of macromolecules across blood 
vessels in normal tissues and tumors [67]. Presently, the dominant channels involved in 
macromolecule extravasation include inter- and trans-endothelial openings (open gaps), 
fenestrations and vesiculovacuolar organelle mediated extravasation [68-70]. Therefore, 
understanding the macroscopic and microscopic arrangement of tumor vasculature and 
the pathways responsible for transvacular transport of macromolecules is crucial to how 
they can be exploited to maximize extravasation of polymeric nanomedicines and 
enhance drug delivery. 
 
 
Macroscopic arrangement 
 
For a tumor to grow beyond a few millimeters, new blood vessels are required to 
increase blood supply to meet metabolic demands of malignant and non-malignant cells. 
Tumor angiogenesis leads to a variety of peculiar inter- and intra- tumor vascular 
morphologies partly driven by growth patterns of cancer cells. Two ideal classifications 
of vascular macroscopic arrangement are peripheral and central vascularization [71]. 
 
In peripheral vascularized tumors, blood vessels are confined to the periphery 
which is well-vascularized compared to the avascular core. The absence of vascular 
volume in the core implies systemic agents extravasate poorly in the center of the tumor. 
Contrarily, for central vascularization, blood vessels are localized and form dendrimer 
like patterns in the tumor core. Typically, macroscopic arrangement of tumor vasculature 
represents various degrees of these categories. Regardless of the organization of 
microvessels in tumors, it is clear that heterogeneity in vascular distribution and low 
vascular volume pose serious barriers to drug delivery. Hence, approaches that facilitate 
vascularization of tumors may improve polymeric nanomedicine extravasation and 
cancer therapy. 
 
 
Tumor blood vessel wall structure 
 
Tumor blood vessels can be classified into nine categories as described by Warren 
[72]. These include: arteries and arterioles, non-fenestrated capillaries, fenestrated 
capillaries, discontinuous capillaries, blood channels without endothelial lining, capillary 
sprouts, post-capillary sprouts, venules and veins and arterio-venous anastomoses. 
Among the blood vessels, extravasation occurs primarily at the capillaries and post-
capillary venules due to their thin walls and large surface area [73]. The capillary wall 
structure is composed of a single layer of endothelial cells surrounded by a basement 
membrane. Capillary walls are leaky and have a distribution of pores with diameters less 
than 100 nm. Depending on the frequency of pores in the endothelial layer, capillaries 
can be classified as non-fenestrated, fenestrated and sinusoidal [73, 74]. 
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Continuous capillaries 
 
Non-fenestrated capillaries, also known as continuous capillaries, are commonly 
found in cardiac, skeletal and smooth muscles as well as the skin and brain. Due to the 
tight junctions and uninterrupted subendothelial basement membranes, transport of 
molecules across the continuous capillaries is negligible. Since these vessels have an 
intact endothelial basement membrane with pore size less than 2 nm, small molecules, 
however, can extravasate. An important difference between normal and tumor vessels is 
that tumor vessels are dilated and do not contain basement membrane leading to seepage 
of plasma oncotic contents into the interstitium. Unlike peripheral endothelium, the 
endothelial layer of the brain microvasculature is the tightest endothelium and has 
virtually no fenestrations. Therefore, extravasation of macromolecules across the brain is 
particularly difficult due to the presence of continuous capillaries between the blood and 
brain interstitium. However, certain regions of the brain, such as choroids plexus and 
medion eminence are not part of the blood-brain barrier and are more permeable. 
 
 
Fenestrated capillaries 
 
Fenestrated capillaries possess a continuous basement membrane but have 
fenestrations of 40-60 nm in diameter in the endothelium [74]. Fenestrated capillaries are 
found in the kidney, small intestine and salivary glands. The basement membrane 
surrounding fenestrated capillaries reduces the extravasation of nanomedicines, whereas 
macromolecules or drug-polymer conjugates of less than 11 nm in diameter extravasate 
freely. In contrast, glomerular capillaries have fenestrae of 60-80 nm, which allow 
effective permeation of macromolecules or nanomedicines of less than 30 nm in 
diameter. Fenestrated capillaries abound in various tumors, are partly accountable of 
tumor vessel permeability and permit extravasation of macromolecules [75-77]. 
 
 
Discontinuous capillaries 
 
Discontinuous or sinusoidal capillaries have fenestrations of approximately 150 
nm and are common in the liver, spleen, bone marrow, lymph nodes and adrenal cortex. 
The basal membrane in sinusoidal capillaries is absent in the liver, but present in spleen 
and bone marrow. While liver sinusoids contain phagocytic kupffer cells, those of bone 
marrow contain phagocytic reticuloendothelial cells and the spleen contains a large 
number of pinocytic vesicles. 
 
 
Endothelial openings 
 
It is widely believed that the increased permeability of tumor vessels is due to the 
presence of endothelial openings. Evidence provided by Majno and coworkers suggested 
these endothelial openings to be intercellular in nature [78]. These openings occur when 
neighboring endothelial cells sufficiently contract to overcome cell-cell and cell-matrix 
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adhesion forces and pull away from each other. Using scanning electron microscopy 
(SEM), McDonald et. al. have shown that inter-endothelial openings are not simply holes 
in tumor vasculature. From their studies, they demonstrated  inter-endothelial openings to 
be of two types: vertical gaps and oblique slits [79]. These pores range from 0.1 to 3 µm 
in diameter and have been shown to occur 100 times more frequently than trans-
endothelial openings [70, 79]. Hence, this has led to the long-standing assumption that 
inter-endothelial openings may account for abnormal leakiness of tumor vessels. 
Although the mechanism for pore formation and closure is still not well understood, 
vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) and other 
cytokines have been shown to induce pores in endothelium that otherwise possessed no 
gaps [68, 80]. 
 
 
Vesiculo-vacuolar organelle mediated extravasation 
 
The other competing hypothesis proposes extravasation via interconnected 
vesiculovacuolar organelles (VVOs). Dvorak and coworkers have demonstrated that 
VVOs are a major route of macromolecule extravasation at VEGF/VPF and tumor-
derived cytokine augmented hyperpermeable sites [81]. VVOs are morphologically 
similar to bunches of grape-like clusters approximately 50 to 415 nm in diameter and are 
frequently deployed at intervals in the cytoplasm of endothelial cells [82-84]. In one 
study where macromolecular tracers (e.g., anionic ferritn) were injected intravenously in 
TA3/St mammary carcinoma bearing mice, these tracers were found in VVOs within 
seconds and the VVOs provided a transcytotic pathway for the macromolecules to 
extravasate from tumor blood vessels [82]. Regardless of the controversy surrounding the 
dominant pathway for macromolecule extravasation, the consensus is that extravasation 
pathways for macromolecules and nanoparticles are channel-like structures [85]. 
 
 
Extravasation across Microvascular Wall 
 
Solute transport across vessel walls is either diffusion or convection controlled 
(Figure 2-4). Diffusion is a function of vessel surface area and the driving force for this 
mode of transport is the concentration gradient established by plasma and interstitial 
concentration differences. Convection on the other hand is governed by the rate of fluid 
flow which in turn is determined by a pressure gradient. This pressure gradient is the 
difference between the resultant hydrostatic pressure (i.e., vascular minus interstitial) and 
the resultant osmotic pressure. The vascular permeability (P) constant relates the 
diffusive mass flux to the concentration gradient while the hydraulic conductivity (Lp) 
relates fluid flux to pressure gradients. For transport of macromolecules in normal tissue 
the primary mode of transport is convection, whilst that for small molecules is diffusion 
[86]. However, the mechanism of macromolecule extravasation in tumors is different due 
to high interstitial fluid pressure and leaky vasculature. Paradoxically, macromolecules 
generally exhibit poor extravasation in tumors although their blood vessels are leakier 
compared to normal tissue. This is due to the dominant effect of interstitial hypertension 
reducing fluid movement and consequently convective transport, thus overcompensating   
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Figure 2-4. Schematic representation of convective and diffusive transport of 
polymeric nanomedicines across microvascular wall and the effect of pore cut off 
size. 
  
Convective Transport
Diffusive 
Transport Effect of pore cut off size
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for the potential enhanced extravasation which may result from the leaky vasculature. 
Since the pressure gradient progressively gets steeper from tumor periphery to the core, 
extravasation of macromolecules is superior in the tumor periphery as against the tumor 
core [87]. For instance, Jain and colleagues showed higher accumulation of monoclonal 
antibodies at the tumor normal tissue interface [18].  
 
 
Barriers to Drug Delivery across Tumor Capillaries 
 
As alluded to above, a number of important factors related to the pathophysiology 
of tumors limit optimal drug delivery. These barriers vary depending on tumor type and 
microenvironment. The key then in successfully utilizing polymeric nanomedicines for  
treating solid tumors is to overcome or exploit these obstacles. Below we highlight some 
important barriers which hinder drug delivery and extravasation. 
 
 
Chaotic blood supply 
 
The first barrier is the chaotic blood supply to tumors. Significant structural and 
functional differences exist between tumor and normal vessels. In contrast to well 
organized microvessels in normal tissue, tumor vessels are frequently saccular, dilated 
and tortuous [73, 88, 89]. Their distribution, density, diameter as well as blood flow rate 
also differ throughout tumor. Presently, it is still not clear the relationship between the 
number of blood vessels in the tumor and its volume. For example, Jain and collaborators 
report a decrease in vascular volume while others report a constant vascular fraction over 
the tumor life span. Typically, tumors have a well-vascularized periphery, a seminecrotic 
core and an avascular necrotic central region. Hence, the extravasation of polymer 
therapeutics is often restricted to the tumor periphery. Polymeric nanomedicines however 
need to be sufficiently perfused to optimally deliver drugs to tumors. As such attention 
has been given to normalizing the tumor vasculature to enhance perfusion and the 
consequent extravasation of polymeric nanomedicines into tumors [90, 91]. 
 
 
Poor permeability of tumor vasculature 
 
The next barrier is the poor permeability of tumor vasculature. Permeability of 
tumor blood vessels vary based on the type and location of tumors, leading to 
heterogeneous distribution of blood-borne therapies [68, 92, 93]. Hence, it is possible that 
tumor vessels in different locations (or in a similar microenvironment within the same 
tumor) display contrasting degrees of vascular leakiness. This structural feature often 
results in erratic interstitial drug delivery.  
 
Blood brain barrier (BBB) consists of endothelial cells, pericytes, astrogline and 
macrophages and serves as a physical barrier to drug permeability to the brain. Drug 
permeability across BBB greatly depends on its octanol/water partition coefficient. Drugs 
with high octanol/water partition coefficient easily extravasate the BBB. However, some 
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drugs with low octanol/water partition coefficient can also permeate BBB due to active or 
facilitated transport, which some substances with high octanol/water permeability poorly 
penetrate the BBB due to active transport back to the blood [94]. 
 
 
Limited transport across the interstitium 
 
The third barrier relates to the ability of drug delivery systems to traverse the 
interstitium and selectively target and eliminate cancerous cells. Two key issues here are 
interstitial transport and interstitial hypertension. Size, charge, shape and 
physicochemical properties of the interstitium are important parameters governing 
interstitial transport. For example, large size hinders tissue penetration of 
macromolecules, while cationic liposomes have been shown to target the intravascular 
tumor compartment better than anionic and neutral liposomes of similar size [95, 96]. 
Hence, studies elucidating the effects of size, charge and shape of macromolecules on 
their transport in a variety of tumor types and locations are important in overcoming this 
obstacle. Interstitial hypertension creates a pressure gradient favoring the movement of 
drug molecules out of the tumor into the vascular compartment [97]. This results in 
reduced macromolecular delivery and transport since convection is its major mode of 
transport [22]. 
 
 
Multidrug resistance 
 
Multidrug resistance (MDR) is another important barrier limiting the success of 
chemotherapy and resulting in observed clinical drug resistance. MDR arises when 
cancer cells become insensitive and cross-resistant to cytotoxic effects of structural and 
functionally diverse anticancer agents targeting a range of distinct molecular targets [98]. 
Since MDR implies cancer cells are irresponsive to normal dosing regimen of 
chemotherapeutic drugs, higher doses and frequency are often required in the clinic. A 
major consequence of this is the detrimental side effects on otherwise healthy organs and 
tissues due to high dose intake of anticancer agents to obtain desired therapeutic effect. 
The mechanisms responsible for MDR and approaches for reversing MDR using 
polymeric nanomedicines are discussed below. 
 
 
Mechanism responsible for multidrug resistance 
 
The mechanisms underlying MDR may broadly be classified as pump or non-
pump mediated [99]. Table 2-1 summarizes some of these mechanisms and therapeutic 
strategies for overcoming them. For pump mediated MDR, it has been shown that 
overexpression of members of the ABC transporter super-family such as p-glycoprotein 
(P-gp), multidrug resistance-associated proteins (MRP) and breast cancer resistance 
protein (BCRP) are responsible for increased cellular drug efflux [100-102]. These 
transporters compromise potency of chemotherapy when they reduce drug concentration 
within the cell after pumping penetrated anticancer drugs out of the cells cytoplasm.  To  
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Table 2-1. Multidrug resistance mechanisms. 
 
Type of multidrug resistance Mechanism Therapeutic agents and strategies 
to overcome drug resistance 
   
Pump Mediated Mechanism   
Enhanced cellular drug efflux  Overexpression of ATP-binding 
cassette transporters (e.g., P-gp, 
MRP,BCRP) 
Polymeric nanomedicines (e.g., 
Pluronics); MDR reversal agents 
(e.g., PSC833, XR9576, Ixabepilone, 
SMART compounds); Combination 
therapy (e.g., bicalumatide and 
embelin) 
Non-Pump Mediated Mechanism   
Dysfunctional apoptotic pathway Overexpression of antiapoptotic 
proteins (XIAP and Bcl-2) 
XIAP inhibitor (e.g., embelin), Bcl-2 
inhibitor (e.g., ABT-737), antisense 
therapy (e.g., Genasense, G3139) 
 Reduced sphingolipid ceramide 
generation or enhanced ceramide 
metabolism 
Ceremide generation activator (e.g., 
gefitinib); ceramide metabolism 
inhibitors (e.g., LCL204,  
N-oleoylethanolamine) 
Drug detoxification Overexpressed glutathione S-
transferase 
γ- Glutamylcysteine synthestase 
   
 
Part of this table adapted with permission from Wong et al., Multidrug Resistance in Solid Tumor and Its Reversal, in R.I. 
Mahato, Y. Lu (Eds.), Pharmaceutical Perspectives of Cancer Therapeutics, Springer, New York, 2009, pp. 121-148.  
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date, P-gp is the most well studied and characterized ABC transporter. It is a 170-kDa 
ATP-dependent glycoprotein capable of transporting a wide range of structurally and 
functionally different therapeutic moieties and hence causes cross-resistance to a host of 
drugs. Some P-gp substrates include taxanes (docetaxel, paclitaxel) and anthracyclines 
(doxorubicin, epirubicin) [103]. In contrast to P-gp, multiple MRP (MRP-1 to MRP-8) 
members are responsible for drug resistance in cancer with each member being highly 
specific for a particular substrate. Although BCRP was originally identified in breast 
cancer, it has been shown to be present in other normal tissues such as the colon [104]. 
However, BCRP is overexpressed in tumors and is highly resistant to mitoxantrone[105]. 
A key question is how ABC transporter MDR phenotype is conferred in solid tumors. In 
the case of P-gp, MDR phenotype has been shown to be native or acquired. For example, 
it is intrinsically expressed in epithelial cells of kidney, liver and pancreas and 
higherbasal expression is observed in cancers related to these organs [103]. P-gp MDR 
phenotype may also be acquired after short exposure to high doses or prolonged exposure 
to sub-therapeutic levels of anticancer agents.  
 
Although overexpression of ABC transporters may be considered the primary 
cause of MDR, other non-pump mediated mechanisms prevent cancer cell death and lead 
to drug resistance. Most of these mechanisms result in reduced drug activity due to 
dysfunctional molecular pathways. For example, a defect in the apoptotic machinery 
leading to overexpression of antiapoptotic proteins (e.g., BCl-2, XIAP) does not prevent 
intracellular drug accumulation but rather simply prevents cells from undergoing 
programmed cell death. Also, Minko and coworkers have shown that doxorubicin treated 
cancer cells resulted in overexpression of glutathione-S and UDP transferases [106]. 
These two proteins detoxify drugs and reduce drug efficacy in tumors. Additionally, the 
structural complexity of solid tumors poses multiple pharmacokinetic and 
pharmacodynamic barriers which lead to drug resistance. Some examples include loss of 
drug activity in the acidic tumor microenvironment due to deactivation and acquisition of 
drug resistance mechanisms in cancer cells located in hypoxic regions of tumors. 
 
 
Reversing multidrug resistance using polymeric nanomedicines 
 
Polymeric nanomedicines are well suited for overcoming MDR in a number of 
ways. First, the delivery vehicles themselves can hinder the proper functioning of 
transporters [107]. Recently, it has been hypothesized that block-copolymers such as 
pluronics may disturb the configuration of the lipid bilayer anchoring ABC transporters 
and consequently hinders their ability to pump drugs out of the cell [108, 109]. In 
addition, it has been suggested that pluronics decrease enzymatic activity of 
glutathione/glutathione S-transferase (GSH/GST) and hence decrease drug detoxification 
by these enzymes [110]. Furthermore, pluronics tilt the balance of the apoptotic 
machinery in favor of pro-apoptotic signaling by reducing mitochondrial membrane 
potential of MDR cells and facilitating cytochrome C release [111]. Experimental 
evidence demonstrates the validity of these hypotheses. Recently, Batrakova et al., have 
shown that pluronics P85 can enhance accumulation of P-gp substrates in tumors and 
promote apoptosis in preclinical mice models bearing leukemia and Lewis lung MDR 
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tumors [112]. In another study, ε-caprolactone modified poloxomer 188 nanoparticles 
containing paclitaxel increased uptake in MCF-7 paclitaxel resistant human breast cancer 
cell lines [113]. 
 
Second, MDR reversal agents may be encapsulated in polymeric nanomedicines 
to facilitate drug delivery and overcome MDR. Since most MDR reversal agents are 
lipophilic and have other unfavorable physicochemical properties, they can be more 
selectively and efficiently administered to target sites using lipophilic-based polymeric 
vehicles thereby improving efficacy. In a recent study, D-α-tocopheryl polyethylene 
glycol 1000 succinate (TPGS, a known P-gp modulator)-poly lactide (PLA) nanoparticles 
was used to efficiently encapsulate and deliver doxorubicin to drug resistant breast cancer 
cells (MCF-7/ADR). This system resulted in increased inhibition of P-gp activity, cell 
proliferation and enhanced intracellular drug accumulation and nuclear localization [114]. 
We have also used PEG-PLA copolymer to significantly increase the solubility of a novel 
microtubule destabilizer methoxybenzoyl-ary-thiazole (SMART-100) (Figure 2-5A) 
highly potent in a broad-spectrum of cancer cell types by up to 100,000 fold [115, 116]. 
In addition, our studies revealed SMART-100 to be more potent in drug resistant prostate 
cancer cells (DU-145-TXR) compared to paclitaxel (Figure 2-5B and C). 
 
Finally, combination therapy using multiple anticancer drugs is a promising 
approach to overcome drug resistance. This strategy appears to outsmart cancer cells 
since it becomes difficult for them to simultaneously develop multiple resistance 
mechanisms to counteract treatment. We have shown that combining bicalutamide (non-
steroidal antiandrogen) and embelin (XIAP inhibitor) (Figure 2-6A) leads to synergistic 
anticancer effects in hormone refractory human prostate cancer cells (C4-2) [11]. Our 
strategy involved concurrently targeting the androgen receptor and XIAP signaling 
pathways (Figure 2-6B) both of which are pivotal to progression and metastasis of 
prostate cancer. We found anticancer effect to be schedule dependent with simultaneous 
treatment being more efficacious than sequential administration (Figure 2-6C). 
Polymeric nanomedicines can be used to enhance efficacy of combination therapy in vivo 
as we demonstrated using PEG-PLA micelles. It has also been shown that polymer-lipid 
hybrid nanoparticles (PLN) used to administer doxorubicin and mitomycin-C inhibited 
colony-forming potential in drug resistant breast cancer cells [117]. 
 
 
Inappropriate animal models 
 
While several animal models are presently used in studying drug delivery systems 
in cancer, these models are typically xenografts generated by injecting a variety of cell 
lines subcutaneously. Although adequate for proof of concept studies, the tumor 
microenvironment in xenografts is distinctly different from that in human tumors and 
does not truly reflect what pertains in humans. Orthotopic models are more appropriate 
since tumors are established in the organ of interest and can result in metastatic disease. 
However, these models often require invasive procedures and are difficult to establish 
(e.g., injecting tumor cells into the prostate of mouse models). Additionally, tumor 
growth and metastasis in orthotopic models cannot typically be visualized with the naked   
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Figure 2-5. Chemical structure and anticancer effect of SMART-100.  
 
(A) Chemical structure of SMART-100. (B) Anticancer effect of paclitaxel on DU-145 
and DU145-TXR cell growth and (C) Anticancer effect of SMART-100 on DU-145 and 
DU145-TXR cell growth. SMART-100 is highly potent regardless of MDR status. 
Reproduced with permission from Li F, Lu Y, Li W, Miller DD, Mahato RI. Synthesis, 
formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. J 
Control Release. 2010;143:151-8. 
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Figure 2-6. Anticancer effect of antiandrogen and XIAP inhibitor based 
combination therapy.  
 
(A) Chemical structures of bicalutamide (Bic) and embelin (Emb). (B) Schematic 
diagram showing the combined effect of bicalutamide and embelin on apoptosis in 
androgen-sensitive cells and on tumor regression and (C) Combination Index (CI) of 
simultaneous and sequential treatment of bicalutamide and embelin in C4–2 cells. 5×103 
cells were simultaneously treated with a combination of bicalutamide and embelin or 
sequentially [(bicalutamide followed by embelin) or (embelin followed by 
bicalutamide)]. Combination index (CI) was calculated by the formula: CI = 
(d1/D501)+(d2/D502),whereD501 is the dose of bicalutamide required to produce 50% 
effect alone, and d1 is the dose of bicalutamide required to produce the same 50% effect 
in combinationwith d2.D502 is similarly the dose of embelin required to produce 50% 
effect alone, and d2 is the dose ofembelin required to produce the same 50% effect in 
combination with d1. 10 μM bicalutamide was combined with 0, 5, 10, 25 and 50 μM 
embelin. The CI values are interpreted as follows: > 1.0, synergism; 1.0, additive; and 
< 1.0, antagonism. Reproduced with permission from Danquah M, Li F, Duke CB, 3rd, 
Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating 
prostate cancer. Pharm Res. 2009;26:2081-92. 
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eye. However, orthotopic tumor growth can now be monitored using current technologies 
such as bioluminescence and microultrasound. 
 
 
Strategies for Enhanced Extravasation 
 
To improve the therapeutic potential of polymeric nanomedicines, they should be 
designed to bypass at least one of the physiological barriers described above. To date, 
approaches taken to overcome these barriers have relied on either targeting the tumor 
vasculature or lowering interstitial hypertension. A few of these strategies are highlighted 
below. 
 
 
Targeting the tumor vasculature 
 
From a therapeutic standpoint, tumor blood vessels are excellent targets due to 
their peculiar features which distinguish them from normal blood vessels. Furthermore, 
they lack the genetic stability which facilitates the development of drug resistance in 
cancer cells. Extravasation of polymeric nanomedicines can be improved by using 
radiation to further increase the permeability of the tumor vessels. This can be done using 
an external source or radioisotope targeted macromolecules. To date, tremendous effort 
has been channeled using this approach to investigate the effects of radiation tumor blood 
flow and vascular volume. Typically, scientists have reported on the extent of 
macromolecule extravasation in one hour or the effects of radiation on the time course of 
tissue uptake.  Potchen and coworkers [118] determined tissue pharmacokinetics of 
albumin in Gardener lymphosarcoma tumors, skin, muscle and plasma in C3H mice 48 
hours after radiation (3000 R; single dose). The tissue to plasma ratio increased by 
~200%, 80% and 70% in tumor, muscle and skin, respectively by 48 hours after albumin 
injection. The authors also observed no significant increase in tumor vascular volume 
(using labeled RBCs). From these results, they surmised that radiation resulted in an 
increase in vascular permeability in tumors. 
 
In another study, Song and coworkers [119-121] investigated the quantity of 
albumin extravasated in 1 hour, and vascular volume , measured using labeled RBCs in 
three tumors: Walker 256 carcinoma in Sprague-Dawley rats; a neuroblastoma in A/J 
mice; and the SCL carcinoma in A/J mice, and observed a tumor dependent response. 
They found that quantity of albumin extravasated in 1 hour increased in W256 2 days 
after 200 R and 1 day after 3000 R without an increase in vascular volume. However, 
both the quantity of albumin extravasated in 1 hour and vascular volume decreased for all 
doses thereafter. Similarly in the neuroblastoma, quantity of albumin extravasated in 1 
hour increased immediately after radiation with doses of 250--20001R, and decreased 
after 1-2 days. Vascular volume did not change significantly in the beginning; however, it 
decreased from day 3 after 250--500 R and from day 1 after 1000-2000 R radiation. The 
response of SCL tumor was entirely different. This tumor showed a short term (1 day) 
increase followed by a slight decrease (~ 25%) in vascular volume 7 days after 1000-
2000 R radiation. The tissue uptake, quantity of albumin extravasated in 1 hour, remained 
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fairly constant and decreased by < 20% in 7 days after radiation. From these experiments, 
the authors’ surmised that the decrease in quantity of albumin extravasated in 1 hour 
probably resulted from a decrease in vascular volume/surface area due to radiative 
reorganization and disturbance of the vascular network. 
 
Hyperthermia can also boost tumor blood vessel permeability and lead to 
enhanced drug delivery which could possibly translate into better efficacy [122-125]. To 
date, elevated temperatures have been shown to increase the permeability of tumor 
vessels to ferretin [126], Evans blue dye [127],antibodies [128-130], and liposomes [122, 
131]. Recently Kong et al. showed mild heating  of tumors to confer the most benefit for 
nanoparticle based drug delivery [131]. Several scientists have tried to elucidate the 
mechanism by which hyperthermia affects vascular permeability. For example, Wilhelm 
and Mason [132] explained the observed thermal induced increase in vascular 
permeability to be due to the liberation of endogeneous vasoactive agents such as 
bradykinin, histamine, and serotonin.  
 
Another approach to targeting tumor vasculature involves coupling 
chemotherapeutic drugs to ligands (antibodies, peptides and proteins) that bind 
specifically to markers suchs as aminopeptidase-N, αvβ3 and αvβ5 overexpressed on 
tumor vasculature [133]. For example, pro-apoptotic peptides and tumor necrosis factor-α 
coupled to peptides targeting the above-mentioned such markers include have been 
shown to reduce tumor growth in vivo [133-135]. 
 
 
Lowering tumor interstitial hypertension 
 
Since interstitial hypertension correlates with inefficient extravasation of 
macromolecules it is an attractive target for improving transvascular transport. One way 
this may be achieved is by using drugs designed to increase systemic blood pressure or 
reduce contractility of extracellular matrix [21, 136]. Currently, the use of VEGF 
inhibitors such as bevacizumab or anti-VEGF antibody is a popular approach that has 
proved potent in animals and patients [137]. VEGF is overexpressed in tumors and 
known to account for leakiness in tumor vasculature [138]. In one study, a monoclonal 
antibody against VEGF was used to treat mice bearing subcutaneous human glioblastoma 
tumors and it was found to reduce tumor IFP by more than 70% [139]. Tong and 
coworkers recently showed decreased interstitial hypertension caused by targeting VEGF 
to result in pressure gradients favoring extravasation and hence improving drug 
penetration in tumors [90]. Similar results have been demonstrated in clinical studies 
where decreased IFP was observed in patients with rectal carcinomas upon treatment with 
bevacizumab and when combined with 5-fluorouracil and leucovorin significantly 
improved patient survival [140, 141]. The enhanced therapeutic effect of VEGF 
inhibitors is considered to occur via normalization of tumor vessels resulting in reduced 
vascular permeability and consequently decreased IFP in tumors. 
 
Tumor IFP can also be lowered using PDGF antagonists. Unlike VEGF inhibitors, 
PDGF antagonists target the interaction between stromal fibroblast and the extracellular 
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matrix. Imatinib is a selective small-molecule PDGF receptor inhibitor which has been 
shown to lower IFP [142] and increase delivery and potency of taxol, 5-fluorouracil [143] 
and epthilone B [144] when used in combination . PDGF specific DNA aptamers have 
also been found to lower IFP in mice bearing KAT-4 thyroid carcinoma [143].  
 
Transforming growth factor-β (TGF-β) receptors antagonists have been found to 
lower interstitial hypertension by decreasing the amount of extracellular-matrix 
molecules [145] and also through normalization of tumor vessels [146]. Lammerts and 
coworkers observed that blockade of TGF-β resulted in a dose-dependent decrease of IFP 
in mice bearing KAT-4 thyroid carcinoma. Interestingly, this effect was seen 5-10 days 
after administration of the TGF-β inhibitor, suggesting that a reorganization of the tumor 
tissue was necessary to observe the effect. Furthermore, one study showed that the 
combination of a prostaglandin E1 and 5-fluorouracil resulted enhance therapeutic effect 
in rodent tumors by reducing IFP [147]. 
 
Finally, administration of anti-inflammatory and chemotherapy agents has been 
shown to lower IFP in tumors. For instance, dexamethasone was observed to lower IFP in 
xenograft human colon carcinoma LSI74T tumors. It was suggested that dexamethasone 
decreased the matrix molecule content and reduced the permeability of tumor blood 
vessels. Recently, paclitaxel was shown to reduce compression of tumor vessels leading 
to lower IFP in preclinical studies [148]. Taghian et. al. also showed in their experiments 
that breast cancer patients treated with paclitaxel displayed a lowering of interstitial 
hypertension. In contrast, treatment with doxorubicin did not reduce IFP [149]. 
Consequently, combination therapy utilizing paclitaxel in conjunction with other target 
specific chemotherapy drugs can improve therapeutic outcome in cancer patients. 
 
 
Increasing aqueous solubility of potent anti-cancer drugs 
 
As mentioned previously, low aqueous solubility of potent anticancer drugs is a 
major impediment to their delivery and efficacy. Polymeric nanomedicines are capable of 
increasing the aqueous solubility of lipophilic drugs and offer a number of important 
advantages over traditional solubilizing agents such as DMSO. First, they are less toxic 
than their traditional counterparts and consequently prevent adverse effects on healthy 
tissues. Adverse effects of anticancer drugs often result in termination of therapy or at 
best limit use to sub therapeutic doses. Second, polymeric nanomedicines can be actively 
targeted to make them site-specific. Targeting enhances drug uptake by cancerous cells, 
improves efficacy and further reduces adverse effects. Polymeric nanomedicines may 
broadly be classified as particulate carriers and bioconjugates. Below, we discuss 
polymeric micelles which are classic examples of particulate carriers and how they assist 
in enhancing drug solubility and extravasation.  
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Polymer–drug conjugates 
 
Polymer–drug conjugates are drug delivery systems composed of a drug 
chemically bound to a polymeric carrier by a biodegradable covalent bond. The 
attachment of drug to polymeric carrier can result in several important advantages 
compared to free drug which can potentially facilitate extravasation and cancer therapy. 
These include: (i) enhanced drug solubility, (ii) longer circulation times and consequent 
passive targeting [150], (iii) reduced toxicity [151], (iv) ability to bypass drug resistance 
[152] and (v) ability to be actively targeted [153]. However, to achieve such benefits, 
special attention should be given to a number of features required for effective design. 
For example, the polymer must be non-toxic and capable of decent drug loading to 
potency ratio. Also, the polymer–drug system should be stable whilst in transit to the 
tumor site but be able to release the drug in a desired manner once it reaches the tumor. 
To date several polymer–drug conjugates are in clinical trials [154, 155]. Most of these 
systems are designed for one drug moiety. However, polymer–drug conjugates for 
combination therapy are presently being actively designed to treat cancer [12]. 
 
 
Polymeric micelles 
 
Polymeric micelles are nanosized self-assembled supramolecular core-shell 
spherical structures. The core is composed of the hydrophobic portion of the copolymer 
and is capable of solubilizing a considerable amount of highly water insoluble drugs. The 
hydrophilic component of the copolymer forms the shell (corona) which provides steric 
stabilization. They also have stealth properties which prevent recognition by the 
reticuloendothelial system (RES) and therefore minimize elimination of the micelles from 
the bloodstream [156]. Thus, these so called ‘stealth’ properties of the PEO shell result in 
increased blood circulation times and prevention of plasma protein binding [157]. In 
addition, the small size ensures preferential accumulation in tumor cells via the enhanced 
permeability and retention (EPR) effect [150, 158]. 
 
 
Physics of drug encapsulation 
 
Polymeric micelles can enhance drug solubility by physical entrapment 
(encapsulation) or chemical conjugation. While chemical conjugation can result in high 
drug loadings, it is not suitable for all drugs since some therapeutic agents do not have 
functional groups necessary for conjugation and cannot be modified without altering 
pharmacologic effect. In contrast, physical entrapment is suitable for a wide range of 
drugs. However, the extent of drug encapsulation depends of compatibility between drug 
and core-forming block of micelle [159, 160] and core-forming block length [161, 162]. 
The effect of these parameters is measured in terms of drug loading density (ratio of 
weight of encapsulated drug to weight of micelle) and drug loading efficiency (ratio of 
weight of encapsulated drug to weight of drug initially fed). High drug loading density 
and encapsulation efficiency are desirable to facilitate clinical translation of micelles 
since this translates into smaller amount of polymer and processing cost. 
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Compatibility between drug and core forming block 
 
Improvement in the extent of compatibility between a drug and the core forming 
block of the micelle may translate into superior encapsulation efficiency [163-166]. 
Polymer/drug compatibility may be characterized by Flory-Huggins interaction parameter 
(χFH) which accounts for the forces of interaction between the polymer and the drug. The 
low χFH values suggest that the polymer is thermodynamically a good solvent for the 
drug.  Flory-Huggins interaction parameter (χFH) which characterizes polymer-drug 
compatibility is calculated using Equations 2-1 and 2-2:  
 
         Δ = ��𝛿𝑑 − 𝛿𝑝�𝑝𝑜𝑙𝑎𝑟𝑖𝑡𝑦2 + �𝛿𝑑 − 𝛿𝑝�𝑑𝑖𝑠𝑝𝑒𝑟𝑠𝑖𝑜𝑛2 + �𝛿𝑑 − 𝛿𝑝�ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛2 �12     (Eq. 2-1) 
 
                                                           𝜒𝐹𝐻 = 𝛥2𝑉𝑑𝑅𝑇                                                  (Eq. 2-2) 
 
where Δ2 is the solubility difference between the drug (d) and the core of the polymeric 
micelle (p). Vd is the molar volume of the drug, T is the temperature in Kelvin and R is 
the gas constant. (δx)d, (δx)p and (δx)h are Hansen partial solubility parameters for the drug 
and the hydrophobic block of the block copolymer. 
 
To design a micelle system with improved drug loading, it is prudent to first 
perform an in silico study to assess the Flory-Huggins interaction parameter (χFH) 
between drug and the block copolymers. As χFH approaches zero, compatibility between 
the polymer and the drug progressively increases since the polymer increasingly becomes 
a better thermodynamic solvent for the drug, resulting in improved drug solubilization.  
 
Our group and others have explored the possibility of predicting drug 
solubilization in micelles based on thermodynamics and found our predictions to closely 
approximate experimental results [164, 167-171]. For example, we recently utilized this 
approach to match two anticancer drugs: bicalutamide and embelin with novel block 
copolymers. In one study, 5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (carbonate 
monomer) was introduced into the poly (ethylene glycol)-b-poly (L-Lactide) (PEG-b-
PLLA) copolymer backbone to form poly (ethylene glycol)-b-poly (carbonate-co-lactide) 
(PEG-b-(CB-co-LA)) copolymer. The chemical structure and molecular model of (PEG-
b-(CB-co-LA)) copolymer are shown in (Figure 2-7A and B). Our predictions based on 
χFH values of PEG-b-(CB-co-LA) and PEG-b-PLLA copolymers indicated PEG-b-(CB-
co-LA) to be a better thermodynamic solvent for bicalutamide due to its lower χFH value.  
 
Experimental evidence confirmed this prediction since PEG-b-(CB-co-LA) 
increased drug loading of bicalutamide by up to four-fold (Figure 2-7C) and improved 
thermodynamic solubility by 10 fold (Figure 2-7D). It is noteworthy that both drug 
loading and thermodynamic stability were carbonate content dependent.  
 
Using a dodecanol lipid grafted onto a poly (ethylene glycol)-b-poly carbonate 
(PEG-b-PBC) copolymer, we were able to increase loading efficiency of embelin from  
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Figure 2-7. Effect of carbonate content on key poly (ethylene glycol)-b-poly 
(carbonate-co-lactide) micelle properties. 
 
(A) Chemical structure of poly (ethylene glycol)-b-poly (carbonate-co-lactide).  
(B) Molecular modeling of PEG-b-P(CB-co-LA) block copolymer; molecular modeling 
was performed using Molecular Pro Software. (C) Effect of carbonate content on 
bicalutamide loading and (D) Effect of carbonate content on CMC. Reproduced with 
permission from Danquah M, Fujiwara T, Mahato RI. Self-assembling 
methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug 
delivery. Biomaterials. 2010;31:2358-70. 
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40% for PEG-b-PBC to 100% for poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-
propylene carbonate-graft-dodecanol) (PEG-PCD) lipopolymer at 5% theoretical loading 
(Figure 2-8A and C). This observed increase in drug loading is partly due to structural 
similarity between embelin and the lipid modified hydrophobic core of PEG-PCD 
copolymer. Furthermore, it has been shown that polymer-drug compatibility heavily 
depends on the three-dimensional arrangement and conformation of the different moieties 
composing the structure of polymer and drug. Mahmud and coworkers have also reported 
similar results for increasing loading of cucurbitacin I by attaching cholesterol to the poly 
(caprolactone) of poly(ethylene glycol)-b-poly(caprolactone) copolymer. Although the 
underlying assumptions governing χFH are not entirely applicable to micelles, the trend of 
its value still provides good indication of drug-core compatibility and can be a logical 
justification to match a drug to a specific polymer or tailor a new one for it. 
 
Another important feature of PEG-PCD lipopolymer is its potential to enhance 
both thermodynamic and kinetic stability. When compared to conventional PEG-lipid 
conjugates, PEG-PCD lipopolymer carries multiple dodecanol lipid chains grafted onto 
the polycarbonate backbone (Figure 2-8B). Hence, PEG-PCD lipopolymer is capable of 
forming physical entanglement based cross-linked structures which can enhance 
hydrophobic interaction in the hydrophobic core. Our studies show PEG-PCD 
lipopolymer to have a lower CMC value (~10-8M) compared to traditional PEG-lipid 
conjugates and is expected to demonstrate better in vivo stability. 
 
 
Length of core forming block 
 
The length of the hydrophobic core is an important factor which determines the 
cargo space available for a drug. For a constant hydrophilic block length, an increase in 
hydrophobic core length typically results in higher drug loading density [172, 173]. This 
is made possible partly due to a reduction in the pressure-volume work needed to put a 
drug molecule into the micelle resulting from a larger hydrophobic cargo space. For 
instance, we have shown that increasing PCD block molecular weights of 1.5k, 4k and 
7.25k of PEG-b-PCD copolymer correspondingly increased micelle size from 25 nm to 
42.6 to 129 nm, respectively. 
 
 
Conclusions and Future Perspectives 
 
Experimental evidence suggests that the barrier posed by tumor vasculature can 
potentially be overcome thereby enhancing the extravasation of polymeric nanomedicines 
to tumors. With advances made in targeting tumor blood vessels and lowering IFP, 
research focus should be placed on elucidating mechanisms responsible for barrier 
formation. Future studies should also be centered on “tailor-made” polymeric 
nanomedicines highly efficient and effective in circumventing the vascular barrier. In 
particular, thought should be given to site-specific multicompartment polymeric 
nanomedicines. Such systems will be composed of high binding affinity ligands specific 
for overexpressed proteins in tumor blood vessels and possess at the minimum a  
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Figure 2-8. Influence of lipid substituent group on polymer architecture and 
embelin loading. 
 
(A) Chemical structure of poly (ethylene glycol)-b-poly (carbonate) (PEG-PBC) and 
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-
dodecanol) (PEG-PCD). (B) Schematic of architectural structure of PEG-lipid and PEG-
PCD lipolymer and (C) effect of dodecanol grafted carbonate hydrophobic core on 
embelin loading. Reproduced with permission from Li F, Danquah M, Mahato RI. 
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. 
Biomacromolecules. 2010;11:2610-20. 
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bicompartmental core containing agents capable of lowering IFP or altering tumor 
vasculature as well as potent anticancer agents. Time invested in refining the components 
of these systems will result in design rules which will facilitate customization of 
polymeric nanomedicines with phenomenal extravasation for various cancers. Finally, 
another key challenge which needs to be addressed is improving drug delivery to the 
avascular core. Logical steps will be to find ways that can re-establish the vascular 
network in the core of the tumor and improve extravasation at these sites.  
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CHAPTER 3.    MICELLAR DELIVERY OF BICALUTAMIDE AND EMBELIN 
FOR TREATING PROSTATE CANCER* 
 
 
Introduction 
 
Prostate cancer is the most pervasive malignancy diagnosed in men and remains 
the second leading cause of cancer-related mortality affecting men in the United States 
[174]. The progression of prostate cancer has been found to be androgen-dependent with 
androgen playing a key role in the proliferation, differentiation, and survival of prostate 
cancer cells [175-178]. Consequently, androgen ablation, especially the use of 
antiandrogens, has been used as a standard treatment for men with prostate cancer. 
Antiandrogens may be divided into two classes: steroidal and nonsteroidal. Steroidal 
antiandrogens, including cyproterone acetate, interfere with androgen receptor (AR) 
binding, blocks 5α-reductase, and have progesterone-like antigonadotropic activity. The 
clinical potency of cyproterone has been limited due to loss of erectile potency, influence 
on carbohydrate metabolism, and associated cardiovascular and hepatocellular toxicity 
[179, 180]. 
 
Nonsteroidal antiandrogens have been developed to avoid the side effects 
associated with steroidal antiandrogen therapy. Three compounds, namely: flutamide 
(EulexinTM), nilutamide and bicalutamide (CasodexTM), are available for clinical use. 
Among them, bicalutamide is the most widely used in androgen ablation therapy due to 
its relatively long half-life and tolerable side effects [181]. The initial treatment of 
prostate cancer with bicalutamide yields response in up to 85% of patients. However, it is 
not curative, since prolonged treatment results in mutations in the AR, which converts 
bicalutamide from an antagonist into an agonist leading to drug resistance and the 
occurrence of hormone-refractory prostate cancer (HRPC). 
 
Resistance to apoptosis is a common feature associated with the progression of 
prostate cancer from androgen-dependence to HRPC. This defect in the apoptotic 
machinery prevents neoplastic cells from being naturally eliminated due to the 
downregulation of proapoptotic and overexpression of antiapoptotic proteins, resulting in 
an imbalance between the rates of proliferation and apoptosis. Hence, regulators of 
apoptosis have emerged as attractive targets in the development of therapeutic strategies 
for treating prostate cancer. Among the key regulators of apoptosis is the inhibitor of 
apoptosis (IAP) family which suppress caspase activity endogenously preventing cell 
death [182-184]. The most thoroughly characterized and most potent IAP protein is the 
X-chromosome-linked IAP (XIAP) [184]. XIAP protein binds and inhibits the initiator 
caspase-9 and effector caspases-3 and -7 through the binding of its BIR3 domain and the 
linker region between BIR1 and BIR2, respectively; consequently inhibiting both  
 
 
* Danquah M, Li F, Duke CB, 3rd, Miller DD, Mahato RI. Micellar Delivery of 
Bicalutamide and Embelin for Treating Prostate Cancer. Pharmaceutical Research. 
2009;26:2081-92.  
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intrinsic and extrinsic apoptotic pathways [185-188]. Recently, expression levels of XIAP 
in human prostate cancer cells was found to correlate with apoptotic resistance [189, 
190]. 
 
Embelin is a novel cell permeable small molecule inhibitor of XIAP, which was 
discovered by structure-based computational screening of a three-dimensional structure 
library of natural products derived from traditional Chinese medicine [191]. Embelin 
binds to the XIAP BIR3 domain preventing its binding to and inhibition of caspase-9 and 
effector caspases-3 and -7 [191]. Also, embelin has been shown to possess antitumor and 
anti-inflammatory properties, as well as decrease testosterone levels [192, 193]. Recently, 
embelin was shown to block nuclear factor-κB (NF-κB) signaling pathway resulting in 
the suppression of NF-κB-regulated antiapoptotic and metastatic gene products, making it 
a potential effective suppressor of tumor cell survival, proliferation, angiogenesis, 
invasion, and inflammation [194]. 
 
Presently, there are limited treatment options for HRPC and a number of 
therapeutic strategies including combination therapy are the subject of intense research. 
Several studies have examined the effect of combining radiation, chemotherapeutic, and 
hormonal agents in treating prostate cancer. Traditionally, the exploration of combination 
therapy for treating hormone-refractory prostate cancer involves clinically combining 
well known cytotoxic chemotherapeutic agents (e.g., docetaxel and paclitaxel) and testing 
their potency in man.  While these studies have shown some drug combinations to have 
synergistic effect in treating prostate cancer, the advantage may be marginal since their 
toxicity might exceed their benefit. A current approach in combination therapy requires a 
paradigm shift, in which the drug regimen incorporates chemotherapeutic agents which 
are selectively toxic to cancer cells. Therefore, one of our goals was to identify and 
explore a new combination of therapeutic agents for treating HRPC which is 
simultaneously potent and less toxic to humans; and can potentially be used for clinical 
treatment. Since embelin is a powerful inhibitor of XIAP and has minimal effects on 
normal human prostate epithelial cells [191], we investigated its cytotoxic effect as a 
single-agent and possible synergism in combination with bicalutamide in two androgen 
receptor containing human prostate cancer cell lines: LNCaP, which is androgen 
dependent and C4-2, which is androgen independent.  The structures of bicalutamide and 
embelin are shown in Figure 3-1A. We hypothesize that therapeutic combinations of 
bicalutamide and embelin will have a synergistic effect on growth inhibition and 
apoptosis of LNCaP and C4-2 cells as well as tumor regression in xenograft mouse 
models considering their mechanism of action (Figure 3-1B).  
 
Polymeric micelles are known to improve the solubility, stability, site specificity 
and hence therapeutic efficacy of hydrophobic drugs. These micelles self-assemble into 
nanosized (20-60 nm), spherical structures with a hydrophobic core capable of 
solubilizing a considerable amount of highly water insoluble drugs. The stealth properties 
associated with poly(ethylene oxide) (PEO) hydrophilic corona of polymeric micelles 
prevents recognition by the reticuloendothelial system (RES) and therefore minimizes 
elimination of the micelles from the bloodstream [156].  Thus, these so called ‘stealth’ 
properties of the PEO shell result in increased blood circulation times and prevention of   
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Figure 3-1. Therapeutic strategy for bicalutamide and embelin based 
combination therapy. 
 
(A) Chemical structures of bicalutamide and embelin and (B) schematic diagram showing 
the combined effect of bicalutamide and embelin on apoptosis in androgen-sensitive cells 
and on tumor regression.  
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plasma protein binding [157]. In addition, the small size ensures preferential 
accumulation in tumor cells via the enhanced permeability and retention (EPR) effect 
[158, 195]. 
 
In this study, polymeric micelles were fabricated using poly(ethylene glycol)-b-
poly(lactic acid) [PEG-PLA] copolymer and used for enhancing the water solubility and 
bioavailability of bicalutamide and embelin to improve their efficacy. The enhanced drug 
water solubility and bioavailability translate into a reduction in the administered dose and 
possible toxicity in normal cells. In the current study, PLA was selected as the 
hydrophobic core-forming block since it is Food and Drug Administration (FDA) 
approved for clinical use and hence may facilitate the translation of our therapeutic 
agents for clinical applications. In addition, the in vitro synergistic or additive 
antiproliferative effects of combined bicalutamide and embelin, each possessing distinct 
cytotoxic mechanisms, was studied in both androgen dependent (LNCaP) and  
androgen independent (C4-2) human prostate cancer cells, while mechanistic studies on 
the induction of apoptotic cell death by bicalutamide was also conducted. Finally, the 
ability of sequential exposure to bicalutamide-loaded micelles followed by embelin-
loaded micelles to regress prostate cancer tumors in xenograft mice models was 
examined.  
 
 
Materials and Methods 
 
 
Materials 
 
PEG (5100)-b-PLA (4500) copolymer (Mn = 9600) was purchased from Polymer 
Source (Montreal, Canada). Embelin was purchased from Sigma-Aldrich (St. Louis, MO) 
while bicalutamide was synthesized as described by Mukherjee et al. [196] RPMI 1640 
medium was obtained from Invitrogen (Carlsbad, CA) and human prostate cancer cells 
C4-2 and lymph node prostate adenocarcinoma (LNCaP) were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). Caspase-GloTM 3/7, 8 and 9 assay and 
RNA extraction kits were purchased from Promega (Madison, WI). SYBR Green real 
time PCR master mix and reverse transcription reagents were purchased from Applied 
Biosystems (Foster city, CA). Human Total XIAP ELISA kit was purchased from R&D 
Systems (Minneapolis, MN). All other reagents were obtained from Sigma-Aldrich (St. 
Louis, MO) unless otherwise stated and were used as received. 
 
 
In vitro cell viability assays 
 
Human prostate cancer cells, LNCaP and C4-2 cells (American Type Culture 
Collection) were incubated in RPMI 1640 media supplemented with 2mM L-glutamine, 
10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in humidified 
environment of 5% CO2 and subcultured every 3-4 days to maintain exponential growth. 
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Cells were seeded in 96-well plates at a density of 5 x 103 viable cells/well and 
incubated for 48 h to permit cell attachment. The cells were exposed to bicalutamide or 
embelin at concentrations ranging from 1 to 100 µM for 24 h. At the end of treatment, 20 
µl of MTT (5 mg/ml) was added to each well and incubated for 3-4 h. The plates were 
then centrifuged at 1500 x g for 2 min and the medium aspirated. The residual formazan 
crystals were solubilized with 100 µl DMSO and the plate analyzed using a microplate 
reader recording absorbance values at a test wavelength of 560 nm. Cell viability for a 
given concentration was expressed as a percentage of the intensity of controls. 
 
 
Caspase detection 
 
Caspase-Glo 3/7, 8 and 9 assay kits purchased from Promega (Madison, WI)) 
were used to analyze caspase 3, 8 and 9 activities, respectively, as per the manufacturer’s 
protocol. Briefly, 100 µl Caspase-Glo reagent was added to 100 µl of culture 
supernatants in 96-well plates and incubated at room temperature for 1 h. The contents 
were then transferred into disposable culture tubes and luminescence was determined 
using a Berthold Detection Systems Sirius luminometer (Pforzheim, Germany). 
 
 
XIAP expression analysis 
 
The mRNA and protein level expression of XIAP in LNCaP and C4-2 cells after 
treatment with embelin for 48 h was assayed using quantitative real-time PCR and 
ELISA, respectively. Briefly, total RNA was isolated using RNAeasy mini isolation kit 
from Promega. RNA concentration was measured by UV spectrophotometry with a 
Biomate 3 spectrophotometer. One hundred and fifty nanograms (ng) of extracted RNA 
was converted into cDNA using Multi-Scribe reverse transcriptase and random hexamers 
(Applied Biosystems, Inc., Foster City, CA) by incubation at 25°C for 10 min, followed 
by reverse transcription at 48°C for 30 min and enzyme inactivation at 95°C for 5 min. 
To determine the level of XIAP expression, the following XIAP-specific primers were 
used: Forward: 5′-TGT TTC AGC ATC AAC ACT GGC ACG-3′; Reverse: 5′-TGC 
ATG ACA ACT AAA GCA CCG GAC-3′ (NM_001167).  The PCR conditions included 
denaturation at 95°C for 10 min, followed by 40 cycles of amplification by sequential 
denaturation at 95°C for 15 s and primer annealing as well as strand extension for 1 min. 
XIAP gene expression was normalized to β-actin as internal control. To confirm the 
amplification specificity, the PCR products were subjected to melting curve analysis. The 
expressed XIAP levels were quantified and normalized to the total amount of cDNA 
used.  
 
For XIAP protein expression, total protein was isolated by lysing cells. XIAP 
levels were measured as per the protocol of Human Total XIAP ELISA kit obtained from 
R&D Systems (Minneapolis, MN). Results were normalized by measuring the total 
protein using a BCA assay kit.  
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Isobologram analysis 
 
The dose-response interaction between bicalutamide and embelin at the point of 
IC50 was assessed to be synergistic, additive or antagonistic using the isobologram 
method of analysis of Steel and Peckham [197]. Dose–response curves were plotted for 
the effects of bicalutamide and embelin on human prostate cancer LNCaP and C4-2 cell 
viability. From these curves, the combined drug IC50 values were determined for each 
curve. Specifically, LNCaP and C4-2 cells were treated with embelin (0, 5, 10, 25 and 50 
µM) and bicalutamide (0, 10, 25 and 50 µM) either simultaneously or sequentially and 
cell viability assessed using MTT assay resulting in the above-mentioned dose-response 
curves. The combination index (CI) was calculated by Equation 3-1: 
   
 
                                             2D
d2
1D
d1 CI
5050
+=
                                                    (Eq. 3-1) 
 
where D501 is the dose of agent 1 (bicalutamide) required to produce 50 percentage effect 
alone, and d1 is the dose of agent 1 required to produce the same 50 percentage effect in 
combination with d2. Similarly, D502 is the dose of agent 2 (embelin) required to produce 
50 percentage effect alone, and d2 is the dose of agent 2 required to produce the same 50 
percentage effect in combination with d1. The CI values were interpreted as follows:  
< 1.0, synergism; 1.0, additive effect; > 1.0, antagonism. Each experiment was performed 
three times. The parameters d1 and d2 in equation 1 were obtained as follows: when a 
dose of bicalutamide (d1) was selected the incremental effect produced by adding 
embelin starting from 0 to 50 µM was assessed. The concentration of embelin that when 
combined with d1 resulted in the inhibition of 50% cell growth was designated d2. 
 
 
Fabrication of drug-loaded micelles 
 
The film sonication method was used to load bicalutamide and embelin into the 
core of polyethylene glycol-polylactic acid (PEG-PLA) micelles. All experiments were 
performed using a theoretical loading of 5% unless otherwise stated. Briefly, 1 mg of 
bicalutamide or embelin and 19 mg of PEG-PLA was dissolved in 5ml methanol. The 
mixture was allowed to stir for 5 min and the solvent evaporated. The resulting film was 
hydrated and sonicated for 7 min using a Misonix ultrasonic liquid processor 
(Farmingdale, NY) with an output power of 25 W. The resultant formulation was then 
centrifuged at 5,000 rpm for 10 min to separate micelles from residual free drug. 
Subsequently, the supernatant was filtered using a 0.22 µm nylon filter. The micelle 
preparation was immediately lyophilized for two days and stored at 4°C to prolong shelf-
life and avoid untimely release of the drug.  
 
 
Critical micelle concentration 
 
Fluorescence spectroscopy was used to estimate the critical micelle concentration 
(CMC) of PEG-PLA copolymer using pyrene as a hydrophobic fluorescent probe. Nine 
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samples of PEG-PLA dissolved in methanol with concentrations ranging from 1 x 10-8 to 
1g/L were prepared and allowed to equilibrate with a constant pyrene concentration of 6 
x 10-7 M for 48 h at room temperature. The fluorescence spectra of pyrene were recorded 
with a Molecular Devices SpectraMax M2/M2e spectrofluorometer (Sunnyvale, CA). An 
excitation wavelength of 390 nm was used and the emission spectra recorded from 320 to 
450 nm with both bandwidths set at 2 nm. Peak height intensity ratio (I3/I1) of the third 
peak (I3 at 338 nm) to the first peak (I1 at 333 nm) was plotted against the logarithm of 
polymer concentration. The value of the CMC was obtained as the point of intersection of 
two tangents drawn to the curve at high and low concentrations, respectively. 
 
 
Drug loading density and encapsulation efficiency 
 
Drug loading was determined as follows: Lyophilized drug-loaded micelles were 
dissolved in methanol and the drug present in solution measured by ultraviolet 
spectroscopy. The weight of drug loaded in the micelles was calculated using a 
calibration curve. Background absorbance interference from PEG-PLA copolymer was 
accounted for by measuring the absorbance of blank PEG-PLA micelles under the same 
conditions. The micelle drug loading content and encapsulation efficiency were obtained 
by Equations 3-2 and 3-3. 
 
x100%
  micelle ofweight 
micellein  drug ofweight  density  loading drug =  
 
(Eq. 3-2) 
 
x100%
  fed originally drug ofweight 
micellein  drug ofweight  efficiencyion encapsulat drug =  
 
(Eq. 3-3) 
 
 
Size and size distribution 
 
Mean particle size and size distribution of drug-loaded micelles were measured 
via dynamic light scattering using a Malvern instruments Zetasizer Nano Series 
(Worcestershire, United Kingdom). Samples were diluted to appropriate concentrations 
and analyzed at room temperature with a 90° detection angle. Mean micelle size was 
obtained as a Z-average which is an intensity mean. All measurements were repeated 7 
times and reported as the mean diameter ± SD for triplicate samples. 
 
 
Solubility studies of drug-loaded micelles 
 
The water solubility of free drug (bicalutamide or embelin) and drug-loaded 
micelles was determined by shaking an excess amount of free drug and 3mg of drug-
loaded micelles in 1 mL water, respectively. The suspension was then centrifuged at 8000 
x g for 10 min and filtered on 0.2 µm cellulose membrane. The amount of bicalutamide 
in the saturated solution was evaluated by UV spectroscopy as described above. 
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In vivo efficacy assessment of bicalutamide-loaded micelles in xenografts 
 
All animal experiments were performed in accordance with NIH animal use 
guidelines and the protocol approved by the Animal Care and Use Committee at the 
University of Tennessee Health Science Center. Xenograft flank tumors were induced in 
8 week old male BALB/C nude mice purchased from The Jackson Laboratory (Bar 
Harbor, ME) by subcutaneous injection of 3 million LNCaP cells suspended in 1:1 media 
and matrigel. When tumors reached approximately 150 mm3, mice were randomized into 
three groups of 5 mice, minimizing weight and tumor size differences. Each group was 
treated with intratumoral injection of saline, sonicated bicalutamide suspension or 
bicalutamide-loaded micelles (20 mg/kg) three times a week. Tumors were measured 
with a caliper prior to each injection, and their volumes calculated using the formula: 
(width2 x length)/2.  
 
 
Results 
 
 
Effect of bicalutamide on apoptosis 
 
To determine whether prostate cancer cell death by bicalutamide is also 
associated with apoptosis, we determined the activation of initiator caspases 8 and 9, and 
effector caspase 3 at 48 h post-incubation of LNCaP cells with bicalutamide using 
caspase luminescence assay. Results were normalized by measuring the total protein 
using BCA protein assay kit. As shown in Figure 3-2, relatively high levels of caspase 3 
and 9 compared to caspase 8 were observed at the drug concentrations of 50 and 100 
µg/ml. 
 
 
Effect of embelin on caspase activation and XIAP inhibiton 
 
Resistance to apoptosis is a characteristic feature of prostate cancer and XIAP is 
known to inhibit the activation of the initiator caspase 9 and the effector caspase 3 which 
is the committed step in the apoptotic pathway. Hence, we determined the levels of 
caspase activation and XIAP expression levels in LNCaP and C4-2 cells after treatment 
with 5 µM embelin (XIAP inhibitor) for 48 h. As demonstrated in Figure 3-3A, caspase 
activation was higher in the embelin treated cells. Specifically, caspase 8 had lower 
activation levels compared to caspases 3 and 9, with caspase 9 activity being the highest. 
However, the caspase 3 and 9 activation was found to be lower in C4-2 cells compared to 
LNCaP cells. To determine whether the differential levels of caspase activity in LNCaP 
and C4-2 cells correlate with XIAP expression, we measured baseline XIAP expression 
in both cells and the effect of embelin in inhibiting XIAP expression using ELISA and 
real time RT-PCR, respectively (Figure 3-3B). The data show that C4-2 cells have higher 
baseline XIAP expression levels than LNCaP, and treatment with 5µM embelin resulted 
in a decrease in XIAP expression in both cell lines. However, the decrease in XIAP   
 41 
 
 
  
Figure 3-2. Effect of bicalutamide on the activation of caspases in LNCaP cells. 
 
At 48h postincubation with the drug at a dose of 0 (control), 10, 50 and 100 µg/ml, cells 
were lyzed to determine caspase 3, 8 and 9 activities in terms of relative light units 
(RLU) and total protein using a BCA protein assay kit. Results are presented as the mean 
± S.D. of triplicates. 
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Figure 3-3. Effect of Embelin on caspase activation and XIAP inhibition in 
LNCaP and C4-2 prostate cancer cells. 
 
(A) Embelin effectively activates caspases 3, 8 and 9 in LNCaP and C4-2 cells. 
Activation of caspases is higher in LNCaP cells which have comparatively lower XIAP 
expression. Results are presented as the mean ± S.D. of triplicates. (B) XIAP expression 
in LNCaP and C4-2 cells using RT-PCR and ELISA. 
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expression upon treatment with embelin was more pronounced in LNCaP cells compared 
to C4-2 cells.  
 
 
Effect of bicalutamide and embelin on prostate cancer cell growth 
 
To determine whether embelin can be used for treating androgen dependent and 
hormone refractory prostate cancer, we determined the IC50 values of both bicalutamide 
and embelin in two androgen receptor containing human prostate cancer cells, androgen 
sensitive LNCaP and hormone refractory C4-2 prostate cancer cells. As shown in  
Figure 3-4, embelin was more potent than bicalutamide in killing prostate tumor cells 
irrespective of their androgen status. LNCaP cells were more sensitive to bicalutamide 
compared to C4-2 cells, with a 50% inhibitory concentration (IC50) of approximately 43 
and 93 µM, respectively (Figure 3-4A). Hence, C4-2 cells which are androgen 
independent and AR positive displayed a two-fold resistance to bicalutamide compared to 
LNCaP cells which are androgen dependent.  In contrast, embelin exhibited superior 
antiproliferative activity in LNCaP and C4-2 cells, with IC50 of ~ 5 µM (Figure 3-4B). 
However, both cell lines displayed similar sensitivity to embelin at the concentrations 
examined.  
 
We used the isobologram method of Steel and Peckham [197] to assess whether 
the simultaneous or sequential combination of these two drugs could confer synergistic, 
additive, or antagonistic effects. Combination index (CI) was determined after treating 1 
x 104 C4-2 cells with a combination of bicalutamide and embelin. Cell viability was 
determined by MTT assay and the resulting dose-response curves are shown in  
Figure 3-5. CI was calculated by the formula:CI = (d1/D501) + (d2/D502), where D501 is 
the dose of  bicalutamide required to produce 50% effect alone, and d1 is the dose of 
bicalutamide required to produce the same 50% effect in combination with d2. D502 is 
similarly the dose of embelin required to produce 50% effect alone, and d2 is the dose of 
embelin required to produce the same 50% effect in combination with d1. The CI values 
are interpreted as follows: < 1.0, synergism; 1.0, additive; and > 1.0, antagonism. The 
data is reported in Tables 3-1, 3-2 and 3-3. These results suggest that the cytotoxic effect 
of the combination of bicalutamide and embelin was dependent on the treatment schedule 
and cell line. When the combination of these two drugs were used, simultaneous 
exposure and sequential treatment of bicalutamide followed by embelin was synergistic 
in C4-2 cells, while additive and antagonistic effects were observed for LNCaP cells. 
Sequential treatment of embelin followed by bicalutamide was additive and antagonistic 
for both cell lines. 
 
 
Characterization of polymeric micelles  
 
Micelles were fabricated with polyethylene glycol-b-polylactic acid (PEG-PLA) 
di-block copolymer using the film sonication method. We determined the critical micelle 
concentration (CMC) using pyrene as a hydrophobic probe to observe micelle formation  
 
 44 
 
 
 
Figure 3-4. Effect of drug treatment on cell viability in prostate cancer cells (C4-2 
and LNCaP). 
 
(A) C4-2 and LNCaP cells treated with increasing concentrations of bicalutamide (0–100 
μM) for 24h. (B) C4-2 and LNCaP cells treated with increasing concentrations of 
embelin (0–25μM) for 24h. Results are expressed as the percentage of control.   
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Figure 3-5. Dose-response curves for bicalutamide and embelin combination in 
human prostate cancer cells. 
 
(A) and (B) Simultaneous exposure to bicalutamide and embelin in C4-2 and LNCaP 
cells, respectively. (C) and (D) Sequential exposure to bicalutamide followed by embelin 
in C4-2 and LNCaP cells, respectively. (E) and (F) Sequential exposure to embelin 
followed by bicalutamide in C4-2 and LNCaP cells, respectively.  
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Table 3-1. Synergistic antiproliferative activity of bicalutamide (d1 = 10μM) and 
embelin in human prostate cancer cells. 
 
Drug combination Cell line d1 (µM) d2 (µM) CI 
     
Bicalutamide + Embelin C4-2 10 1.59 0.42 
 LNCaP 10 4.66 1.09 
     
Bicalutamide → Embelin C4-2 10 4.51 0.87 
 LNCaP 10 5.90 1.05 
     
Embelin → Bicalutamide C4-2 10 5.65 1.22 
 LNCaP 10 8.09 1.08 
     
 
Combination Index (CI) of simultaneous and sequential treatment of bicalutamide and 
embelin in C4-2 and LNCaP cells. 5 x 10
3
 cells were simultaneously treated with a 
combination of bicalutamide and embelin or sequentially [(bicalutamide followed by 
embelin) or (embelin followed by bicalutamide)]. Cell viability was determined by MTT 
assay. The combination index (CI) was calculated by the formula: CI = (d1/D501) + 
(d2/D502), where D501 is the dose of  bicalutamide required to produce 50% effect alone, 
and d1 is the dose of bicalutamide required to produce the same 50% effect in 
combination with d2. D502 is similarly the dose of embelin required to produce 50% 
effect alone, and d2 is the dose of embelin required to produce the same 50% effect in 
combination with d1. 10 µM bicalutamide was combined with 0,5,10,25 and 50 µM 
embelin. The CI values are interpreted as follows: < 1.0, synergism; 1.0, additive; and  
> 1.0, antagonism. Each experiment was done in triplicate. 
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Table 3-2. Synergistic antiproliferative activity of bicalutamide (d1 = 25μM) and 
embelin in human prostate. 
 
Drug combination Cell line dl (µM) d2 (µM) CI 
     
Bicalutamide + Embelin C4-2 25 2.74 0.81 
 LNCaP 25 5.46 1.61 
     
Bicalutamide → Embelin C4-2 25 3.85 0.92 
 LNCaP 25 4.47 1.20 
     
Embelin → Bicalutamide C4-2 25 5.80 1.41 
 LNCaP 25 8.88 1.51 
     
 
Combination Index (CI) of simultaneous and sequential treatment of bicalutamide and 
embelin in C4-2 and LNCaP cells. 5 x 10
3
 cells were simultaneously treated with a 
combination of bicalutamide and embelin or sequentially [(bicalutamide followed by 
embelin) or (embelin followed by bicalutamide)]. Cell viability was determined by MTT 
assay. The combination index (CI) was calculated by the formula: CI = (d1/D501) + 
(d2/D502), where D501 is the dose of  bicalutamide required to produce 50% effect alone, 
and d1 is the dose of bicalutamide required to produce the same 50% effect in 
combination with d2. D502 is similarly the dose of embelin required to produce 50%  
effect alone, and d2 is the dose of embelin required to produce the same 50%  effect in 
combination with d1. 25 µM bicalutamide was combined with 0,5,10,25 and 50 µM 
embelin. The CI values are interpreted as follows: < 1.0, synergism; 1.0, additive; and 
> 1.0, antagonism. Each experiment was done in triplicate. 
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Table 3-3. Synergistic antiproliferative activity of bicalutamide (d1 = 50μM) and 
embelin in human prostate.  
 
Drug combination Cell line dl (µM) d2 (µM) CI 
     
Bicalutamide + Embelin C4-2 50 1.90 0.91 
 LNCaP 50 4.27 1.94 
     
Bicalutamide → Embelin C4-2 50 3.26 1.09 
 LNCaP 50 3.42 1.63 
     
Embelin → Bicalutamide C4-2 50 6.33 1.78 
 LNCaP 50 7.71 1.96 
     
 
Combination Index (CI) of simultaneous and sequential treatment of bicalutamide and 
embelin in C4-2 and LNCaP cells. 5 x 10
3
 cells were simultaneously treated with a 
combination of bicalutamide and embelin or sequentially [(bicalutamide followed by 
embelin) or (embelin followed by bicalutamide)]. Cell viability was determined by MTT 
assay. The combination index (CI) was calculated by the formula: CI = (d1/D501)  + 
(d2/D502), where D501 is the dose of  bicalutamide required to produce 50% effect alone, 
and d1 is the dose of bicalutamide required to produce the same 50% effect in 
combination with d2. D502 is similarly the dose of embelin required to produce 50% 
effect alone, and d2 is the dose of embelin required to produce the same 50% effect in 
combination with d1. 50 µM bicalutamide was combined with 0,5,10,25 and 50 µM 
embelin. The CI values are interpreted as follows: < 1.0, synergism; 1.0, additive; and 
> 1.0, antagonism. Each experiment was done in triplicate. 
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by monitoring polarity changes in the micellar microenvironment [198, 199]. Changes in 
the vibrational band intensity ratio (I3/I1) with polymer concentration was used to detect  
the onset of micelle formation, where I3 at 338 nm and I1 at 333 nm correspond to the 
(0,2) and (0,0) bands, respectively [200]. The CMC obtained at the point of inflection of 
the I3/I1 versus the logarithm of polymer concentration curve was approximately 1 mg/L  
(data not shown). The particle size distribution of these micelles before and after drug 
loading was measured by dynamic light scattering with mean particle size in the range of 
30 to 50 nm.  
 
 
Drug encapsulation efficiency and micellar solubility 
 
The film sonication method was chosen for the fabrication of bicalutamide and 
embelin-loaded micelles since it yields micelles with higher drug loading [201]. 
Preliminary experiments were performed to optimize formulation parameters such as 
sonication time, output power and the volume of water used for film hydration. This was 
done to obtain the highest drug loading possible. A sonication time of 7 min, output  
power of 25 W and hydration volume of 5 ml (i.e., a micelle concentration of 4 mg/ml) 
proved optimal. 
 
To determine the maximum amount of drug that could be loaded into the micelles, 
the theoretical loading of bicalutamide and embelin into PEG-PLA micelles was 
systematically increased from 1 to 20% w/w. There was a linear relationship between the 
amount of embelin incorporated into the micelles with increasing theoretical loading. In 
contrast, the loading density for bicalutamide could not increase when the theoretical 
drug loading reached 10% or higher. At all theoretical loadings, the loading density of 
embelin was higher than that of bicalutamide especially at theoretical loading above 10% 
(Figure 3-6A). From the experimental results, a theoretical loading of 5% w/w was 
chosen for all in vitro and in vivo experiments in this study since it was the optimum 
formulation in terms of drug loading, encapsulation efficiency, and yield.  
 
The effect of micellar solubilization on the aqueous solubility of bicalutamide and 
embelin-loaded micelles was determined by shaking an excess amount of free drug or 3 
mg of drug-loaded micelles in 1ml water, respectively. Free bicalutamide and embelin 
exhibit very low water solubility of ~ 1 µg/ml, respectively. However, bicalutamide and 
embelin-loaded micelles resulted in a significant increase in drug solubility with 
increasing theoretical loading (Figure 3-6B). At 10% w/w a 60-fold increase in water 
solubility was observed for a micelle concentration of 3 mg/ml. It is noteworthy that at 
each theoretical loading, the amount of drug brought into solution is essentially 
equivalent to the amount of drug successfully incorporated in the polymer.  
 
 
In vivo efficacy assessment of drug-loaded micelles in xenografts  
 
Following in vitro characterization of antiandrogen loaded polymeric micelles in 
terms of particle size, micellar solubilization, drug loading and inhibitory effect on  
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Figure 3-6. Effect of theoretical loading on drug loading density and solubility. 
 
(A) Drug loading- or density and (B) micellar solubilization of bicalutamide and embelin. 
Water solubility of the drug was determined at 25°C. Both loading efficiency into PEG-
PLA micelles and increase in aqueous solubility due to micellar solubization were higher 
for embelin than bicalutamide. 
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LNCaP cell proliferation, we decided to test bicalutamide-loaded micelles in mice 
bearing LNCaP xenografts.  Xenograft flank tumors were induced in 8 week old male  
BALB/C nude mice by subcutaneous injection of 3 million LNCaP cells suspended in 1:1 
media and matrigel. When tumors reached approximately 150 mm3, mice were  
randomized into three groups of 5 mice. Each group was treated with intratumoral 
injection of saline, bicalutamide suspension and bicalutamide-loaded micelles at the dose 
of 20 mg/kg three times a week. Tumors were measured with a caliper prior to each 
injection, and their volumes calculated using the formula: (width2 x length)/2. As shown 
in Figure 3-7, tumor growth was effectively regressed upon treatment with bicalutamide 
up to 20 days post-treatment. Formulation into PEG-PLA polymeric micelles further 
regressed tumor growth and this effect was more significant in case of bicalulamide.  
 
Unfortunately, these tumors became insensitive to bicalutamide at 20 days after 
treatment and began to grow. Since antiapoptotic proteins, including XIAP, is known to 
get upregulated in hormone refractory prostate cancer, we decided to treat these tumors 
subsequently with emblin, which is an effective XIAP inhibitor. As shown in Figure 3-7, 
sequential treatment with embelin resulted in regression of hormone insensitive tumors.  
 
 
Discussion 
 
Prostate cancer is the second leading cause of death in men in North America. 
Since androgens play an important role in progression of prostate cancer, androgen 
ablation and blockade of androgen action are the two most common modalities for 
treating prostate cancer. Although bicalutamide is one of the most widely used 
nonsteroidal antiandrogens for treating prostate cancer, it is highly hydrophobic and 
prolonged exposure leads to drug resistance, the occurrence of hormone refractory 
prostate cancer and an increased propensity for metastasis [202-205].  Since hormone 
refractory tumors are resistant to apoptosis and overexpress XIAP, the objective of this 
study was to see whether small molecule XIAP inhibitor such as embelin can be used to 
treat bicalutamide irresponsive tumors. 
 
Since the precise cellular mechanism by which bicalutamide induces apoptosis is 
still not well understood, we first measured the activity of caspases 3, 8 and 9, since 
caspase 9 upregulation represents mitochondrial pathway and caspase 8 upregulation 
represents extrinsic pathway [206]. As shown in Figure 3-2, there was dose dependent 
increase in all three caspases. However, the level was very high in the case of 3 and 9. 
Our results are in good agreement with the work of Lee et al. [207], who also reported 
caspase 3 levels to be 5-fold higher than caspase 8 when LNCaP cells were treated with 
bicalutamide. Further, AR gene silencing has been reported to result in massive prostate 
tumor cell death through mitochondrial pathway regardless of their androgen sensitivity 
[208]. These results suggest that bicalutamide mainly follows mitochondrial pathway.   
 
Prolonged treatment with bicalutamide is known to convert androgen sensitive 
prostate cancer cells into apoptosis resistant hormone refractory cells due to 
overexpression of antiapoptotic genes including Bcl-2, Bcl-XL and XIAP [209]. Among 
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Figure 3-7. Effect of bicalutamide and embelin-loaded micelles on growth of 
tumors derived from LNCaP prostate cancer cells in nude mice. 
 
Nude mice bearing 150-mm3 LNCaP tumors were given an intratumoral injection of 20 
mg/kg bicalutamide three times a week and tumor size was measured prior to each 
injection. Tumor growth regression was significantly higher for bicalutamide-loaded 
micelles compared to the free drug up to 20 days post-treatment. Since tumors became 
insensitive to bicalutamide at 20 days after treatment and began to grow, bicalutamide 
treatment was discontinued and embelin-loaded micelles were administered from day 28, 
which resulted in regression of hormone insensitive tumors. Points are mean tumor size 
(n = 5); bars, SE. 
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them, XIAP is the most potent in inhibiting apoptosis via inhibition of effector caspases. 
XIAP inhibitors are known to inhibit caspases, promote mitochondrial permeability,  
Bcl-2 cleavage and Bak conformational change [210]. Among various XIAP inhibitors, 
small molecule embelin is quite promising and known to inhibit caspase 9 and effector 
caspases [191]. Therefore, we determined whether embelin can activate caspases in 
LNCaP and C4-2 cells (Figure 3-3). We observed increased caspase 3 and 9 activity 
upon treatment with embelin in both cell lines. Our results are in good agreement with 
Nikolovska-Coleska et. al. [191] who first showed the ability of embelin to induce 
caspase 3 and 9 activation in prostate cancer cells by inhibiting the activity of XIAP. 
While these authors studied the effect of embelin in LNCaP and other prostate cancer 
cells, they did not examine C4-2 cells and to the best of our knowledge no study using 
embelin has been done in C4-2 cells. In our study, we found caspase 3 and 9 activation to 
be lower in C4-2 cells compared to LNCaP cells which we attributed to higher levels of 
XIAP expression in C4-2 cells. ELISA and real time RT-PCR analysis on LNCaP and 
C4-2 cells revealed higher baseline XIAP expression in C4-2 cells and treatment with 
5µM embelin resulted in a decrease in XIAP expression in both cell lines. It is 
noteworthy that the decrease in XIAP expression upon treatment with embelin was more 
pronounced in LNCaP cells compared to C4-2 cells (Figure 3-3). This outcome appears 
to correlate with the relative caspase 3 and 9 activation levels observed in LNCaP and 
C4-2 cells. 
 
We examined the ability of bicalutamide and embelin for treating androgen 
dependent prostate cancer as well as hormone refractory advanced prostate cancer by 
observing their effect on cell proliferation. Embelin was more potent than bicalutamide in 
killing prostate tumor cells irrespective of their androgen status since it was effective in 
inhibiting the proliferation of androgen dependent LNCaP and hormone refractory C4-2 
cells (Figure 3-4). Isobologram analysis suggests that the simultaneous administration of 
bicalutamide and embelin and the sequential treatment of bicalutamide followed by 
embelin provide synergistic effect on the growth inhibition of hormone refractory C4-2 
prostate cancer cells but additive and antagonistic effects in LNCaP cells (Figure 3-5 and 
Tables 3-1, 3-2 and 3-3). The efficacy of the above treatment schedules possibly stems 
from bicalutamide sensitizing the cells by androgen ablation to embelin mediated 
apoptosis. In contrast, the treatment schedule of embelin followed by bicalutamide was 
additive and antagonistic for both cell lines. However, since the definition of synergism is 
more stringent in the isobologram method of analysis compared to clinical synergism 
where drug combinations must simply produce a better tumor response than either drug 
alone, the observed antagonistic effects in our drug combination study may be equal or 
superior to that of bicalutamide or embelin alone [211].  
 
Since bicalutamide and embelin are highly hydrophobic, their limited solubility in 
water can hamper their clinical use by systemic administration. Moreover, the historical 
use of DMSO to bring water insoluble drugs into true solution for clinical use is of great 
concern since DMSO is harmful to the liver and kidney and causes dose-dependent 
hemolysis. A potential approach to addressing these problems is to improve their aqueous 
solubility using polymeric micelles. Formulation of these drugs into PEG-PLA micelles 
significantly improved their aqueous solubility and drug loading density increased with 
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increasing theoretical loading up to 20% for embelin and 10% for bicalutamide  
(Figure 3-6). Embelin had higher drug loading compared to bicalutamide, possibly due to 
better hydrogen bonding between the carbonyl group of the PLA hydrophobic core-
forming block and the hydroxyl groups of embelin. Similar observations has also been 
reported for quercetin which has three hydroxyl groups [212]. Differences in their drug 
loading efficiency and micellar solubilization are also related to their different physico-
chemical properties as calculated using the Advanced Chemistry Development 
(ACD/Labs) Software V8.14 for Solaris (Ó 1994-2009 ACD/Labs): The log D (pH = 7), 
log P and pKa values for bicalutamide are 4.94, 9.44 and 11.49, respectively; and those of 
embelin are 1.20, 5.70 and 2.59, respectively. Micelle size was in the range of 30-50 nm, 
which is expected to allow enhanced capillary permeability and delivery to tumor and 
inflammatory sites. Furthermore, the small size of the micelles would facilitate the 
release of encapsulated drug due to the high surface area to volume ratio.  
 
Following in vitro characterization, bicalutamide-loaded micelles were evaluated 
in mice bearing LNCaP xenografts. Tumor regression was more significant up to 20 days 
post-treatment with bicalutamide-loaded micelles compared to free bicalutamide. 
Unfortunately, tumors became insensitive to bicalutamide afterwards and began to grow. 
This finding is not surprising, since prostate cancer is known to become resistant to 
bicalutamide after prolonged treatment, leading to tumor cell proliferation. Subsequent 
treatment with emblin-loaded micelles resulted in regression of hormone insensitive 
tumors. This result clearly suggests that combination of bicalutamide with embelin has 
the potential to be used for treating advanced prostate tumor and metastasis. Sirotnak et 
al. have also shown synergistic effect of bicalultamide with ZD1839 (Iressa) which 
inhibits EGFR. However they used extremely high dose (150 mg/kg for ZD1839 and 100 
mg/kg for bicalutamide) and did not measure tumor growth beyond 18 days. In our study 
there was significant tumor regression up to 20 days when we treated mice with 
bicalutamide-loaded micelles, but the tumors began to grow beyond 20 days and 
therefore we stopped treatment with bicalutamide on day 28 and treated mice with 
embelin a week later [213]. Synergistic effect has also been shown in prostate cancer cell 
lines between bicalutamide and genistein which is an isoflavone [214].  
 
A major goal of this study was to demonstrate proof of principle that the 
combination of an androgen receptor antagonist (bicalutamide) and XIAP inhibitor 
(embelin) was capable of regressing prostate cancer tumors. Since both bicalutamide and 
embelin are highly hydrophobic and the conventional use of DMSO to solubilize drugs is 
harmful to the liver and kidney and causes dose-dependent hemolysis, we chose to use 
polymeric micelles. While the drug solubilization results are not dramatic, they were 
suitable for intratumoral injections for our xenograft models. For future studies involving 
systemic administration, we plan to optimize the selection of the hydrophobic block of 
our copolymer to increase the “cargo” space and enhance drug solubilization. Our 
laboratory is currently synthesizing polymers to address this issue and preliminary data 
suggests it may be able to enhance solubilization several fold compared to the poly lactic 
acid hydrophobic core used in this study. We are also conjugating targeting ligands to the 
polymeric micelles to enhance site-specific delivery after systemic administration. In 
 55 
 
conclusion, micellar delivery of antiandrogen and XIAP inhibitors has potential to treat 
advanced prostate cancer.  
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CHAPTER 4.    SELF-ASSEMBLING METHOXYPOLY(ETHYLENE GLYCOL)-
B-POLY(CARBONATE-CO-L-LACTIDE) BLOCK COPOLYMERS FOR 
DRUG DELIVERY* 
 
 
Introduction 
 
Androgens are known to play a pivotal role in the development and maintenance 
of the prostate by interacting with the androgen receptor (AR) [215]. Consequently, 
androgen ablation, especially the use of antiandrogens, has been used as a standard 
treatment for men with prostate cancer. Among various antiandrogens, bicalutamide 
(CasodexTM) is the most widely used non-steroidal antiandrogen for treating early stage 
prostate cancer due to its relatively long half life and tolerable side effects [216]. 
However, bicalutamide exhibits poor aqueous solubility (5µg/mL), which results in poor 
and variable drug absorption across the gastro intestinal tract. Furthermore, bicalutamide 
cannot be administered systemically, as traditional approaches to increase its aqueous 
solubility using solubilizing agents such as dimethyl sulfoxide (DMSO) and Cremophor 
EL is not practical in humans due to hemolysis, acute hypertensive reactions and 
neuropathies [217]. 
 
One way of improving the solubility of hydrophobic drugs and in particular 
bicalutamide is by using polymeric micelles. Micelles are attractive drug delivery 
vehicles primarily because they can solubilize hydrophobic drugs in their core leading to 
improved bioavailability and drug stability. Furthermore, micelles are capable of 
preventing drug degradation, minimizing the adverse effects of the drug on visceral 
organs and have the possibility of being made site-specific [218]. A number of 
amphiphilic diblock copolymers composed of polyethylene glycol (PEG) and various 
biodegradable hydrophobic cores capable of forming micelles have been reported in the 
literature. Examples include: poly (ethylene glycol)-b-poly (aspartic acid) [PEG-b-PAA] 
[219], poly (ethylene glycol)-b-poly(lactide-co-glycolic acid) [PEG-b-PLGA][220], poly 
(ethylene glycol)-b-poly(caprolactone) [PEG-b-PCL] [221] and poly (ethylene glycol)-b-
poly(D,L-lactide) [PEG-b-PDLLA] [222]. Key properties of these micelle systems such 
as size, stability, drug release kinetics and drug loading have also been well studied.  
 
We have recently demonstrated the feasibility of using PEG-b-PDLLA micelles to 
increase the aqueous solubility of bicalutamide. Although we were able to increase the 
aqueous solubility of bicalutamide, we observed only moderate drug loading levels which 
may not be high enough for systemic administration. To solve this problem, the focus of 
the present study was to specifically design and develop a new family of biodegradable 
amphiphilic copolymers to improve the aqueous solubility of bicalutamide by enhancing 
its loading levels. Our strategy involves modifying the polyester component 
 
 
*Danquah M, Fujiwara T, Mahato RI. Self-assembling methoxypoly(ethylene glycol)-b-
poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials. 
2010;31:2358-70.  
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of the well established PEG-b-polyester copolymer into polyester/polycarbonate 
copolymer system. The semicrystalline poly (L-lactide) was chosen as the polyester block 
because it is FDA approved, possesses good mechanical properties which may provide 
adequate stability to the micelle system and is known for its application as a drug 
delivery material [223-225]. For the carbonate block we selected the cyclic 5-methyl-5- 
benzyloxycarbonyl-1,3-dioxane-2-one carbonate monomer. 5-methyl-5-
benzyloxycarbonyl-1,3-dioxane-2-one is a modification of 5-benzyloxycarbonyl-1,3-
dioxane-2-one which is an intermediate in the synthesis of numerous antiviral compounds 
[226]. This carbonate monomer was chosen since polycarbonates are biodegradable, 
exhibit low toxicity and possess tunable mechanical properties [227-229]. Furthermore, 
polycarbonate degrades into carbon dioxide and benzyl alcohol, which unlike the 
degradation products of poly (L-lactide) [e.g. lactic acid] are less acidic, has less effect on 
microenvironment pH and as such will not result in local inflammation. We hypothesize 
that the introduction of the carbonate monomer would provide additional degrees of 
freedom to tailor a micelle delivery system that is relatively stable, exhibits improved 
sustained release and has a hydrophobic core that is more compatible with bicalutamide 
leading to enhanced drug loading.  
 
Improvement in the extent of compatibility between a drug and the core forming 
block of the micelle may translate into superior encapsulation efficiency [163-166]. A 
number of groups have explored the possibility of predicting drug solubilization in 
micelles based on thermodynamics and found their predictions to closely approximate 
experimental results [164, 167-169]. Polymer/drug compatibility may be characterized by 
the Flory-Huggins interaction parameter (χFH) which accounts for the forces of interaction 
between the polymer and the drug; and low χFH values suggest that the polymer is 
thermodynamically a good solvent for the drug. To design a micelle system with 
improved drug loading, we first performed an in silico study using the Molecular Pro 
Software to assess the Flory-Huggins interaction parameter (χFH) between bicalutamide 
and poly(L-lactide) (PLLA) and a series of poly(carbonate-co-lactide) copolymer with 
varying carbonate to lactide ratios based on group contribution method. 
   
In this study, a series of poly (ethylene glycol)-b-poly(carbonate-co-lactide) 
copolymers were synthesized and characterized. Also, the influence of carbonate content 
on key micelle properties such as size, drug loading, stability and release kinetics was 
investigated. Furthermore, the microstructure of the micelle core block was analyzed to 
examine the influence of co-monomer sequence distribution on the physicochemical 
properties of the copolymer and thermal analysis was used to elucidate the impact of 
carbonate introduction on the crystalline or amorphous nature of the hydrophobic core. 
Finally, the efficacy of bicalutamide-loaded micelles was assessed in lymph node 
adenocarcinoma (LNCaP) human prostate cancer cell lines. 
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Materials and Methods 
 
 
Materials 
  
2,2-bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, 
Mn = 5000, PDI = 1.03), stannous 2-ethylhexanoate (Sn(Oct)2), dicyclohexycarbodiimide 
(DCC), dimethylaminopyridine (DMAP) and benzyl bromide were purchased from 
Sigma Aldrich (St. Louis, MO) and used as received. L-lactide (LA) was purchased from 
PURAC Biochem bv (Gorinchem, The Netherlands) and recrystallized from ethyl acetate 
several times. All other reagents were obtained from Sigma Aldrich and used without 
further purification. 
 
 
Computation of solubility and Flory-Huggins interaction parameters (χFH) of 
bicalutamide with core of peg-b-plla/ peg-b-poly(carbonate-co-lactide) micelles 
 
The Flory-Huggins interaction parameter (χFH) which characterizes polymer-drug 
compatibility was calculated using Equations 4-1 and 4-2: 
 
       Δ = ��𝛿𝑑 − 𝛿𝑝�𝑝𝑜𝑙𝑎𝑟𝑖𝑡𝑦2 + �𝛿𝑑 − 𝛿𝑝�𝑑𝑖𝑠𝑝𝑒𝑟𝑠𝑖𝑜𝑛2 + �𝛿𝑑 − 𝛿𝑝�ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛2 �12         (Eq. 4-1) 
 
                                                           𝜒𝐹𝐻 = 𝛥2𝑉𝑑𝑅𝑇                                                    (Eq. 4-2) 
 
where Δ2 is the solubility difference between the drug (d) and the core of the polymeric 
micelle (p). Vd is the molar volume of the drug, T is the temperature in Kelvin and R is 
the gas constant.  
 
The Hansen partial solubility parameters [(δx)d, (δx)p, (δx)h)] for the drug 
(bicalutamide) and the hydrophobic block of PEG-b-PLLA and PEG-b-poly(carbonate-
co-lactide)  [PEG-b-P(CB-co-LA)] copolymers used in equation 1 were estimated using 
the Molecular Modeling Pro software from ChemSW (Fairfield, CA). This software 
approximates solubility parameters using the Hansen theory of solubility group 
contribution method. (δx)d, (δx)p and (δx)h refers to the partial solubility parameters 
accounting for Van der Waals forces of dispersion between atoms, permanent dipole-
dipole forces between molecules and the proclivity of molecules hydrogen bonding, 
respectively. Here, subscript x refers to the drug or polymer core. 
 
 
Synthesis of 5-Methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one 
 
A mixture of 2,2-bis(hydroxymethyl)propionic acid (22.5 g, 0.168 mol), 
potassium hydroxide (88% assay;10.75 g, 0.169 mol), and dimethylformamide (DMF) 
(125 mL) was heated to 100°C for 1 h with stirring at which point homogenous 
potassium salt solution was formed. Benzyl bromide (34.5 g, 0.202 mol) was added 
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dropwise to the warm solution, and stirring was continued at 100°C for 16 h. Upon 
completion of the reaction, the mixuture was cooled and the solvent was removed under 
vacuum. The residue was dissolved in ethyl acetate (150 mL), hexanes (150 mL), and 
water (100 mL). The organic layer was retained, washed with water (100 mL), dried 
(Na2SO4), and evaporated. The resulting solid was recrystallized from toluene to give 
pure benzyl 2,2-bis(methylol)propionate, as white crystals (20 g, 58%). 
 
Benzyl 2,2-bis(methylol)propionate (11.2 g, 0.05 mol) was dissolved in pyridine 
(25 mL, 0.3 mol) and CH2Cl2 (150 mL), and the solution was chilled to −78°C under N2. 
A solution of triphosgene (7.5 g, 25.0 mmol) in CH2Cl2 was added dropwise over 1 h, 
after which the reaction mixture was stirred at room temperature for 2 h. The reaction 
was quenched by the addition of saturated aqueous NH4Cl (75 mL). Subsequently, the 
organic layer was washed with 1 M aqueous HCl (3 x 100 mL), saturated aqueous 
NaHCO3 (1 x 100 mL), dried (Na2SO4), filtered and evaporated to give 5-methyl-5-
benzyloxycarbonyl-1,3-dioxane-2-one as a white solid (10.6 g, 95%). The ensuing solid 
was recrystallized from ethyl acetate prior to polymerization. 
 
 
Synthesis of peg-b-poly(carbonate-co-lactide) 
 
Stannous 2-ethylhexanoate (10 mol% relative to mPEG) was added to the mixture 
of prescribed quantities of PEG, lactide and base monomer in a dried polymerization 
flask under the protection of nitrogen atmosphere. The reaction mixture was heated to 
130°C for 24 h with stirring. Afterward, the product was cooled to room temperature to 
terminate the reaction. The copolymer was dissolved in chloroform and precipitated in a 
large amount of diethyl ether and hexane (1:2), filtered and dried under vacuum at room 
temperature. 
 
 
Polymer characterization 
 
 
Nuclear magnetic resonance (NMR) 
 
1H NMR spectra were recorded on a JOEL (270 MHz, T = 25ºC) and 13C spectra 
were recorded with a Varian (500 MHz, T = 25ºC) using deuterated chloroform (CDCl3) 
and deuterated dimethyl sulfoxide (DMSO-d6), respectively as solvents. The chemical 
shifts were calibrated using tetramethylsilane as an internal reference and given in parts 
per million. 
 
 
Gel permeation chromatography (GPC) 
 
A Shimadzu 20A GPC system equipped with two Jordi Gel DVB500 columns and 
a differential refractive index detector was used to determine the molecular weight and 
polydispersity index (PDI) of the copolymers. Tetrahydrofuran (THF) was used as eluent 
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at a flow rate of 1 mL/min at 35ºC. A series of narrow polystyrene standards (900 – 
100,000 g/mol) were used for calibration and the data was processed using a LCSolution 
ver.1.21 GPC option software. 
 
 
Differential scanning calorimetry (DSC) 
 
A TA Instruments DSC Q 2000 module was used to determine the thermal 
properties of the synthesized copolymers. Samples were placed in aluminum pans under 
nitrogen heated from 25°C to 100°C, cooled to -90°C to remove thermal history and 
heated to 100°C at a rate of 10ºC/min.  
 
 
Critical micelle concentration (CMC) 
 
Fluorescence spectroscopy was used to estimate the critical micelle concentration 
(CMC) of PEG-b-PLLA and PEG-b-P(CB-co-LA) copolymer using pyrene as a 
hydrophobic fluorescent probe. Twelve samples of PEG-b-PLLA or PEG-b-P(CB-co-
LA) dissolved in methanol with concentrations ranging from 1×10–8 to 1 g/L were 
prepared and allowed to equilibrate with a constant pyrene concentration of 6×10–7 M for 
48 h at room temperature. The fluorescence spectra of pyrene were recorded with a 
Molecular Devices SpectraMax M2/M2e spectrofluorometer (Sunnyvale, CA). An 
excitation wavelength of 390 nm was used and the emission spectra recorded from 320 to 
450 nm with both bandwidths set at 2 nm. Peak height intensity ratio (I3/I1) of the third 
peak (I3 at 338 nm) to the first peak (I1 at 333 nm) was plotted against the logarithm of 
polymer concentration. The value of the CMC was obtained as the point of intersection of 
two tangents drawn to the curve at high and low concentrations, respectively. 
 
 
Preparation of bicalutamide-loaded micelles 
 
Bicalutamide-loaded micelles were prepared using the film sonication method as 
previously described with slight modifications [230]. In brief, 5 mg of bicalutamide and 
95 mg of PEG-b-PLLA or PEG-b-P(CB-co-LA) was dissolved in 5 ml chloroform. The 
mixture was vortexed for 5 min to ensure homogeneity and the solvent evaporated under 
N2 flow. The resulting film was hydrated in 10 mL phosphate buffered saline (PBS) to 
yield a final concentration of 10 mg/mL and sonicated for 10 min using a Misonix 
ultrasonic liquid processor (Farmingdale, NY) with an amplitude of 50. The ensuing 
formulation was then centrifuged at 5,000 rpm for 10 min to separate micelles from 
residual free drug. Subsequently, the supernatant was filtered using a 0.22 μm nylon 
filter. The micelle preparation was lyophilized for 48 h and stored at 4°C to prolong 
shelf-life and avoid untimely release of the drug.  
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Drug loading and encapsulation efficiency 
 
Drug loading was determined as follows: 100 mg lyophilized bicalutamide-loaded 
micelles were dissolved in chloroform and the drug present in solution measured by 
ultraviolet spectroscopy. The weight of drug loaded in the micelles was calculated using a 
calibration curve and background absorbance interference from PEG-b-PLLA or PEG-b-
P(CB-co-LA) copolymer was accounted for by measuring the absorbance of blank PEG-
b-PLLA or PEG-b-P(CB-co-LA) under the same conditions. Drug loading content and 
encapsulation efficiency were then determined using Equations 4-3 and 4-4 as follows: 
 
x100%
  micelle ofweight 
micellein  drug ofweight  density  loading drug =  
 
(Eq. 4-3) 
 
x100%
  fed originally drug ofweight 
micellein  drug ofweight  efficiencyion encapsulat drug =  
 
(Eq. -4-4) 
 
 
Particle size distribution 
 
Mean particle size and size distribution of drug-loaded micelles were determined 
by dynamic light scattering (DLS) using a Zetasizer (Malvern Instruments, 
Worcestershire, UK) at a 1 mg/mL polymer concentration. Samples were analyzed at 
room temperature with a 90° detection angle and the mean micelle size was obtained as a 
Z-average. All measurements were repeated seven times and reported as the mean 
diameter ± SD for triplicate samples. 
 
 
Transmission electron microscopy 
 
Micelles prepared using PEG-b-P(CB-co-LA) copolymer were visualized using a 
JEM-100S (Japan) transmission electron microscope (TEM). Five microliters of micelle 
suspension was loaded on a copper grid, followed by blotting of excess liquid and air-
dried before negative staining with 1% uranyl acetate. The grid was visualized under the 
electron microscope at 60 kV and magnifications ranging from 50,000x to 100,000x. 
 
 
Bicalutamide release from micelles 
 
The dialysis technique was employed to study the release of bicalutamide from 
the various copolymer micelles in PBS (pH 7.2). Bicalutamide-loaded micelles with a 
final bialutamide concentration of 0.2 mg/ml were placed into a dialysis membrane with a 
molecular weight cut-off of 8000 Da and dialyzed against 50 ml PBS (pH 7.2) in a 
thermo-controlled shaker with a stirring speed of 100 rpm. 1 ml samples were withdrawn 
at specified times for a period of seven days and assayed with a validated UV 
spectrophotometer by measuring the absorbance of the solution at 270 nm. The samples 
taken for measurement were replaced with fresh media and the cumulative amount of 
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drug released into the media at each time point was evaluated as the percentage of total 
drug release to the initial amount of the drug. All experiments were performed in 
triplicate and the data reported as the mean of the three individual experiments.  
 
 
In vitro cytotoxicity of bicalutamide-loaded micelles 
 
The ability of bicalutamide and bicalutamide-loaded micelles to inhibit cell 
proliferation was evaluated using LNCaP human prostate cell line. Cells were cultured in 
RPMI 1640 media supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS) 
and 1% antibiotic-antimycotic at 37°C in humidified environment of 5% CO2 and 
subcultured every 3 days to ensure exponential growth. The cells were then seeded in 96-
well plates at a density of 5×103 viable cells/well and incubated for 48 h to permit cell 
attachment. The cells were exposed to bicalutamide dissolved in methanol or 
bicalutamide-loaded micelles at concentrations ranging from 1 to 100 μM for 48 h. At the 
end of treatment, 20 μl of MTT soultion (5 mg/ml) was added to each well and incubated 
for 4 h. The plates were then centrifuged at 1,500×g for 2 min and the medium aspirated. 
The residual formazan crystals were solubilized with 100 μl DMSO and the plate 
analyzed using a microplate reader. The absorbance values were recorded at a test 
wavelength of 560 nm. Cell viability for a given concentration was expressed as a 
percentage of the intensity of controls. The data was reported as the mean of triplicate 
experiments. 
 
 
Results 
 
 
Design of diblock copolymer based on enhanced compatibility between bicalutamide and 
hydrophobic core 
 
Using PEG-b-PLLA copolymer as a template, a series of diblock copolymers 
were designed by modifying the PLLA hydrophobic core with a carbonate monomer (i.e., 
5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one). The goal here was to enhance the 
compatibility between bicalutamide and the hydrophobic core of the micelle. Since the 
Flory-Huggins interaction parameter (χFH) has been shown to be a good indicator of 
polymer-drug compatibility [164, 166, 169], we determined χFH for PLLA and P(CB-co-
LA) using equation 2. The Hansen partial solubility parameters for bicalutamide, PLLA 
and P(CB-co-LA) were obtained based on the group contribution method using the 
Molecular Modeling Pro software (Table 4-1). The partial solubility parameters which 
account for dispersive forces between atoms, permanent dipole interactions between 
molecules and the tendency of molecules to hydrogen bond were used to calculate the 
solubility parameter which was subsequently used to compute the interaction parameter. 
Generally, as χFH approaches zero, compatibility between the polymer and the drug 
progressively increases since the polymer increasingly becomes a better thermodynamic 
solvent for the drug, resulting in improved drug solubilzation. The interaction parameter 
between bicalutamide and PLLA was calculated to be 11.06 while the interaction  
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Table 4-1. Calculated Hansen Solubility Parameters of bicalutamide, PLLA and P(CB-co-LA). 
 
 
a Total solubility parameters computed using partial solubility parameters and Equation 4-3.  b Flory-Huggins interaction 
parameters between bicalutamide and PLLA/ P(CB-co-LA) were calculated using Equation 4-4. 
 
 
 
Drug/polymer δ polarity 
(J/cm3)1/2 
δ dispersion 
(J/cm3)1/2 
δ hydrogen 
(J/cm3)1/2 
Total solubility 
parameters a 
χsp
 b 
      
Bicalutamide 8.89 19.66 12.43 24.90 - 
PLLA 2.48 19.73 20.92 28.68 11.06 
P(CB-co-LA)   1.43 21.62 8.48 23.27 7.34 
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parameter between bicalutamide and P(CB-co-LA) was computed to be 7.34. Hence, by 
introducing a carbonate monomer (5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one)  
into the PLLA hydrophobic core, our design suggested a potential increase in 
compatibility between bicalutamide and the micelle core and provided a logical 
justification for the synthesis of the poly (ethylene glycol)-b-poly(carbonate-co-lactide) 
[PEG-b-P(CB-co-LA)] copolymers.  
 
 
Synthesis and characterization of 5-Methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one 
 
The cyclic carbonate monomer (5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-
one) was synthesized as described by Pratt et. al. with slight modifications (Figure 4-1, 
Stage 1) [231]. Briefly, 2,2-bis(hydroxymethyl)propionic acid was used to obtain benzyl 
2,2-bis(methylol)propionate as an intermediate compound which was subsequently 
reacted with triphosgene to obtain the cyclic carbonate monomer. The chemical structure 
of the monomer was confirmed by mass and 1H NMR spectroscopy. From the mass 
spectrum, the molecular ion peak agreed with the calculated molecular weight of the 
synthesized monomer (250 g/mol). Also, as depicted in Figure 4-2A, the signal d at 7.5 
ppm is characteristic of the phenyl ring protons in the monomer; while the signal b at 4.2 
and 4.7 ppm was assigned to the methylene protons present in the carbonate ring. Other 
peak assignments include signals a and c at 1.3 and 5.2 ppm, representing methyl and 
benzyl CH2 protons, respectively in the monomer.  
 
 
Synthesis and characterization of peg-b-poly(carbonate-co-lactide) copolymer 
 
The synthesis route of PEG-b-P(CB-co-LA) is delineated in Figure 4-1, Stage 2. 
A series of PEG-b-P(CB-co-LA) copolymers with varying carbonate (10, 20 and 40 
mol%) content were synthesized by a one pot ring opening polymerization of L-lactide 
and 5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one using methoxy-PEG as the 
macroinitiator and stannous 2-ethylhexanoate as a catalyst. Among the series, the percent 
conversion of PEG-b-P(CB-co-LA) copolymer from carbonate was the highest for the 10 
mol% series and was estimated to be 87% based on 1H NMR spectroscopy. Further 1H 
NMR analyses was used to verify the composition of PEG-b-P(CB-co-LA) copolymers. 
From Figure 4-2B, the following resonance peaks were observed for the copolymers at δ: 
1.24 (CH3 in CB unit, s, 3H); δ: 1.55-1.57 (CH3 in LA unit, s, 3H); δ: 3.65 (CH2 in PEG, 
m, 4H); δ: 4.25-4.35 (CH2 in CB main chain m, 4H); δ: 5.12 (CH in LA unit q, 1H, and 
CH2 in CB side group, s, 2H) δ: 7.3(phenyl, m, 5H). All signals are assigned as methoxy 
poly(ethylene glycol) [mPEG], polymerized LA and CB units. The presence of the 7.3 
ppm multiplet peak indicates the existence of the carbonate group in the copolymer 
structure. In addition, the disappearance of the signal b at 4.2 and 4.7 ppm in the 
carbonate monomer (Figure 4-1A) and the emergence of the multiplet peak at δ:4.25-
4.35 ppm in the copolymer (Figure 4-1B) confirms the successful ring opening 
polymerization of the carbonate monomer and the formation of PEG-b-P(CB-co-LA) 
copolymers.  
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Figure 4-1. Synthesis method of PEG-b-P(CB-co-LA) copolymers. 
 
Stage 1: 5-Methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (carbonate monomer). 
Conditions: (i) KOH, DMF, 100°C, 15 h. (ii) Triphosgene, pyridine, CH2Cl2, -78 to 0°C. 
Stage 2: Ring opening polymerization of L-Lactide and 5-Methyl-5-benzyloxycarbonyl-
1,3-dioxane-2-one initiated by poly (ethylene glycol). 
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Figure 4-2. 1H NMR spectra in CDCl3 of (A) 5-Methyl-5-benzyloxycarbonyl-1,3-
dioxane-2-one (carbonate monomer) and (B) PEG114-b-P(CB9-co-LA33) copolymer. 
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Table 4-2 summarizes some characteristics of the synthesized PEG-b-PLLA and 
PEG-b-P(CB-co-LA) copolymers. The block copolymer molecular weight was calculated 
based on a comparative analysis of the four methylene protons of PEG (δ = 3.65 ppm), 
one methylene proton of lactide (δ = 5.12 ppm) and the five protons associated with the 
phenyl ring in the carbonate monomer observed in the 1H NMR spectrum. It is worth 
mentioning that since the lactide proton peak at 5.12 ppm is confounded with the signal 
from the two protons of the carbonate monomer, two- fifth of the carbonate signal at 7.3 
ppm was subtracted from the 5.12 ppm signal to obtain the actual lactide peak intensity 
used for molecular weight calculations. For the three copolymers studied: PEG114-b-
P(CB5-co-LA32), PEG114-b-P(CB8-co-LA24) and PEG114-b-P(CB9-co-LA5); the molecular 
weight were 8604 g mol-1, 8679 g mol-1 and 7510 g mol-1, respectively. Hence, the 
calculated molecular weight from 1H NMR spectroscopy was less than the predicted 
value of 10,000 g/mol. The computed molecular weights suggests the degree of 
polymerization (DP) of the P(CB-co-LA) core to be lower than the theoretical value. The 
calculated DP for 10, 20 and 40 mol% carbonate is 37, 32 and 14, respectively; while the 
theoretical DP for 10, 20 and 40 mol% carbonate is 54, 44 and 34, respectively. Gel 
permeation chromatography (GPC) analysis revealed PEG-b-P(CB-co-LA) copolymers 
to be broader than PEG-b-PLLA as evinced by the polydispersity index (Mw/Mn = 1.37, 
1.40 and 1.51) for PEG-b-P(CB-co-LA) copolymers compared to Mw/Mn = 1.07 for 
PEG-b-PLLA with the breadth of polydispersity increasing with carbonate. Furthermore, 
PEG-b-P(CB-co-LA) copolymers exhibited a unimodal peak and a representative plot 
comparing the GPC chromatograms for PEG-b-PLLA and PEG114-b-P(CB8-co-LA24) is 
shown in Figure 4-3. The unimodal peaks observed for the copolymer series suggests 
that successful copolymerization took place and that the insertion of carbonate and lactide 
monomers in the P(CB-co-LA) core was random.  
 
 
Preparation and characterization of peg-b-poly(carbonate-co-lactide) copolymer micelles 
 
The film sonication method described in a previous publication [230] was used to 
prepare both unloaded and bicalutamide-loaded polymeric micelles from the synthesized 
PEG-b-PLLA and PEG-b-P(CB-co-LA) copolymers[230]. The size distribution for both 
unloaded and bicalutamide-loaded polymeric micellar formulations as determined by 
dynamic light scattering (DLS) was relatively broad with a PDI of approximately 0.2, 
reflecting the possible presence of a population of aggregates. Figure 4-4A shows a 
typical size distribution plot obtained from DLS of PEG-b-P(CB-co-LA) micelles using a 
polymer concentration of 10 mg/mL. The size distribution is bimodal with a smaller size 
population ~ 53 nm (58%) and a larger population ~ 162 nm (42%). Effective 
hydrodynamic diameter for both unloaded and bicalutamide-loaded PEG-b-PLLA and 
PEG-b-P(CB-co-LA) micelles reported as the z-average based on mean intensitiy was 
determined by DLS. In the case of the unloaded micelles, the average diameter was found 
to range from 107 to 135 nm, while the average diameter of bicalutamide-loaded micelles 
ranged from 99 to 123 nm (Table 4-3). In both cases the 20 mol% carbonate copolymer 
had the largest average diameter while the 40 mol% carbonate copolymer had the 
smallest average diameter. 
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Table 4-2. Effect of carbonate content on the molecular weight as determined by 1H NMR and GPC and CMC of 
micelles at 25°C. 
 
 
a Subscripts reflect degree of polymerization of each monomer obtained from 1H NMR spectroscopy. b Mol% indicates 
carbonate content in P(CB-co-LA) block copolymer. Molecular weight calculated from 1H NMR spectroscopy,  
Mn,NMR = Mn,PEG + Mn,Carbonate + Mn,L-Lactide. cCMC (g/L) normalized with Mn from GPC. 
Block copolymer a Carbonate 
(mol%)b 
Theoretical 
mol. wt.   
(g /mol) 
Mn 
(NMR) 
Mn 
(GPC) 
Mw 
(GPC) 
Mw/Mn 
(GPC) 
CMC 
(g/L) 
CMCx107 
(mol-1)c 
 
          
PEG114-b-PLLA62 0 10000 9460 9104 9741 1.07 0.03 32.95  
PEG114-b-P(CB5-co-LA32)   10 10000 8604 6228 8533 1.37 0.005 8.03  
PEG114-b-P(CB8-co-LA24)  20 10000 8679 6384 8925 1.40 0.002 3.13  
PEG114-b-P(CB9-co-LA5) 40 10000 7510 5694 8573 1.51 0.004 7.02  
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Figure 4-3. Gel permeation chromatograms of PEG-b-PLLA and PEG114-b-
P(CB9-co-LA33)  copolymers. 
 
(A) PEG-b-PLLA [Mn = 9460 g/mol, Mw/Mn = 1.07] and (B) PEG114-b-P(CB9-co-LA33) 
[Mn = 9720 g/mol, Mw/Mn = 1.40] copolymers, both acquired in THF. 
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Figure 4-4. Micelle size distribution and surface morphology. 
 
(A) Dynamic light scattering histogram; and (B) transmission electron micrograph of 
micelle formulated with PEG-b-P(CB-co-LA) copolymer obtained using uranyl acetate 
staining.
                           
                               
          
B 
A 
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Table 4-3. Effect of polymer composition on drug loading and particle size of bicalutamide-loaded micelles. 
 
 
a Subscripts reflect degree of polymerization of each monomer obtained from 1H NMR spectroscopy. 
b Percentage of drug loaded into micelles based on 5% theoretical loading. c Mean particle size was determined 
by dynamic light scattering.  
Block copolymer a Drug loading 
(%) ± SD b 
Encap. efficiency 
(%) ± SD 
Bicalutamide/polymer 
core (mol%) 
Mean diameter  
± SD (nm)c 
     
PEG114-b-PLLA62 1.0 ± 0.31 22.04 ± 3.82 22 110 ± 0.9 
PEG114-b-P(CB5-co-LA32)   3.36 ± 0.18 72.68 ± 4.27 876 101 ± 1.0 
PEG114-b-P(CB8-co-LA24)  4.10 ± 0.23 81.96 ± 2.54 1097 123 ± 1.5 
PEG114-b-P(CB9-co-LA5) 1.38 ± 0.46 27.56 ± 2.91 779 99 ± 1.4 
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Particle size and surface morphology of these micelles were also determined by 
transmission electron microscopy (TEM). The polymer micelles have a broad size 
distribution with mean number average diameter below 50 nm (Figure 4-4B), which is 
lower than the z-average diameters obtained from DLS. TEM images also reveal a 
tendency for micellar aggregation and confirm that PEG-b-P(CB-co-LA) formed true 
spherical micelles in water with distinct boundaries as anticipated.  
 
The polymer micelles were further characterized by fluorescence spectroscopy to 
determine the critical micelle concentration (CMC). The CMC of the synthesized block 
copolymers decreased upon introduction of the carbonate monomer from ~3.3 to ~0.3 
µM for 0 and 20 mol% carbonate, respectively (Figure 4-5 and Table 4-2). The lower 
CMC values suggest that the inclusion of the carbonate moiety results in block 
copolymers thermodynamically more favored to self-assemble. The amount of 
bicalutamide loaded into micelles was calculated using equation 3 based on a 5% 
theoretical loading (i.e., 5 mg drug/ 100 mg polymer). PEG-b-P(CB-co-LA) copolymers 
exhibited higher drug loading compared to PEG-b-PLLA copolymer (Table 4-3). Among 
PEG-b-P(CB-co-LA) copolymer series, the highest loading (4.10%)  was observed for 
PEG114-b-P(CB8-co-LA24) copolymers which was at least four-fold better than PEG-b-
PLLA copolymer with regards to drug loading and had an encapsulation efficiency of 
approximately 82%. For PEG114-b-P(CB5-co-LA32) the drug loading was 3.36% which is 
about three times higher than that of PEG-b-PLLA and its encapsulation efficiency was 
roughly 73%. PEG114-b-P(CB9-co-LA5) copolymer had a drug loading of 1.38% and an 
encapsulation efficiency of 28% which is only slightly better than PEG-b-PLLA which 
had a drug loading of 1% and an encapsulation efficiency of 22%.  Since the degree of 
polymerization of P(CB-co-LA) hydrophobic core varied across the series, the drug 
loading was also assessed on a molar basis with respect to just the hydrophobic core (i.e., 
mol bicalutamide/mol hydrophobic core) to normalize the data. Here again, PEG114-b-
P(CB8-co-LA24) had the highest loading (1097%), followed by PEG114-b-P(CB5-co-LA32) 
and then PEG114-b-P(CB9-co-LA5)  which had 876% and 779% loading, respectively. In 
all cases, the drug loading on a molar basis in PEG-b-P(CB-co-LA) copolymer series was 
several fold higher than that of PEG-b-PLLA copolymer. 
 
To establish that PEG-b-P(CB-co-LA) micelles are capable of forming core-shell 
structures, the 1H NMR spectra of micelle samples in deuterated water (D2O) and 
DMSO-d6 was compared. Typical spectra for PEG114-b-P(CB8-co-LA24) micelles are 
shown in Figure 4-6. In D2O, only the PEG proton peaks can be detected while the 
signals for PLLA and polycarbonate are not evident. On the contrary, distinct peaks for 
PLLA and polycarbonate were observed in DMSO-d6 in addition to the PEG signal, 
suggesting that PEG-b-P(CB-co-LA) micelle form core-shell structures capable of 
encapsulating bicalutamide. This result is consistent with what is reported in the literature 
since the PEG forms the corona of the micelle and enhances its solvation in D2O while 
PLLA, polycarbonate and the encapsulated bicalutamide are in the core of the micelle 
and have restricted mobility in D2O. 
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Figure 4-5. Plots of intensity ratio I338/I333 from pyrene fluorescence emission 
spectra versus log concentration (g/L) of PEG-b-PLLA and PEG-b-P(CB-co-LA) 
copolymers. 
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Figure 4-6. 1H NMR spectra of bicalutamide-loaded PEG114-b-P(CB8-co-LA24) 
micelles. 
 
(A) In deuterated water (D2O) and (B) in DMSO-d6. 
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Sequence analysis 
 
Sequence distribution in a copolymer is frequently analyzed in terms of monomer 
triads. Considering that the hydrophobic core of the synthesized PEG-b-P(CB-co-LA) 
copolymers is made up of two monomers: carbonate (C) and lactide (L), this system has 
eight possible theoretical triads. Prior to the analysis of triads in the copolymer, the 
complete assignment for the carbonyl peaks in PEG-b-P(CB-co-LA) copolymer based on 
13C NMR spectra of homopolymers (PLLA and polycarbonate) was first determined and 
the results are shown in Figure 4-7A. To elucidate the arrangement of triads in PEG-b-
P(CB-co-LA) copolymer, 13C NMR spectrum was expanded for clarity (Figure 4-7B). 
The resonance peak at 169.6 ppm is assigned to the central carbonyl of LLL and LLC 
triads. Further upfield the resonance peak occurring at 169.45 ppm, which is due to the 
central carbonyl in the CLC and CLL triads. The resonance peak at 154.35 ppm is 
assigned to the central carbonyl of CCC and CCL triads, while the resonance peak at 
154.15 ppm is due to the central carbonyl of the LCL and LCC triads. The above data 
together with the observed splitting of the carbonyl peaks strongly suggests that the 
hydrophobic core PEG-b-P(CB-co-LA)  is a random copolymer.  Having confirmed the 
formation of random copolymers, the influence of carbonate monomer on the distribution 
of L-L and C-C sequence was assessed by comparing the 13C NMR spectra of 10, 20 and 
40 mol% carbonate copolymers.  From Figure 4-8, increasing CB contents from 10 to 40 
mol% decreases L-L sequence and increases C-C sequence (particularly for 40%). 
 
 
Thermal analysis 
 
The thermal properties of the synthesized block copolymers were examined using 
differential scanning calorimetry (DSC) and the thermograms of PEG-b-PLLA and PEG-
b-P(CB-co-LA) copolymers are shown in Figure 4-9. Within the temperature range 
examined (-90 to 175°C), two endotherm peaks at 51.5 and 155°C were observed for 
PEG-b-PLLA copolymer. An exotherm peak was also observed occurring at 88.5°C. To 
the contrary, only one endotherm peak, the fusion of PEG block, was observed for all the 
PEG-b-P(CB-co-LA) copolymers which appeared to shift slightly to higher temperatures 
with increasing carbonate content: 52.1, 52.9 and 53.8°C for 10, 20 and 40 mol%, 
respectively. 
 
 
In vitro release studies of bicalutamide from micelles 
 
The in vitro bicalutamide release study was performed in phosphate buffered 
saline (PBS, pH 7.4) at 37°C and 100 rpm. Figure 4-10 shows the cumulative percentage 
of bicalutamide released from PEG-b-PLLA (0 mol% carbonate) and PEG-b-P(CB-co-
LA) [10, 20 and 40 mol% carbonate] micelles. From the data, the release of bicalutamide 
is rapid from the micelles with 0 mol% carbonate content compared to micelles 
formulated using copolymers containing carbonate monomer. About 60% of the total 
drug was released within 6 h for 0 mol% carbonate content while the 10, 20 and 40 mol% 
carbonate content had a burst release of 40%. The 0 mol% carbonate copolymer used in  
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Figure 4-7. 13C NMR spectra of PEG114-b-P(CB8-co-LA24) copolymer. 
 
(A) Complete spectrum with peak assignments. (B) Expanded spectrum of specified 
regions (152 to 170 ppm) illustrating carbonyl regions of interest for sequence 
distribution analysis.  
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Figure 4-8. 13C NMR spectra comparative plot for 10, 20 and 40 mol% carbonate 
content demonstrating decrease in LLL sequence and increase in CCC sequence 
with increasing carbonate content. 
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Figure 4-9. DSC thermograms of PEG-b-PLLA and PEG-b-P(CB-co-LA) 
copolymers. 
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Figure 4-10. Effect of carbonate content on bicalutamide release from PEG-b-
PLLA and PEG-b-P(CB-co-LA) micelles. 
 
Release experiments were performed in triplicate in PBS at 37°C and 100 rpm. 
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this study had a GPC molecular weight of 5200 g mol-1 to ensure that all copolymers used 
in the release study had similar molecular weights. 
  
 
Evaluation of in vitro cytotoxicity 
 
To determine inhibitory effect of bicalutamide-loaded micelles formulated with 
PEG-b-P(CB-co-LA) copolymer on cell proliferation, the cytotoxicity of free 
bicalutamide dissolved in methanol and that of bicalutamide formulated in micelles was 
evaluated in LNCaP human prostate cancer cell line for 48 h. From Figure 4-11, micelle-
formulated drug showed significant inhibition of LNCaP cell growth in a dose-dependent 
manner, which was similar to that obtained using free drug. The IC50 of bicalutamide-
loaded micelles was 74 µM while that of free drug was 80 µM. However, no direct 
comparison can be made since we had to dissolve free drug in methanol, whereas we 
prepared micelles in PBS.  
 
 
Discussion 
 
In spite of the numerous advantages associated with polymeric micelles as drug 
delivery systems, their application as therapeutics has been limited by low loadings and 
stability. The equilibrium partitioning of a hydrophobic drug into the hydrophobic core of 
polymeric micelles at a specific temperature is governed by the molar free energy of the 
drug, which depends on the mixing entropy and the enthalpy interaction between the drug 
and the polymer, as well as the amount of pressure-volume work required in putting a 
drug molecule into the lipophilic core [232]. It has been shown for polymeric micelles 
that lowering the enthalpy interaction contribution of the free energy improves drug 
loading. This may be achieved by carefully selecting the core-forming block such that its 
solubility parameters and that of the drug are essentially of the same order, indicating 
superior drug-polymer compatibility. The Flory-Huggins interaction parameter (χFH) is a 
good measure of the compatibility between the core-forming block of the copolymer and 
the drug, with lower values pointing to enhanced compatibility and superior loading. 
 
The purpose of this study was to increase bicalutamide loading into micelles by 
designing polymers based on improved drug-polymer solubility determined using the 
Flory-Huggins interaction parameter. Inclusion of carbonate monomer which contains a 
bulky phenyl ring resulted in decreased χFH values. In the strictest sense, χFH values above 
the 0.5 critical value allude to immiscibility between drug and polymer since phase 
separation of the polymer-drug mixture commences, while χFH values below 0.5 suggest 
that the drug and polymer are soluble in each other. The Flory-Huggins theory is based 
on the assumption that the orientation of molecules within the polymer-drug system is 
completely random and that upon mixing the polymer and drug no specific interactions 
are created or destroyed. However, since these assumptions are not entirely true for our 
system, the χFH values obtained was merely used as a guide in predicting enhanced 
compatibility in relative terms based on the observed trend of lower χFH values. It also 
provided a reasonable estimate of the closeness of the solubility parameters of  
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Figure 4-11. Effect of free and PEG-b-P(CB-co-LA) micellar formulation of 
bicalutamide on inhibition of LNCaP cell proliferation  48 h post treatment. 
 
Cell viability was estimated by MTT assay and expressed as percent of 1% methanol or 
blank micelle controls. All data represent the mean ± S.D. of triplicates. 
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P(CB-co- LA) hydrophobic core and that of bicalutamide in the Hansen partial solubility 
three dimensional space compared to PLLA and bicalutamide. 
 
A two-step reaction from 2,2-bis(hydroxymethyl)propionic acid was used to 
obtain the cyclic carbonate monomer (5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one) 
which was subsequently employed in the synthesis of PEG-b-P(CB-co-LA) copolymer 
(Figure 4-1). All copolymers were obtained through ring opening polymerization of 
PEG, lactide and carbonate. Since our objective was to vary hydrophobic group to 
increase drug loading into micelles, we did not vary the molecular of PEG in our 
copolymers to determine the effect of PEG molecular weight on micelle number and 
diameter. 
 
Various synthetic schemes have been reported for synthesizing 5-methyl-5-
benzyloxycarbonyl-1,3-dioxane-2-one [231, 233-235]. However, we employed the 
method described by Pratt et. al. since the yield of the cyclic carbonate monomer is 
higher for this method. The yield of the carbonate monomer (95%) we obtained was 
similar to that obtained by Pratt et. al.[231] and our  characterization data matched the 
literature [234, 236]. The ring opening polymerization of Lactide (LA) and the carbonate 
monomer was performed in bulk at 130°C with Sn(Oct)2 as catalyst (10 mol% relative to 
mPEG) (Figure 4-1). We chose Sn(Oct)2 as a catalyst since it is FDA approved and 
Sn(Oct)2-catalyzed polymerization does not result in racemization of lactide at 
temperatures below 200°C [237].  Also, Sn(Oct)2 is a strong transesterification agent 
yielding copolymers with a randomized microstructure. Guan and coworkers reported 
synthesizing and characterizing a similar copolymer, however, they used Et2Zn as the 
catalyst and a reaction temperature of 100°C [235]. While a 7 h reaction time was 
sufficient for complete polymerization of PEG-b-PLLA, it resulted in incomplete 
polymerization of PEG-b-P(CB-co-LA) copolymers. A reaction time of 24 h was used for 
PEG-b-P(CB-co-LA) copolymers since complete polymerization was observed after 24 h. 
The observed lower DP of P(CB-co-LA) core compared to the predicted DP suggests a 
lowering of the carbonate and lactide monomer reactivity with increasing carbonate 
content. From 1H NMR spectroscopy, the carbonate monomer was observed to have 
higher reactivity compared to lactide. Also, increasing carbonate content from 10 to 40 
mol% resulted in lower reactivity for both carbonate and lactide monomers: carbonate 
reactivity decreased from 87% to 61% while lactide reactivity decreased from 66% to 
24%. Overall, the molecular weight decreases while the molecular weight distribution 
increases with increasing carbonate content. This may be due to progressively higher 
levels of intra-(backbiting) and intermolecular (redistribution) transesterification side 
reactions resulting in the formation of cyclic oligomers as the carbonate content 
increases. 
 
PEG-b-P(CB-co-LA) copolymers self assembled into micelles with a core-shell 
structure (Figure 4-6). The average diameter of micelles formulated from PEG-b-P(CB-
co-LA) copolymers  was in the range of 99 to 123 nm and appeared to be independent of 
carbonate content but correlated well with molecular weight. The introduction of 
carbonate monomer enhanced bicalutamide loading (Table 4-3), which confirmed our 
prediction based on the Flory-Huggins interaction parameter of PEG-b-P(CB-co-LA) 
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having superior bicalutamide loading to PEG-b-PLLA copolymer. However, this increase 
was not linear with carbonate content and seemed to peak at the 20 mol% content where a 
four-fold increase in bicalutamide loading was observed compared to PEG-b-PLLA 
copolymer. We also observed that while the drug loading (as defined by equation 3) in 
PEG114-b-P(CB5-co-LA32) copolymer was approximately three fold higher than that of 
PEG114-b-P(CB9-co-LA5), the drug loading on a molar basis in the hydrophobic core was 
about the same. Hence, the rather low drug loading observed for the 40 mol% carbonate 
series may be due to a couple of factors: (1) its relatively smaller molecular weight 
compared to the 10 and 20 mol% carbonate series and (2) the decreased PEG-b-P(CB-co-
LA) copolymer solubility with increasing carbonate content. As the feed carbonate 
content increases, the reactivity of both the lactide and carbonate decreases. Lactide 
reactivity decreases from 86% to 24% while carbonate reactivity decreases from 82% to 
64% for 0 mol% to 40 mol% carbonate content.  This coupled with the polymer 
degradation effect associated with intramolecular transesterifaction leads to the decreased 
molecular weight observed with increasing carbonate content. It is well known, that drug 
loading is related to the molecular weight of the hydrophobic core. Large hydrophobic 
blocks form large micelle cores and require less amount of work to put a molecule of 
drug into the hydrophobic core due to relatively lower internal pressure. Drug loading is 
also influenced by the interaction between the drug and the copolymer as well as the 
solubility of the copolymer. As the carbonate content increases the interaction between 
bicalutamide and the copolymer increases, however, the solubility of the copolymer 
decreases. Hence, the trade-off between drug-polymer interaction and polymer solubility 
influences the extent of drug loading. At carbonate content up to 20 mol% the effect of 
drug-polymer interaction predominates resulting in the observed improved drug loading, 
while at 40 mol% carbonate content the effect of decreased copolymer solubility 
dominates contributing to the observed reduction in drug loading. As such, the PEG-b-
P(CB-co-LA) 20 mol% carbonate series exhibit optimum drug loading. It is worth 
mentioning that we also synthesized PEG-b-Polycarbonate (PEG-b-PCB) using the same 
polymerization conditions for PEG-b-P (CB-co-LA) copolymer. However, the solubility 
of this polymer in tetrahydrofuran (THF) and commonly used organic solvents was poor; 
making characterization using GPC and NMR difficult. From Table 4-2, drug solubility 
appears to correlate with the CMC. Among the series of copolymers, 0 mol% carbonate 
has the highest CMC value of 32.95 x 10-7 mol-1 and the lowest drug loading of 1.0%  ± 
0.31, while the 20 mol% carbonate series has the lowest CMC value 3.13 x 10-7 mol-1and 
the highest drug loading 4.1% ± 0.23. The decrease in the CMC upon inclusion of the 
carbonate monomer clearly demonstrates that they have higher thermodynamic stability 
compared to PEG-b-PLLA. A high thermodynamic stability is desirable for in vivo 
stability of polymeric micellar systems. 
 
Sequence distribution of random copolymers can influence fundamental polymer 
properties such as solubility, mechanical and thermal properties. The observed decrease 
in L-L sequence and increase in C-C sequence as carbonate content increases can be used 
to elucidate the behavior of the PEG-b-P(CB-co-LA) copolymers. When the ratio of 
lactide to carbonate monomer is small, the lactide segments in the random copolymer are 
sparsely distributed and have a lower probability of interacting with the ethylene oxide 
segments since the lactide is buried in the carbonate segments hence preventing 
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intermolecular interactions. This may explain the observed sharp decrease in lactide 
reactivity (from 66 to 24%). Conversely, at high lactide to carbonate ratios, lactide 
segments tend to undergo intramolecular transesterification and lead to smaller molecular 
weight polymers due degradation. Hence, these two competing phenomena affect 
polymer molecular weight depending on which factor is more dominant and the optimum 
molecular weight is obtained when they are balanced. In the present study, the 20 mol% 
carbonate series exhibited optimum molecular weight which translated into superior drug 
loading and thermodynamic stability.  
 
Thermal analysis of the copolymers by differential scanning calorimetry 
confirmed the semicrystalline nature of PLLA. The two endotherm peaks observed for 
PLLA reflect the melting temperature of PEG (Tm = 51.5°C) and melting temperature of 
PLLA (Tm = 155°C), respectively. Also the exotherm peak occurring at 88.5°C was also 
observed which may signify the onset of cold crystallization. More importantly, the data 
revealed that the introduction of the carbonate monomer into the poly (L-lactide) chain 
resulted in a reduction in crystallinity as demonstrated by the absence of the cold 
crystallization and melting peaks in the copolymers. These results suggest that the 
carbonate monomer randomly incorporated into the PLLA chain and resulted in a 
shortening of lactide sequences thereby hindering the crystallization process. Our data is 
consistent with the literature and other groups have reported similar trends [235, 238].  
 
In vitro release studies clearly showed the introduction of the carbonate monomer 
to result in better sustained release of bicalutamide from the micelle core compared to 
PEG-b-PLLA. The improved sustained release of the carbonate modified copolymers can 
be attributed to better compatibility between bicalutamide and the hydrophobic block of 
the copolymer as well as they being more amorphous compared to PEG-b-PLLA. Both 
PEG-b-PLLA and PEG-b-P(CB-co-LA) copolymers exhibited fast release during the first 
6 h. This burst release is assumed to be due to drug trapped with the PEG corona and at 
the corona-core interface. Increasing carbonate content from 10 to 40 mol% does not 
appear to alter the release profile of bicalutamide over the 150 h period studied.  The 
release behavior of hydrophobic drugs from spherical micelles is known to depend on the 
properties of the hydrophobic core.  The inhibitory effect of bicalutamide-loaded micelles 
formulated with PEG-b-P(CB-co-LA) copolymer on cell proliferation was comparable to 
free drug solubilized in methanol in LNCaP cells. This result suggests that bicalutamide-
loaded micelles formulated with PEG-b-P(CB-co-LA) copolymer did not diminish the 
inhibitory effect of bicalutamide on cell proliferation since the PEG-b-P(CB-co-LA) 
copolymers themselves were not toxic in LNCaP cells. Although methanol is a toxic 
reagent, its intrinsic toxicity does not significantly alter the results since an equivalent of 
1% v/v methanol was used with appropriate controls. Moreover, we have previously used 
dimethyl sulfoxide (DMSO), which was found to kill tumor cells. 
 
 
Conclusions 
 
We established that chemical tailoring of the PEG-b-PLLA micelle core through 
the introduction of carbonate moieties enhanced the solubilization of the highly lipophilic 
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drug bicalutamide. This result was consistent with predictions made based on the Flory-
Huggins interaction parameters computed for polymer/bicalutamide pairs using the group 
contribution method. Bicalutamide loading in PEG-b-P(CB-co-LA) micelles was four 
times better than in PEG-b-PLLA. PEG-b-P(CB-co-LA) copolymers were also shown to 
significantly solubilize bicalutamide as aqueous micellar solutions had drug 
concentrations approximately 800-fold higher than the saturated solubility of 
bicalutamide in water. In water, PEG-b-P(CB-co-LA) copolymers formed spherical 
micelles with CMC values up to 10 times lower than PEG-b-PLLA copolymers (i.e., 0.31 
µM for 20 mol% carbonate and 3.3 µM for 0 mol% carbonate), indicating that 
introduction of carbonate monomer results in copolymers which are more 
thermodynamically favored for self-assembly and exhibit better thermodynamic stability. 
Finally, PEG-b-P(CB-co-LA) copolymers was found to result in slower bicalutamide 
release compared to PEG-b-PLLA copolymers. Even though the inhibitory effect of 
bicalutamide-loaded PEG-b-P(CB-co-LA) micelles on LNCaP cell proliferation was 
similar to free drug these results are quite significant since drug dissolved in methanol 
would not be suitable for clinical application. In conclusion, these studies highlight the 
effect of chemically modifying the PEG-b-PLLA micelle core with a carbonate monomer 
on drug loading, release and stability and demonstrate their potential use as drug delivery 
vehicles. In vivo testing of bicalutamide loaded PEG-b-P(CB-co-LA) micelles for tumor 
treatment is ongoing and will be reported in a separate paper. 
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CHAPTER 5.    COMBINATION THERAPY OF ANTIANDROGEN AND XIAP 
INHIBITOR FOR TREATING ADVANCED PROSTATE CANCER* 
 
 
Introduction 
 
Prostate cancer is the most frequently diagnosed neoplasm and the second leading 
cause of cancer mortality affecting men in the United States [239]. Nearly all prostate 
carcinomas are initially androgen dependent [240]. Hence, the disease is classified as 
hormone-dependent or hormone-refractory depending on the sensitivity of the androgen 
receptor (AR) to androgens. To date, androgen ablation therapy using antiandrogens 
remains the gold standard for treating hormone-dependent prostate cancer and is effective 
in approximately 70% of patients [241]. In spite of its initial efficacy, androgen ablation 
results in remission lasting two to three years after which the disease recurs in its more 
aggressive hormone refractory form for which there is no cure [242, 243]. Consequently, 
there is an urgent need for novel therapeutic strategies for treating hormone refractory 
prostate cancer. 
 
We have previously shown that combination therapy targeting AR and XIAP 
using bicalutamide and embelin is a promising approach to treat prostate cancer [11]. 
However, first generation antiandrogens such as bicalutamide exhibit agonist 
characteristics upon prolonged treatment due to increased AR gene amplification [244, 
245]. Therefore, we hypothesized new antiandrogens more effective than bicalutamide 
will be beneficial in treating advanced prostate cancer when combined with XIAP 
modulation. Hence, our group synthesized a novel antiandrogen ((S)-N-(4-cyano-3-
(trifluoromethyl) phenyl)-3-((4-cyanophenyl)(methyl)amino)-2-hydroxy-2-
methylpropanamide) (CBDIV17)) using bicalutamide as a starting chemical scaffold due 
to its relatively high AR binding affinity and selectivity (Figure 5-1A).  
 
Systemic delivery of anticancer agents to solid tumors is still a challenge. Aside 
being toxic, current solubilizing agents such as Cremophor® EL and DMSO contribute to 
erratic extravasation to tumors leading to sub-optimal therapeutic effects [246]. 
Polymeric micelles are an elegant way to improve the solubility, stability and 
extravasation of drugs to tumors thereby enhancing therapeutic potential [11, 170, 246-
248]. They self-assemble from amphiphilic diblocks and are typically nanosized, 
spherical structures with a hydrophobic core which serves as a cargo space for 
hydrophobic drugs. We recently engineered and synthesized polyethylene glycol-b-poly 
(carbonate-co-lactide) (PEG-b-p(CB-co-LA)) copolymers with excellent drug loading 
and stability for optimal delivery of bicalutamide [170], and we will explore the use of 
this copolymer to formulate CBDIV17 and embelin in this work. 
 
 
*Danquah M, Duke CB, 3rd, Patil R, Miller DD, Mahato RI. Combination Therapy of 
Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer. Pharm Res. 
2012; 29: 2079-91.
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Figure 5-1. Synthesis and characterization of (S)-N-(4-cyano-3-
(trifluoromethyl)phenyl)-3-((4-cyanophenyl)(methyl)amino)-2-hydroxy-2-
methylpropanamide) (CBDIV17).  
 
(A) Synthesis scheme of CBDIV17 and (B) 1H NMR spectrum of CBDIV17. 
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The focus of the present study is three fold: First to demonstrate the superiority of 
CBDIV17 in treating prostate cancer compared to bicalutamide. Second, to evaluate two 
XIAP inhibitors: embelin and 2,5-dihydroxy-3-(2-[4-(2-m-tolyl-ethyl)-phenyl]-ethyl)-
[1,4] benzoquinone (embelin-6g) to determine the more appropriate compound to 
combine with CBDIV17. Third, to show that combination of CBDIV17 and chosen XIAP  
inhibitor is more potent than control or monotherapy in inhibiting cell growth and 
inducing apoptosis in vitro as well as in regressing prostate cancer tumors in xenograft 
mouse model. 
 
 
Materials and Methods 
 
 
Materials 
 
SYBR Green real-time RT-PCR master mix and reverse transcription reagents 
were purchased from Applied Biosystems (Foster City, CA). Human total XIAP ELISA 
kit was purchased from R&D Systems (Minneapolis, MN). Primary and secondary 
antibodies were purchased from Abcam (Cambridge, MA). All other reagents were 
obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated and were used as 
received. 
 
 
Synthesis of CBDIV17 
 
CBDIV17 was synthesized by treating 3-Bromo-2-hydroxy-N-(4-isocyano-3-
trifluoromethyl-phenyl)-2-methyl-propionamide (bromide N) with K2CO3 in 2-propanol 
at reflux for 2 h before filtering the solution. The reaction mixture was concentrated to a 
paste, dissolved in EtOAc, and washed with water before drying using Na2SO4 and 
concentrating to a resin. The epoxide intermediate was then treated with 4-
aminobenzonitrile in 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol at 100 oC overnight. Flash 
chromatography on silica gel (EtOAc/Hexanes 20-100%) afforded (S)-N-(4-cyano-3-
(trifluoromethyl)phenyl)-3-((4-cyanophenylamino)-2-hydroxy-2-methylpropanamide), 
which was treated with MeI and Hünig’s base in a pressure vessel for 3 days at 110 °C. 
Flash chromatography on silica gel (EtOAc/Hexanes 20-100%) afforded CBDIV17.  
 
 
In vitro cell viability assays 
 
LNCaP and C4-2 cells (American Type Culture Collection) were incubated in 
RPMI 1640 media, 10% fetal bovine serum and 1% antibiotic-antimycotic at 37°C in 
humidified environment of 5% CO2 and subcultured every 3-4 days to maintain 
exponential growth. Cells were seeded in 96-well plates at a density of 1 x 104 viable 
cells/well and incubated for 48 h. The cells were exposed to antiandrogen or XIAP 
inhibitor at various concentrations for specified time periods. At the end of treatment, 20 
µl of MTT (5 mg/ml) was added to each well, incubated for 3-4 h and analyzed at a test 
wavelength of 560 nm. Cell viability was expressed as a percentage of the intensity of 
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controls. LNCaP cells are androgen dependent and non-bone metastatic prostate cancer 
cells with low tumorigenicity. In contrast, C4-2 cells (a subline of LNCaP) are androgen 
independent and more tumorigenic compared to LNCaP cells. These cells lines were 
selected as in vitro models since they both express the androgen receptor and possess a 
threonine to alanine mutation of amino acid 877 (T877A) in the androgen receptor [249, 
250]. Furthermore, LNCaP represents hormone dependent prostate cancer whereas C4-2 
is a model for advanced prostate cancer. 
 
 
Real-time RT-PCR 
 
RNA extraction and real-time RT-PCR was performed as previously described 
[11]. Primers are as follows: AR: forward, 5’-AGC CAT TGA GCC AGG TGT AG-3’; 
reverse, 5’-CGT GTA AGT TGC GGA AGC C-3’. PSA: forward, 5’-GTG GGT CCC 
GGT TGT CT-3’; reverse, 5’-AGCCCAGCTCCCTGTCT-3’. XIAP: forward, 5′-TGT 
TTC AGC ATC AAC ACT GGC ACG-3′; reverse, 5′- GCA TGA CAA CTA AAG CAC 
CGG AC-3′. Cyclin D1: forward, 5’- GAT GCC AAC CTC CTC AAC GAC -3’; reverse, 
5’- CTC CTC GCA CTT CTG TTC CTC -3’. 
 
 
Western blot analysis 
 
Cells were treated with embelin and embelin-6g for 96 h. Subsequently, cells 
were lysed using RIPA buffer (Sigma-Aldrich, St. Louis, MO) and protein concentration 
measured with bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL). The 
lysate was boiled for 5 mins, subjected to a 15% SDS-PAGE and transferred to a PVDF 
membrane using iBlotTM system (Invitrogen, Carlsbad, CA). Membranes were blocked 
with 3% BSA in 1x tris buffered saline (TBS) at room temperature for 1 h and then 
incubated with primary antibodies at 4°C overnight, followed by incubation with 
secondary antibody conjugated with horseradish peroxidase (HRP) at room temperature 
for 1 h. The signal of target proteins was detected using Immun-Star HRP 
chemiluminescent kit (BioRad, Hercules, CA) or Li-COR Odyssey® infrared imaging 
system (Li-COR, Lincoln, NE). 
 
 
XIAP detection using ELISA 
 
C4-2 cells were treated with embelin or embelin-6g for 48 h. Cells were lysed and 
XIAP concentration detected using Human XIAP ELISA kit as described in the 
manufacturer’s protocol. 
 
 
Apoptosis and cell cycle analysis 
 
Following treatment with 25 µM antiandrogen for 72 h, cells were trypsinized and 
fixed in 70% ice-cold ethanol and washed with PBS. Samples were resuspended in 500 µl 
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of propidium iodide solution containing RNAse A (BD Pharmingen, San Diego, CA) for 
15 min at room temperature. Relative DNA content per cell was acquired by measuring 
DNA fluorescence using flow cytometry and subsequent analysis performed with Modfit 
program. 
 
 
Confocal microscopy 
 
Confocal microscopy was used to elucidate the effect of XIAP inhibitor on DHT 
stimulated nuclear translocation of AR. Briefly, LNCaP and C4-2 cells were cultured in 
chamber slides in RPMI media and treated with XIAP inhibitor (5 µM) or DMSO for 3 h 
and then incubated with DHT (1 nmol/L) for an additional 3 h. Cells were fixed in 
methanol at room temperature for 10 min, washed with PBS, and incubated with PBS 
containing 10% (w/v) rabbit serum for 2 h at room temperature. Afterwards, the cells 
were treated with anti-AR antibody (1:100 in PBS buffer) 4oC overnight. Cells were then 
washed with PBS and incubated with FITC-conjugated secondary antibody for 1 h at 
room temperature followed by counterstaining with DAPI. Slides were examined under a 
Zeiss LSM-710 confocal microscope at 63× objective lens magnification and data 
processed using a ZEN 2009 LE software. 
 
 
Preparation and characterization of micelles 
 
The film sonication method was used for loading drug into the core of PEG-b-
p(CB-co-LA) micelles at a theoretical drug loading of 5%. Briefly, 5 mg of drug and 95 
mg of PEG-b-p(CB-co-LA) was dissolved in 5 ml methanol. The mixture was allowed to 
stir for 5 min and the solvent evaporated. The resulting film was hydrated and sonicated 
for 7 min using a Misonix ultrasonic liquid processor (Farmingdale, NY) with an output 
power of 25 W. The resultant formulation was then centrifuged at 5,000 rpm for 10 min 
to separate micelles from residual free drug. Subsequently, the supernatant was filtered 
using a 0.22 μm nylon filter. 
 
 
In vivo efficacy of CBDIV17 and embelin-loaded micelles in mouse xenografts 
 
All animal experiments were performed in a humane manner in accordance with 
NIH animal use guidelines and the protocol approved by the Animal Care and Use 
Committee (ACUC) at the University of Tennessee Health Science Center. Xenograft 
flank tumors were induced in 6 week old male athymic nu/nu mice (Jackson Laboratory, 
Bar Harbor, ME) by subcutaneous injection of 3 million C4-2 cells suspended in 1:1 
media and matrigel. When tumors reached approximately 50 mm3, mice were 
randomized into four groups of 7 mice, minimizing weight and tumor size differences. 
Each group was treated with intratumoral injection of blank micelles or drug-loaded 
micelles. Tumors were measured with a caliper prior to each injection, and their volumes 
calculated using the formula of (width2 x length)/2.  
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Results 
 
 
Synthesis and characterization of CBDIV17 
 
CBDIV17 was synthesized as shown in Figure 5-1A and characterized by ESI 
and high-resolution mass spectrometries, 1H NMR (Figure 5-1B) and 13C NMR. MS 
(ESI): calculated for C20H17F3N4O2 402.1, found 400.9 [M - H]. HRMS calculated for 
C20H17F3N4O2 403.13818 found 403.13696. 1H NMR (300 MHz, chloroform-d) 10.42 - 
10.51 (m, 1H), 8.33 - 8.41 (m, 1H), 8.14 - 8.24 (m, 1H), 8.06 (d, J = 8.54 Hz, 1H), 7.43 
(d, J = 9.16 Hz, 2H), 6.84 (d, J = 9.16 Hz, 2H), 6.15 (s, 1H), 3.81 (d, J = 15.26 Hz, 1H), 
3.62 (d, J = 14.95 Hz, 1H), 3.01 (s, 3H), 1.37 - 1.43 (m, 3H) ppm (Figure 5-1). 13C NMR 
(101 MHz, DMSO-d6) δ 175.4, 152.3, 142.9, 136.1, 132.7, 131.3 (q, J = 31.5 Hz), 122.8, 
122.4 (q, J = 276.6 Hz), 120.2, 117.5 (q, J = 5.1 Hz), 115.7, 112.0, 101.9, 95.9, 76.7, 
59.3, 39.7, 39.4 (spt, DMSO), 23.7, 0.0 (s, TMS) ppm.  
 
 
CBDIV17 and bicalutamide inhibit LNCaP and C4-2 cell growth  
 
We first assessed anticancer activity of CBDIV17 and bicalutamide in LNCaP 
and C4-2 cells. Both cells are AR positive and possess the T877A androgen receptor 
mutant. As shown in Figure 5-2A and B, bicalutamide and CBDIV17 exhibited dose-
dependent anticancer activities in both cells when treated with 0, 10, 25 and 50 µM for 72 
h. From our results, CBDIV17 was more potent than bicalutamide at each dose in both 
cell lines. IC50 for CBDIV17 was 12 and 21 µM in LNCaP and C4-2 cells, respectively. 
In contrast, bicalutamide had an IC50 of 46 µM in LNCaP with only a modest anticancer 
effect being observed at 50 µM in C4-2 cells. Furthermore, a time course study using a 
drug concentration of 25 µM for 24 and 72 h revealed the anticancer effect of 
bicalutamide and CBDIV17 to be time-dependent (Figure 5-2C). Our data suggests 
CBDIV17 displays superior anticancer activity in LNCaP cells even after a short 
exposure time. Additionally, there is a dramatic increase in inhibition of prostate cancer 
cell growth for CBDIV17 compared to bicalutamide when cell exposure to drug is 
increased from 24 to 72 h. 
 
We next examined the influence of androgens on the anticancer activity of 
CBDIV17 since it is expected to function as a putative anti-androgen. LNCaP cells were 
cultured in androgen-depleted media with 5% charcoal-stripped serum (CSS). Cells were 
treated for 24 or 72 hours with or without 1nM of the synthetic androgen 5α-
Dihydrotestosterone (DHT) combined with DMSO (vehicle), CBDIV17 and bicalutamide 
(positive control). Our data suggests that treatment of cells with DHT stimulated cell 
growth (Figure 5-3). However, even in the presence of DHT, cell growth was inhibited 
when cells were treated with bicalutamide or CBDIV17, with CBDIV17 being more 
potent than bicalutamide. 
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Figure 5-2. Anticancer effect of antiandrogen on prostate cancer cells. 
 
(A and B) IC50 of bicalutamide and CBDIV17 in LNCaP and C4-2 cells were calculated 
following treatment with 0, 10, 25 and 50 μM of drug for 72 h and cell viability 
determined by MTT assay. (C) Effect of antiandrogen with time was determined by 
exposing LNCaP and C4-2 cells to 25 μM of drug for 24 and 72 h. Cell viability was then 
determined by MTTassay. Results are represented as the mean ± SD of triplicates. *p < 
0.05; **p < 0.01 using student’s unpaired t-test. 
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Figure 5-3. Effect of bicalutamide and CBDIV17 on cell proliferation in the 
presence of androgen. 
 
LNCaP cells were cultured in androgen-depleted media with 5% charcoal-stripped serum 
(CSS). Cells were treated for 24 or 72 hours with or without 1nM of the synthetic 
androgen 5α-Dihydrotestosterone (DHT) combined with DMSO, bicalutamide and 
CBDIV17. Results are represented as the mean ± SD of triplicates. * p < 0.05;  
** p < 0.01 using student’s unpaired t- test. 
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CBDIV 17 and bicalutamide induce apoptosis and alter cell cycle of LNCaP and C4-2 
cells  
 
The effect of bicalutamide and CBDIV17 on the cell cycle of LNCaP and C4-2 
cells was determined following treatment with 25 µM of these drugs for 72 h. We 
observed a significant reduction in the percent of cells in S phase in both cell lines 
(Figure 5-4). In LNCaP cells, 27% of control cells were in the S phase, whereas 16% of 
bicalutamide treated cells and 6.5% of CBDIV17 treated cells were in the S phase. For 
C4-2 cells, 32.6% of control cells were in the S phase whilst 27.7% of bicalutamide 
treated cells and 10.7% of CBDIV17 treated cells were in the S phase. Furthermore, drug 
treatment in LNCaP cells did not result in significant decrease in percent of cells in the 
G2/M phase. In contrast, percent of C4-2 cells in the G2/M phase decreased from 16% in 
control cells to 8.9% in bicalutamide treated cells and to 4.8% in CBDIV17 treated cells. 
 
Treatment with bicalutamide and CBDIV17 resulted in a significant increase in 
the percentage of cells in the G0/G1 phase in both cell lines. LNCaP cell population in 
the G0/G1 phase increased from 67% in control cells to 76% and 87% for bicalutamide 
and CBDIV17 treated cells, respectively. For C4-2 cells, percentage of cells in G0/G1 
phase increased from 51.4% in control cells to 63.3% and 84.5% for bicalutamide and 
CBDIV17 treated cells, respectively. Finally, a significant increase in the sub-G1 phase 
(indicative of apoptosis) was observed upon administration of bicalutamide (13-fold) and 
CBDIV17 (18-fold) to LNCaP cells (Figure 5-4). In C4-2 cells, treatment with 
bicalutamide resulted in a 7-fold increase in sub-G1 whereas CBDIV17 led to a 10-fold 
increase in percentage of cells in subG1 phase. These data demonstrate that CBDIV17 
was more potent than bicalutamide in altering cell cycle leading to G1 arrest, reducing 
DNA synthesis and inducing cell death. 
 
 
Embelin-6g is more potent than embelin in repressing XIAP expression 
 
After demonstrating that CBDIV17 is more potent than bicalutamide, we next 
evaluated the mechanism and therapeutic potential of embelin and embelin-6g (Figure 
5-5A) to determine which XIAP inhibitor should be used in conjunction with CBDIV17 
for combination therapy. Since embelin-6g is reported to be a more potent XIAP inhibitor 
than embelin [251], we examined its effect on XIAP expression. Our observations 
indicated that embelin-6g repressed XIAP mRNA expression by 2-fold compared to 
embelin (Figure 5-5B). We also assessed the effect of these drugs on XIAP protein using 
ELISA. Embelin-6g more potently inhibited XIAP expression compared to embelin with 
the effect being almost twice that of embelin (Figure 5-5C). 
 
 
Embelin and its derivative downregulate AR expression and repress AR mediated activity 
 
In addition to elucidating the effect of embelin and embelin-6g on XIAP 
expression, we investigated the effect of these drugs on the androgen receptor signaling 
axis which is a key regulatory gene involved in prostate cancer. First, we examined the 
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Figure 5-4. Effect of bicalutamide and CBDIV17 on apoptosis and cell cycle of 
LNCaP and C4-2 cells. 
 
Cells were treated with antiandrogen (25 µM) for 72 h, stained with propidium iodide and 
analyzed on a flow cytometer. * p < 0.05 using student’s unpaired t-test. 
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Figure 5-5. Embelin and embelin-6g suppress XIAP expression. 
 
(A) Chemical structures of embelin and embelin-6g. (B) 1x105 C4-2 cells were treated 
with embelin or embelin-6g for 48 h, RNA extracted and XIAP expression at mRNA 
level determined using real-time RT-PCR. (C) 1x106 C4-2 cells were treated with 
embelin or embelin-6g for 96 h, protein isolated and XIAP expression at protein level 
determined using ELISA. * p < 0.05, ** p < 0.01 using student’s unpaired t-test. 
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effect of embelin and embelin-6g on AR expression. 1 x 105 C4-2 cells were treated with 
drug (5 µM) for 48h and the amount of AR message was quantitatively determined by 
real-time RT-PCR. There was a significant decrease in AR mRNA levels (Figure 5-6A) 
with both embelin and embelin-6g reducing AR levels by more than 50% compared to 
control. Additionally, Western blot analysis revealed a decrease in AR protein amounts 
when C4-2 cells were treated with 5 µM embelin or embelin-6g for 96 h (Figure 5-6B).  
 
Furthermore, we evaluated AR transcriptional activity by examining mRNA 
expression of prostate specific antigen (PSA). We observed 50% decrease in PSA mRNA 
levels for both drugs (Figure 5-6A). Additionally, we determined the effect of embelin 
and embelin-6g on intracellular PSA levels. Drug treatment resulted in a decrease in PSA 
protein expression compared to the control (Figure 5-6B). These results demonstrate the 
ability of embelin to modulate AR levels and show direct correlation between AR protein 
amount and its subsequent ability to transactivate PSA. 
 
 
Embelin blocks DHT-stimulated AR nuclear translocation and phosphorylation 
 
To determine whether embelin inhibits AR translocation in C4-2 cells we used 
confocal microscopy to determine the localization of AR in the nucleus. AR was 
diffusively distributed in the nucleus (Figure 5-6C) but cytoplasmic AR translocation to 
the nucleus was significantly decreased upon incubation with embelin. In contrast, 
treatment with 1 nM DHT resulted in a majority of cytoplasmic AR translocating into the 
nucleus. Furthermore, since androgens stimulate phosphorylation of AR Ser81 especially 
in cells possessing T877A mutation, we examined the effect of embelin on AR 
phosphorylation [251]. C4-2 cells were treated with various concentrations of embelin in 
the presence or absence of DHT. A concentration-dependent effect of AR Ser81 
phosphorylation post embelin treatment was observed strongly suggesting embelin 
suppressed DHT-induced AR phosphorylation (Figure 5-6D). 
 
 
Embelin and its derivative inhibit prostate cancer cell growth 
 
We next investigated the anticancer activity of embelin and embelin-6g by 
determining their IC50 values in LNCaP and C4-2 cells. Both drugs were found to be 
equally potent in inhibiting the proliferation of prostate cancer cells regardless of 
androgen status (Figure 5-7A). IC50 was approximately 6.5 µM.  
 
To provide mechanistic insight into the effect of embelin and embelin-6g on cell 
proliferation, we examined whether these drugs modulate the expression of cyclin D1 
which is a known marker of cell proliferation. Treatment of C4-2 cells with 5 µM of 
embelin and embelin-6g for 48 h resulted in suppression of cyclin D1 expression by 
~ 22% (Figure 5-7B). Western blot analysis also revealed inhibition of cyclin D1 when 
cells were treated with drug for 96 h (Figure 5-7C). 
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Figure 5-6. Effect of embelin and embelin-6g on AR and PSA expression. 
 
(A) C4-2 cells were treated with embelin and embelin-6g (5 µM) for 48 h, RNA extracted 
and AR and PSA expression at mRNA level determined using real-time RT-PCR. (B) 
Cells were treated with embelin and embelin-6g (5 µM) for 96 h, protein isolated and AR 
and PSA expression at protein level determined using Western blot. (C) C4-2 cells were 
grown on chamber slides treated in the presence or absence of 5 µM embelin for 12 h 
prior to addition of 1 nM DHT. Cells were fixed, permeabilized and AR immunostained 
with rabbit anti-AR followed by FITC-conjugated secondary antibody and nucleus 
stained with DAPI. (D) Phosphorylated Ser81 AR protein levels in C4-2 cells were 
determined by Western blot analysis. Cells were grown in CSS and treated with Embelin 
(5 or 10 µM), in the presence or absence of 1 nM DHT for 48 h. 
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Figure 5-7. Effect of embelin and embelin-6g on prostate cancer cell proliferation 
and cyclin D1, expression. 
 
(A) LNCaP and C4-2 cells were treated with XIAP inhibitor (0-10 µM) for 96 h and cell 
viability measured using MTT assay. (B) Cells were treated with XIAP inhibitors (5 µM) 
for 48 h, total RNA extracted and cyclin D1 expression at mRNA level determined using 
real-time RT-PCR. (C) 1x106 cells were treated with XIAP inhibitors for 96 h, protein 
isolated and cyclin D1 expression at protein level determined using Western blot. (D) 
LNCaP and C4-2 cells were treated with XIAP inhibitors (0, 2.5 and 5 µM) for 24 and 
cell viability measured using MTT assay.  * p < 0.05, ** p < 0.01 using student’s 
unpaired t-test. 
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Since we were interested in using a XIAP inhibitor which has fast acting activity 
for our combination study, we examined the anticancer activity of embelin and embelin-
6g in LNCaP and C4-2 cells at 18 h post treatment. Our results (Figure 5-7D) suggest 
embelin to be faster acting and more potent than embelin-6g in inhibiting cell growth 
especially in C4-2 cells. Therefore, we selected embelin as the XIAP inhibitor for further 
studies in our combination therapy. 
 
 
Formulation of CBDIV17 and embelin-loaded PEG-b-p(CB-co-LA) micelles and their 
effect on prostate cancer cell growth and migration 
 
Since CBDIV17 and embelin are extremely hydrophobic and we plan to test our 
combination therapy in vivo, we first formulated these drugs into Poly (ethylene glycol)-
b- poly(carbonate-co-lactide) (PEG-b-p(CB-co-LA)) micelles. Micelle size ranged from ~ 
83 to 90 nm and the presence of drug did not significantly affect micelles size. 
Furthermore, (PEG-b-p(CB-co-LA)) micelles were monodisperse and had a PDI of 
approximately 0.11. Encapsulation efficiency for CBDIV17 was 91.2 ± 2.3% at 5% 
theoretical loading but dropped to 55.7 ± 1.4% when theoretical loading increased to 
10%. In contrast, encapsulation efficiency for embelin was 38.4 ± 1.0% at 5% theoretical 
loading and 35.0 ± 0.9% at 10% theoretical loading. Therefore, a 5% theoretical loading 
was used for formulating micelles for further studies.  
 
Following micelle formulation and characterization, we investigated whether the 
combination of CBDIV17 and embelin was more potent than their monotherapy in 
treating prostate cancer. C4-2 cells were treated with embelin (5 µM) or CBDIV17 (25 
µM) alone or in combination for 24 h. Combination therapy was found to be more 
effective than control or monotherapy (Figure 5-8A). Both embelin and CBDIV17 
resulted in approximately 20% decrease in cell growth while combination therapy 
inhibited cell growth by about 70%. 
 
We also determined the effect of combining CBDIV17 and embelin on the 
migration potential of C4-2 cells using the scratch wound assay. We observed embelin to 
have no obvious effect on cell migration under our conditions whereas CBDIV17 had 
some modest effect. The group treated with the combination of CBDIV17 and embelin 
resulted in superior inhibition of cell migration compared to untreated control and each 
drug alone (Figure 5-8B). 
 
 
Effect of CBDIV17 and embelin combination on apoptosis 
 
Since CBDIV17 and embelin combination effectively inhibited cell proliferation 
in vitro, we further tested their effect on cell cycle and apoptosis in C4-2 cells. From 
Figure 5-9A, there was a decrease in percentage of cells in the G2/M and S phases 
following treatment with CBDIV17. Treatment with 25 and 50 µM decreased percent of 
cells in the G2/M phase by 50% while percentage of cells in the S phase decreased by 
30%. Also, we found CBDIV17 showed dose-dependent increase in apoptosis (sub-G1).  
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Figure 5-8. Effect of CBDIV17 and embelin combination on prostate cancer cell 
growth and migration. 
 
(A) Anticancer effect of CBDIV17 and embelin, alone or in combination on C4-2 cells 
was determined following treatment of cells with 25 µM of CBDIV17 and 5 µM embelin 
for 24 h. and cell viability determined by MTT assay. * p < 0.05 using student’s unpaired 
t-test. (B) C4-2 cells were grown to 70% confluence in six well plates and three parallel 
wounds made using pipette tip. Cells were treated with CBDIV17 (25 µM) or embelin (5 
µM) alone or in combination for 48 h after which cells were washed with ice cold 1x PBS 
and imaged under microscope. 
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Figure 5-9. Effect of embelin and CBDIV17 combination on cell cycle and 
apoptosis.  
 
(A) C4-2 cells were treated with vehicle, embelin (5 and 10 µM) and CBDIV17 (25 and 
50 µM) for 72 h, stained with propidium iodide and analyzed on a flow cytometer. (B) 
Cells were treated with vehicle, embelin (5 µM) and CBDIV17 (25 µM) alone or in 
combination for 72 h, stained with propidium iodide and analyzed on a flow cytometer. 
Left panel, cell cycle distribution; Right panel, quantitative analysis of sub G1phase. * p 
< 0.05 using student’s unpaired t-test. 
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The percentage of cells in the sub-G1 phase was around 21% at 25 µM and 38% for 50 
µM. In contrast, percentage of cells in the sub-G1 phase did not differ significantly 
fromthat of control for the concentrations of embelin tested. Notably, we observed 
combination of CBDIV17 (25 µM) and embelin (5 µM) induced apoptosis more potently 
compared to control or either treatment alone. Specifically, percentage of cells in the sub-
G1 phase for combination therapy was 40-fold, 28-fold and 2-fold more, compared to 
control, embelin and CBDIV17, respectively. Additionally, combination of CBDIV17 
(25 µM) and embelin (5 µM) resulted in percentage of cells in the sub-G1 phase 
comparable to that of 50 µM CBDIV17. 
 
 
In vivo efficacy of CBDIV17 and embelin-loaded micelles in mouse xenografts 
 
Since CBDIV17 and embelin combination therapy effectively inhibited prostate 
cancer growth in vitro, we determined the effect of this combination approach in C4-2 
xenograft tumor model. CBDIV17 and embelin were formulated using PEG-b-p(CB-co-
LA) micelles and intratumoral injection of 10 mg/kg CBDIV17 and 10 mg/kg embelin-
loaded micelles was administered on days 0, 3 and 7. CBDIV17 and embelin 
combination inhibited tumor growth more potently compared to the mice treated with 
empty micelles or monotherapy (Figure 5-10A). On day 7 (last day of treatment), the 
tumor size of the combination group was 50% of that in CBDIV17 group, 25% of that in 
embelin group and 18% of that in the control group (Figure 5-10B). Furthermore, the 
body weight loss of mice was less than 5% suggesting minimal toxicity of the treatment 
(Figure 5-10C). Additionally, combination therapy increased tumor-doubling time 
compared to monotherapy and control. For instance, the time it took for tumor to double 
from 50 mm3 to 100 mm3 are as follows: the combination group took 14 days; CBDIV17 
group took 7 days and less than 3 days for embelin and control group. Taken together, 
these results demonstrate that CBDIV17 and embelin combination therapy effectively 
inhibited tumor growth and can prolong survival. 
 
 
Discussion 
 
Since prostate cancer is an androgen-dependent malignancy, current therapies 
including non-steroidal antiandrogens target the AR. However, first generation non-
steroidal anti-androgens do not completely hinder AR activity and eventually become 
agonists in tumor cells partly due to elevated levels of AR. Furthermore, progression to 
hormone refractory prostate cancer is also characterized by resistance to apoptosis. 
Particularly, XIAP is overexpressed and inhibits caspases 9 and 3 thus contributing to a 
defect in the apoptotic machinery [185-188]. Together, AR and XIAP overexpression 
may be a molecular reason leading to drug resistance and indicate that more potent 
antiandrogens, AR downregulating agents and XIAP inhibitors or their combination can 
effectively treat advanced prostate cancer. We have previously demonstrated that 
combination of bicalutamide and embelin is more effective in treating prostate cancer 
compared to monotherapy [11]. However, bicalutamide has limited efficacy in advanced 
prostate cancer (e.g., C4-2 cells) and assumes agonistic properties following prolonged   
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Figure 5-10. Effect of CBDIV17 and embelin-loaded micelles on growth of tumors 
derived from C4-2 prostate cancer cells in nude mice. 
 
(A) Nude mice bearing 50 mm3 C4-2 tumors were given an intratumoral injection of 10 
mg/kg CBDIV17 and 10 mg/kg embelin, alone or in combination (arrows indicate 
injection) and tumor size measured. Tumor growth regression was significantly higher for 
combination therapy group compared to control or monotherapy. Points are mean tumor 
size (n = 7); bars, SE. (B) Tumor suppression (T/C) was computed as the ratio of mean 
tumor volume in treated groups compared with control when last injection was 
administered. (C) Relative body weight was expressed as the body weights at various 
times during treatment normalized with body weights at day 0. * p < 0.05, ** p < 0.01 
using student’s unpaired t-test. 
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treatment. Therefore, the primary objective of this study was to investigate whether a 
novel antiandrogen (CBDIV17) was more potent than bicalutamide and can effectively 
inhibit advanced prostate tumor growth when combined with XIAP inhibitor. We also 
further explored the molecular mechanism for our selected XIAP inhibitors. 
 
To determine the comparative therapeutic benefits of CBDIV17 over 
bicalutamide, we evaluated the biological effects of both drugs in LNCaP and C4-2 cells 
by observing their effect on cell proliferation in the presence or absence of synthetic 
androgen and in inducing apoptosis. Our results show, CBDIV17 to be more potent than 
bicalutamide in inhibiting cell proliferation in a dose and time dependent manner (Figure 
5-2). Furthermore, inhibition of cell growth was only modestly reversed in the presence 
of DHT. This may possibly be due to better cytotoxic effects or its superior ability at the 
molecular level to retain antagonism and hence bypass antiandrogen resistance. Our 
observation suggests CBDIV17 analog to be more potent than bicalutamide regardless of 
AR sensitivity or presence of synthetic androgen and therefore has the potential for 
treating advanced prostate cancer. 
 
Chen et al. synthesized new XIAP inhibitors with better binding affinities than 
embelin by modifying its hydrophobic tail. It was shown that embelin-6g has a two-fold 
better binding affinity to XIAP BIR3 compared to embelin and was potent in inhibiting 
proliferation of human breast and prostate cancer cell lines [251]. Therefore, we were 
interested in how better XIAP binding affinity would translate in terms of potency in 
inhibiting cell growth and inducing apoptosis in prostate cancer cells. Although Chen et 
al. showed better binding affinity for embelin-6g they did not show its effect on XIAP 
gene expression. In our studies, we found embelin-6g to be more potent than embelin in 
repressing XIAP gene expression. At both the mRNA and protein levels, embelin-6g 
appeared to be twice as effective as embelin (Figure 5-5B and C). This result may 
logically extend from embelin-6g’s two-fold better binding affinity compared to embelin. 
However, we observed embelin and embelin-6g to exhibit similar ability in inhibiting 
prostate cancer cell growth despite the difference in their effect on XIAP expression. In 
fact, our findings suggest that embelin elicits a quicker therapeutic response compared to 
embelin-6g and was consequently more potent at short time intervals. Therefore, embelin 
was selected for combination studies with CBDIV17. 
 
We also made an interesting finding regarding the ability of embelin and embelin-
6g to disrupt AR signaling in prostate cancer cells. These XIAP inhibitors also appear to 
decrease AR levels in LNCaP and C4-2 cells. Similar results have also been reported in 
the literature where other drugs exhibit the ability to decrease AR expression [252-254]. 
Examples of these AR down-regulating agents (ARDA) include quercetin, epicatechin, 
and curcumin. Purushottamachar et al. provided clear evidence concerning structural 
requirements common to ARDAs [255]. Typical features include one hydrophobic group, 
one aromatic group, and two hydrogen bond acceptors [255]. Both embelin and embelin-
6g satisfy these structural criteria and hence it may not be surprising that they are capable 
of depleting AR expression. 
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Although the precise mode of action of embelin and embelin-6g in down-
regulating AR inhibition is not fully understood, it is likely that both drugs inhibit AR 
expression through a number of different mechanisms. Since both drugs decrease AR 
expression by more than 50% on the mRNA level, it is possible that mRNA stability or 
inhibition of AR mRNA synthesis may contribute to the effect of these drugs on AR 
expression levels. It is also possible that embelin and embelin-6g hinder androgen-AR 
binding or may disrupt the Hsp90-AR complex. The likelihood of these mechanisms 
which have also been reported by Liu et al. [252] would be consistent with our results 
where we showed the ability of embelin to prevent AR nuclear translocation from the 
cytoplasm to the nucleus in C4-2 cells (Figure 5-6C).  
 
Combination therapy involving XIAP modulation is a promising approach for 
treating solid tumors including prostate cancer [11, 256, 257]. We observed CBDIV17 
and embelin combination to be more potent in inhibiting prostate cancer cell growth and 
in inducing apoptosis in advanced prostate cancer compared to control or monotherapy. 
This superior effect was found to be supra-additive and is consistent with our previous 
findings which showed synergism even for simultaneous administration of bicalutamide 
and embelin in C4-2 cells [11]. The greater potency of CBDIV17 and embelin 
combination therapy may be attributed to the ability of embelin to lower the threshold 
required by XIAP to inhibit apoptosis thereby enhancing CBDIV17 activity several fold. 
From our findings, it is also possible that the ability of embelin to downregulate AR may 
play some role in the observed therapeutic effect of our combination therapy.  
 
Since in vivo substantiation of our cellular observations is imperative for clinical 
translation, CBDIV17 and embelin were formulated into PEG-b-p(CB-co-LA) micelles to 
test our combination approach in vivo due to their extreme hydrophobicity and to avoid 
the detrimental side effects of solubilizing agents such as DMSO and Cremophor® EL 
[7]. CBDIV17 had higher drug loading compared to embelin. This may be due to the 
close structural similarity between CBDIV17 and bicalutamide for which PEG-b-p(CB-
co-LA) was specifally designed to enhance drug loading [170]. Consistent with our in 
vitro data, we found co-administration of embelin and CBDIV17 to be more potent in 
regressing prostate tumor growth compared to control or monotherapy (Figure 5-10A 
and B). Tumor volume at the last injection and at the end of experiment for the 
combination group was approximately 20% of control. A result demonstrating the ability 
of our combination therapy to suppress growth of advanced prostate cancer tumors. Also, 
CBDIV17 was effective in regressing tumor growth at the doses studied compared to 
embelin or control. However, tumor volume increased to 70% of control at the end of the 
experiment compared to 40% of control at the last injection. We found the embelin 
treated group to have tumor volume 75% of the control group when the last injection was 
administered. Nonetheless, there was no difference between embelin treated group and 
control at the end of the study. Our results are in agreement with the findings of Dai et al. 
[258]. However, they orally administered a 6-fold higher dose of embelin (60 mg/kg) 
twice a week for three weeks and used PC-3 xenograft tumors which are AR negative.  
 
In conclusion, we have demonstrated that CBDIV17 is more potent than 
bicalutamide in regressing prostate tumor growth and inducing apoptosis regardless of 
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AR status. Additionally, we have shown that the combination of CBDIV17 and embelin 
is more potent in inhibiting cell growth and inducing apoptosis compared to control or 
monotherapy in vitro and in vivo. Our findings also reveal a novel mechanism regarding 
the ability of embelin and embelin-6g to alter AR signaling pathway. We are currently 
investigating the mode of action by which embelin down-regulates AR gene expression. 
We believe such mechanistic insight will lead to the design of highly potent analogs. The 
current study provides evidence that CBDIV17 and embelin combination is a promising 
therapeutic approach for treating hormone refractory prostate cancer. 
 
 
  
 108 
 
CHAPTER 6.    LACTIC ACID AND CARBONATE BASED CROSSLINKED 
MICELLES FOR DRUG DELIVERY* 
 
 
Introduction 
 
Polymeric micelles are presently under intense investigation as nano-vehicles for 
delivery of low molecular weight chemotherapeutic drugs. Key advantages of polymeric 
micelles include efficient solubilization of hydrophobic agents in their core [259-261] 
and the ability to be made site-specific. Furthermore, they are nanosized supramolecules 
which self-assemble into core-corona structures from amphiphilic block copolymers once 
above the critical micelle concentration (CMC) [261]. These intrinsic physicochemical 
properties of micelles often leads to prolonged blood circulation kinetics[262] and 
preferential tumor accumulation via the enhanced permeation and retention (EPR) effect 
[13, 46, 195]. Nonetheless, poor in vivo stability resulting in premature dissociation and 
subsequent untimely drug release has limited their clinical application [263-266]. 
Polymeric micelles become unstable either due to destabilization by plasma proteins 
(kinetic instability) or dilutions below their critical micelle concentration (CMC) 
(thermodynamic instability) upon systemic administration. 
 
To facilitate clinical translation of polymeric micelle based therapeutics, recent 
research effort has focused on increasing micelle thermodynamic and kinetic stability 
using physical or chemical strategies. Since micelles with low CMC values have better 
thermodynamic stability, typical physical approaches involve strategically altering 
properties of amphiphilic copolymers which can affect the CMC (e.g., chain length and 
chemical composition) [170, 267]. For example, tailoring the hydrophobic core to contain 
aromatic moieties has been shown to improve micelle stability through π-π interactions as 
demonstrated by decreased CMC values [170]. In practice, physically stabilized micelles 
are limited by their inability to prevent micelle destabilization caused by blood 
components. 
 
In contrast, introduction of chemical covalent crosslinks into the shell, core or 
core-corona interface of micelles is a potential approach to stabilize micelles against both 
plasma proteins and sub-critical micelle concentrations [267-270]. Over the past decade, 
shell-crosslinked micelles have been extensively studied [271]. It has been shown that 
shell-crosslinked micelles remain stable upon infinite dilution compared to precursor 
micelles. High core mobility, greater versatility in core composition and properties and 
the membrane-like characteristics of the cross-linked shell layer which can improve 
encapsulation are advantages associated with shell-crosslinked micelles. However, one 
longstanding issue with shell-crosslinked micelles is their low crosslinking efficiency due 
to their need to be prepared at high dilution to prevent intermicellar crosslinking. 
 
 
* Danquah M., Fujiwara T., and Mahato R.I. (2012) Lactic acid and carbonate-based 
crosslinked polymeric micelles for drug delivery.  J. Polymer Sci Part A: Polymer 
Chemistry (Accepted for Publication).  
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Furthermore, shell crosslinking tends to suppress the mobility of the hydrophilic corona 
chains (e.g., PEG). 
 
Core-crosslinked micelles exhibit better crosslinking efficiencies since they do 
not need to be prepared at high dilution to prevent intermicellar crosslinking. Several 
groups have introduced crosslinkable groups into the hydrophobic portion of the block 
copolymer which may be polymerized after micellation to lock the micelle structure. For 
instance, Kataoka’s group reported core-crosslinked micelles prepared using poly 
(ethylene glycol)-b-polylactide (PEG-b-PLA) possessing methacryloyl groups at the end 
of the PLA chain [272, 273]. These methacryloyl groups could be photopolymerized 
using ultraviolet (UV) light or polymerized thermally via the addition of a radical 
initiator. In another paper, Hu et. al. covalently stabilized micelle architecture using a 
hydrophobic polymer block containing crosslinkable double bonds [274]. Recently, Garg 
and coworkers used click chemistry to introduce hydrolyzable cross-links in the core of 
poly-(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micelles [275]. These 
crosslinked micelles also demonstrated enhanced stability under diluted conditions 
without any detrimental effect on the drug encapsulation and in vitro drug release 
profiles. 
 
Armes and coworkers have elegantly stabilized micelles by crosslinking the core-
corona interface using triblock copolymers in which the reactive groups capable of 
undergoing cross-linking are located in the central block [276]. Interfacial crosslinking is 
potentially more beneficial than shell or core-crosslinked micelles since it combines the 
advantages of both methods and may be prepared at high concentrations without 
intermicellar cross-linking and aggregation. In another study, Xu and coworkers showed 
reduction-sensitive reversibly interfacially crosslinked micelles to be stable against 
extensive dilution and physiological salt conditions and retained most drugs even at 
concentrations below the CMC [277]. Yang et al. recently reported preparing interface 
crosslinked micelles using PEG-b-poly(acryloyl carbonate)-b-polycaprolactone (PEG-b-
PAC-b-PCL) triblock copolymer [278]. Once micelles were prepared, the double bonds 
in the acryloyl carbonate were photo-crosslinked using UV light and a photo initiator.  
 
Our group has developed a series of thermodynamically stable (low CMCs) lactic 
acid- and carbonate-based copolymers for micellar drug delivery [170, 247]. To further 
enhance micelle stability and controlled drug release to make our delivery systems 
clinically relevant, we herein report on the synthesis, characterization and in vitro 
evaluation of methoxy poly (ethylene glycol)-b-poly(carbonate-co-lactide-co-5-methyl-5-
allyloxycarbonyl-1,3-dioxan-2-one) [mPEG-b-P(CB-co-LA-co-MAC)] and methoxy poly 
(ethylene glycol)-b-poly (5-methyl-5-allyloxycarbonyl-1,3-dioxan-2-one)-b-
poly(carbonate-co-lactide) [mPEG-b-PMAC-b-P(CB-co-LA)] biodegradable copolymers 
for core and core-corona interface crosslinked micelles. Effect of polymer composition 
and crosslinking moiety location on key micelle properties was also investigated. Self-
aggregation behavior, morphology and stability of non-crosslinked and crosslinked 
micelles were determined by dynamic light scattering (DLS), transmission electron 
microscopy (TEM), 1H NMR spectroscopy and fluorescence spectroscopy. Furthermore, 
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influence of crosslink location on micelle stability against physiological simulating 
dilution and serum conditions as well as drug release was investigated.  
 
 
Materials and Methods 
 
 
Materials 
 
2,2-bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, 
Mn = 5000, PDI = 1.03), tin(II) 2-ethylhexanoate (Sn(Oct)2), dimethylaminopyridine 
(DMAP), allyl bromide and benzyl bromide were purchased from Sigma Aldrich (St. 
Louis, MO) and used as received. L-lactide (LA) was purchased from PURAC Biochem 
bv (Gorinchem, The Netherlands) and recrystallized from toluene several times. 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and hydroxybenzotriazole 
(HOBt) were obtained from AK Scientific (Palo Alto, CA). 1,8-Diazabicyclo[5.4.0] 
undec-7-ene (DBU) was purchased from Sigma Aldrich, dried over calcium hydride and 
distilled. All other reagents were obtained from Sigma Aldrich and used without further 
purification. 
 
 
Synthesis of 5-Methyl-5-allyl-1,3-dioxane-2-one 
 
 
Method 1 
 
5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (CB) monomer was first 
synthesized as described by Danquah et al. [170]. Briefly, 2,2- 
bis(hydroxymethyl)propionic acid (0.168 mol) and potassium hydroxide (0.169 mol) 
were dissolved in 125 mL of dimethylformamide (DMF) by heating at 100 °C for 1 h. 
Subsequently, benzyl bromide (0.202 mol) was added dropwise to the reaction mixture 
and allowed to stir at 100 °C for 15 h. The solvent was then removed under reduced 
pressure, the residue dissolved in ethyl acetate (150 mL), hexanes (150 mL) and water 
(100 mL), and dried over Na2SO4. The organic layer solvent was removed under vacuum 
and recrystallized from toluene to yield pure benzyl 2,2-bis(methylol)propionate. Next, 
benzyl 2,2-bis(methylol)- propionate (0.05 mol) was dissolved in a mixture of CH2Cl2 
(150 mL) and pyridine (25 mL) and the solution chilled to -78 °C. A solution of 
triphosgene (25 mmol) in CH2Cl2 was added dropwise to the reaction mixture over 1 h 
and stirred for an additional 2 h at the room temperature. The reaction was then quenched 
with saturated aqueous NH4Cl (75 mL) and the organic layer sequentially washed with 1 
M aqueous HCl (3 x 100 mL) and saturated aqueous NaHCO3 (1 x 100 mL), dried with 
Na2SO4, and evaporated under vacuum to give 5-methyl-5-benzyloxycarbonyl-1,3-
dioxane-2-one (CB). The crude product was purified by recrystallization from ethyl 
acetate to obtain white crystals. 
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5-Methyl-5-allyl-1,3-dioxane-2-one (MAC) monomer was then synthesized by 
first subjecting CB to catalytic hydrogenation and reacting the subsequent product with 
allyl alcohol. In brief, CB (3 g) was dissolved in ethyl acetate (30 mL) containing 600 mg 
Pd/C. The Parr bottle was purged thrice with H2, charged to 50 psi and the reaction 
allowed to proceed for 3 h. Subsequently, Pd/C catalyst was separated by centrifugation, 
the solvent filtered and evaporated under vacuum to give 5-methyl-2-oxo-1,3-dioxane-5-
carboxylic acid (MTC-OH) as a white crystal. Next, MTC-OH (3 mmol), allyl alcohol 
(2.5 mmol), HOBT (3.6 mmol), and EDC (4.5 mmol) were dissolved in 
dimethylformamide (DMF) (20 mL) to which triethylamine (TEA) (3.5 mmol) was later 
added and the reaction allowed to proceed for 18 h. Afterward, 20 mL ethyl acetate was 
added to the mixture and then washed with water. The organic layer was dried over 
Na2SO4, evaporated under vacuum and the crude product purified by column 
chromatography to give MAC as white crystals. 
 
 
Method 2 
 
MAC was synthesized as described by Hu et al.[274]. Briefly, a mixture of 2,2-
bis(hydroxymethyl)propionic acid (9.0 g, 67.11 mmol), potassium hydroxide (88% assay; 
4.30 g, 76.79 mmol), and DMF (50 mL) was heated to 100°C for 1 h with stirring at 
which point a homogenous potassium salt solution was formed. Allyl bromide (5.8 mL, 
67.11 mmol) was added dropwise to the warm solution, and stirring was continued at 
45°C for 48 h. Upon completion of the reaction, the mixture was cooled, solvent removed 
under vacuum and the residue dissolved in methylene chloride (200 mL) and water (100 
mL). The organic layer was retained, washed with water (100 mL), dried (Na2SO4), and 
evaporated to yield a viscous yellowish liquid (70%). 
 
Allyl 2,2-bis(methylol)propionate (10 g, 58 mmol) and ethyl chloroformate (16.5 
mL, 0.173 mol) were dissolved in tetrahydrofuran (THF) (200 mL ), and the solution was 
stirred at 0°C for 30 min under N2. Subsequently, TEA (24.2 mL, 0.173 mol) was added 
dropwise over 30 min, after which the reaction mixture was removed from the ice bath 
and stirred at room temperature overnight. TEA-HCl precipitate was filtered and the 
filtrate concentrated under reduced pressure. The ensuing solid was recrystallized from 
THF/ether to obtain white crystals (8 g). 
 
 
Synthesis of mPEG-b-P(lactide-co-carbonate-co-MAC) 
 
The following reaction mixture was prepared in a fume hood under ambient 
atmosphere. mPEG (150 mg), lactide (100 mg), CB (100 mg) and MAC (20 mg) were 
dissolved in CH2Cl2 (6 mL) in a 25 mL reaction vessel. DBU (30 µL) was added and the 
reaction carried out for 3 h after which benzoic acid (40 mg) was added. The resulting 
solution was concentrated to approximately 50% of the initial volume and added 
dropwise into excess of cold isopropanol with stirring. The polymer was then dried under 
vacuum. 
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Synthesis of mPEG-b-PMAC-b-P(lactide-co-carbonate) 
 
The following reaction mixture was prepared in a fume hood under ambient 
atmosphere. mPEG (150 mg) and MAC (40 mg) were dissolved in CH2Cl2 (3 mL) in a 25 
mL reaction vessel. DBU (15 µL) was added and the reaction carried out for 2 h to yield 
mPEG-b-PMAC. To this solution a mixture (3 mL) of CB (100 mg) and LA (100 mg) 
was infused into the reaction vessel at a rate of 1 mL/min. DBU (15 µL) was then added 
and the reaction allowed to proceed for 3 h, after which benzoic acid (40 mg) was added. 
PEG-b-PMAC-b-P(CB-co-LA) copolymer was purified by concentrating the reaction 
mixture to approximately 50% of the initial volume, added dropwise into excess of cold 
isopropanol and dried under vacuum. 
 
 
Polymer characterization  
 
 
Nuclear magnetic resonance (NMR) 
 
1H NMR, 13C NMR, 2D-COSY and 1H-13C HSQC spectra were recorded on a 
Bruker (400 MHz, T = 25°C) using deuterated chloroform (CDCl3) and deuterated 
dimethyl sulfoxide (DMSO-d6) as solvents. The chemical shifts were calibrated using 
tetramethylsilane as an internal reference and given in parts per million. 
 
 
Gel permeation chromatography (GPC) 
 
A Waters GPC system equipped with a GPC column (AM Gel 103/5) and a 
differential refractive index detector was used to determine weight (Mw) and number 
(Mn) average molecular weight and polydispersity index (PDI) of synthesized 
copolymers. THF was used as an eluent at a flow rate of 1 mL/min. A series of narrow 
polystyrene standards (700-40000 g/mol) were used for calibration and the data was 
processed using a Breeze 2 software. 
 
 
Infrared (IR) spectra 
 
Copolymer composition and degree of crosslinking was confirmed with Fourier 
Transform infrared (FT-IR) spectra using a Perkin-Elmer FT-IR spectrometer.  
 
 
Critical micelle concentration (CMC) 
 
Fluorescence spectroscopy was used to estimate the critical micelle concentration 
(CMC) of mPEG-b-P(LA-co-CB-co-MAC) and mPEG-b-PMAC-b-P(CB-co-LA) 
copolymers using pyrene as a hydrophobic fluorescent probe as described previously 
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[11]. Fluorescence spectra of pyrene were recorded with a Molecular Devices 
SpectraMax M2/M2e spectrofluorometer (Sunnyvale, CA) with excitation wavelength 
338 nm (I3) and 333 nm (I1) and emission wavelength of 390 nm. The intensity ratio 
(I3/I1) was plotted against the logarithm of polymer concentration and CMC obtained as 
the point of intersection of two tangents drawn to the curve at high and low 
concentrations, respectively. 
 
 
Preparation of micelles and crosslinking 
 
mPEG-b-P(LA-co-CB-co-MAC) and mPEG-b-PMAC-b-P(CB-co-LA) micelles 
were prepared using the film sonication method as previously described with slight 
modifications [11]. Briefly, 20 mg of the copolymer was dissolved in CH2Cl2 (2 mL). 
The mixture was sonicated for 5 min to ensure homogeneity and the solvent evaporated 
under a flow of N2. The resulting film was hydrated (10 mL) and sonicated for 10 min 
using a Misonix ultrasonic liquid processor (Farmingdale, NY) with an amplitude of 70. 
The ensuing formulation was then centrifuged at 5,000 rpm for 10 min and the 
supernatant filtered using a 0.22 μm nylon filter.  
  
Micelles were stabilized by polymerization of the allyl moieties. Briefly, the 
micelle solution was first deoxygenated by bubbling with argon for 1 h. A solution of 
2,2-azo-bis(isobutyronitrile) (AIBN) (1.0 wt. % of polymer) in THF was then added and 
stirred for 2 h followed by heating to 70 °C for 24 h. 
 
 
Drug loading and encapsulation efficiency 
 
Bicalutamide loaded micelles were prepared as described above. 1 mg drug and 
19 mg copolymer were dissolved in CH2Cl2 (2 mL) and evaporated under a stream of N2. 
The film was then hydrated with 10 mL of PBS, sonicated and filtered through a 0.22 µm 
filter. Acetonitrile was used to extract the loaded drug and the amount of bicalutamide 
determined using UV spectroscopy at 270 nm. Drug loading content and encapsulation 
efficiency were then determined using Equations 6-1 and 6-2 as follows: 
 
x100%
  micelle ofweight 
micellein  drug ofweight  density  loading drug =  
 
(Eq. 6-1) 
 
x100%
  fed originally drug ofweight 
micellein  drug ofweight  efficiencyion encapsulat drug =  
 
(Eq. -6-2) 
 
 
Particle size distribution and morphology 
 
Mean particle size (intensity mean) and size distribution of non-crosslinked and 
crosslinked micelles were determined by dynamic light scattering (DLS) using a 
Zetasizer (Malvern Instruments, Worcestershire, UK) at a 1 mg/mL polymer 
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concentration. Samples were analyzed at room temperature with a 90° detection angle 
and the mean micelle size was obtained as a Z-average. Five repeat measurements were 
performed and data reported as the mean diameter ± SD. Non-crosslinked and 
crosslinked micelles prepared using mPEG-b-P(LA-co-CB-co-MAC) and mPEG-b-
PMAC-b-P(CB-co-LA) copolymers were visualized using a JEM-100S (Japan) 
transmission electron microscope (TEM). Micelles were loaded on a copper grid, 
followed by blotting of excess liquid prior to negative staining with 1% uranyl acetate. 
The grid was visualized under the electron microscope at 60 kV and magnifications 
ranging from 50,000x to 100,000x . 
 
 
In vitro drug release from micelles 
 
The dialysis technique was used to study the release profile of bicalutamide from 
non-crosslinked and crosslinked micelles in phosphate buffered saline (PBS) (pH 7.2) 
with 0.1% Tween-80. Bicalutamide-loaded micelles with a final bialutamide 
concentration of 0.2 mg/ml were placed into a dialysis membrane with a molecular 
weight cut-off of 2000 Da and dialyzed against 50 ml PBS (pH 7.2) in a thermo-
controlled shaker with a stirring speed of 150 rpm. 1 ml samples were taken at specified 
times and assayed with a validated UV spectrophotometer by measuring the absorbance 
of the solution at 270 nm. The cumulative amount of drug released into the media at each 
time point was evaluated as the percentage of total drug release to the initial amount of 
the drug. All experiments were performed in triplicate and the data reported as the mean 
of the three individual experiments.  
 
 
Assessment of in vitro micelle stability 
 
The stability of non-crosslinked and crosslinked micelles in PBS (pH 7.4) and 
under physiologically simulating conditions (45 mg/mL BSA) was assessed by DLS. For 
stability in serum, micelle solution at a final polymer concentration of 20 µg/mL was 
incubated in BSA (45 mg/mL) at 37°C for 24 and 48 h with gentle shaking at 100 rpm. 
Particle size distribution of 1 mL aliquots was determined by DLS (n = 3).  
 
 
In vitro cytotoxicity of bicalutamide-loaded micelles 
 
The ability of bicalutamide-loaded PEG-b-PMAC-b-P(CB-co-LA) and PEG-b-
P(CB-co-LA-co-MAC) non-crosslinked (NCM) and crosslinked micelles (CM) to inhibit 
cell proliferation was evaluated using LNCaP human prostate cancer cell line. 3 x 103 
cells were incubated with bicalutamide-loaded micelle formulations (0, 25 and 50 µM of 
drug) for 24 and 48 h. At the end of treatment, MTT solution (10% v/v) was added to 
each well, incubated for 4 h, residual formazan crystals solubilized with DMSO and the 
plate analyzed using a microplate reader (560 nm). Cell viability was expressed as a 
percentage of control and data reported as the mean of triplicate experiments. 
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Results   
 
 
Synthesis and characterization of 5-Methyl-5-allyl-1,3-dioxane-2-one 
 
To facilitate micelle stabilization via crosslinking, we synthesized MAC which is 
a cyclic monomer containing a double bond functional moiety. Figure 6-1A illustrates 
the reaction pathway for synthesizing the MAC monomer. Drawing from our experience 
in synthesizing six-membered cyclic carbonate monomers, we first synthesized MAC 
using method 1 according to the procedure previously reported by Pratt et al.[231] with 
slight modification. This method allowed the synthesis of 5-methyl-5-
benzyloxycarbonyl-1,3-dioxane-2-one (CB) intermediate which is an integral component 
of our lactic-acid and carbonate-based copolymers. To this end, 2,2-
bis(hydroxymethyl)propionic acid was reacted with benzyl bromide to give benzyl 2,2-
bis(methylol)propionate which was then reacted with triphosgene to obtain CB (MW:250 
g/mol). The chemical structure of CB was confirmed using mass and 1H NMR 
spectroscopy and our results matched the literature [170, 247]. CB was then 
dehydrogenated using Pd/C catalyst to give 5-methyl-2-oxo-1,3-dioxane-5-carboxylic 
acid (MTC-OH; 30% of CB) (MW:160 g/mol). Next, MTC-OH was coupled to allyl 
alcohol using EDC HOBt chemistry and purified using column chromatography to obtain 
MAC. 
 
However, since we had large quantities of CB from previous studies, coupled with 
significant yield drops in step 1C (Figure 6-1A) and the time consuming column 
purification step associated with this method, we explored an alternative synthesis route 
(method 2). In this method, 2,2-bis(hydroxymethyl)propionic acid was reacted with allyl 
bromide to yield allyl 2,2-bis(methylol)propionate (MW: 174 g/mol) which was 
subsequently reacted with ethyl chloroformate and TEA to give MAC (70%) and purified 
by recrystallization. Figure 6-1B shows the 1H NMR spectrum (CDCl3) of MAC with 
peak assignments. The signal d at 5.8 ppm and e at 5.23-5.42 ppm are characteristic of 
the acryloyl protons in the monomer; while the signal b at 4.2 and 4.7 ppm denote 
methylene protons present in the carbonate ring. Other peak assignments include signals 
a and c at 1.38 and 4.72 ppm, assigned to methyl protons in the carbonate ring and 
methylene protons next to the ester, respectively. The structure of MAC was further 
confirmed using FT-IR spectrometry (Figure 6-2). Prominent absorbance peaks were 
observed at 1651 cm-1 and 1731 cm-1 for C = C and C = O stretches, respectively. 
 
 
Synthesis and characterization of mPEG-b-PMAC-b-P(CB-co-LA) copolymer 
 
mPEG-b-PMAC-b-P(CB-co-LA) copolymer was obtained by first reacting mPEG 
and MAC to give mPEG-b-PMAC copolymer followed by the addition of CB and LA 
(Figure 6-3). A kinetic study was performed to determine the optimal time required 
before the addition of CB and LA monomer. From Figure 6-4A and B, a maximum 
MAC conversion of 80% was achieved at a time of 105 min and maintained at 120 mins  
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Figure 6-1. Synthesis and characterization of 5-methyl-5-allyl-1,3-dioxane-2-one 
(MAC).  
 
(A) Synthesis scheme for 5-methyl-5-allyl-1,3-dioxane-2-one (MAC). Conditions: (1A) 
KOH, DMF, 100°C, 15h. (1B) Triphosgene, pyridine, CH2Cl2, -78 – 0°C. (1C) Pd/C  
(10%), H2, ethyl acetate, RT, 40 psi, 3 h. (1D) EDC, HOBT, TEA, DMF, RT, 18 h. (2A) 
KOH, DMF, preheat to 100°C, 1h, 45°C, 48h. (2B) ClCO2Et, THF, TEA, 0°C, 30 min, 
RT, 12h.  (B) 1H NMR spectrum of MAC in CDCl3. (C) FT-IR spectrum of MAC. 
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Figure 6-2. FT-IR spectrum of 5-methyl-5-allyl-1,3-dioxane-2-one (MAC).  
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Figure 6-3. Synthesis method for preparation of interface-crosslinked micelles. 
 
Conditions: (i) DBU, CH2Cl2, RT, 3 h. (ii) AIBN, 60°C. 
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Figure 6-4. Methoxy poly (ethylene glycol) and MAC copolymerization in 
CH2Cl2 at room temperature.  
 
Reaction progress was monitored by 1H NMR spectroscopy. (A) Plot of ln (1/(1-x)) vs. 
time (x = monomer conversion); (B) Observed MAC conversion during synthesis of 
mPEG-b-PMAC copolymer. (C) 1H NMR spectrum of methoxy poly (ethylene glycol)-
b-poly (5-methyl-5-allyl-1,3-dioxane-2-one) (mPEG-b-PMAC) copolymer in CDCl3. 
  
a
bde+f c
O
O O O
H
O O
O
x p
a b b
c
d
e
f
C
0
0.4
0.8
1.2
1.6
2
0 20 40 60 80 100 120 140
ln
 (1
/(1
-x
))
Time (min)
0
20
40
60
80
100
0 20 40 60 80 100 120 140
M
A
C
 C
on
ve
rs
io
n 
(%
)
Time (min)
A B
-1
 120 
 
when DBU amount was 5µL/mL. The observed conversion saturation could possibly be 
due to lower MAC concentrations. A plot of ln (1/(1-x)) vs time resulted in a straight line 
with a 70 min-1 rate constant. Since MAC conversion remained constant post 105 min, 
PEG-b-PMAC polymerization was carried for 2h and characterized using 1H NMR 
spectroscopy before the addition of CB and LA. A typical 1H NMR spectrum for mPEG-
b-PMAC copolymer is displayed in Figure 6-4C. 
 
The successful synthesis of mPEG-b-PMAC-b-P(CB-co-LA) copolymer was 
confirmed using 1H NMR spectroscopy and GPC. The presence of characteristic 
resonance peaks for mPEG (3.65 ppm), LA (1.5-1.57, 5.12 ppm), CB (1.24, 4.25-4.35, 
5.2, 7.3 ppm) and MAC (4.2-4.4, 4.6, 5.3-5.8 ppm) clearly confirmed the co-occurrence 
of all the monomers (Figure 6-5A). Some characteristics of the synthesized mPEG-b-
PMAC-b-P(CB-co-LA) copolymer are summarized in Table 6-1. Copolymer molecular 
weight was determined by comparative analysis of the mPEG (i.e., CH2-CH2- at 3.65 
ppm), lactide (i.e., CH at 5.12), CB (i.e., C6H5 at 7.3 ppm) and MAC (-CH2-CH = CH2 
at 5.8 ppm) characteristic proton peaks from 1H NMR spectrum. mPEG-b-PMAC-b-
P(CB co-LA) molecular weight was determined to be 10558 g mol-1 from 1H NMR 
spectrum. GPC measurements also confirmed successful copolymer synthesis and 
showed the resulting copolymer to have a narrow polydispersity of 1.08 and Mn of 9752 
g mol-1 co-LA) molecular weight was determined to be 10558 g mol-1 from 1H NMR 
spectrum. GPC measurements also confirmed successful copolymer synthesis and 
showed the resulting copolymer to have a narrow polydispersity of 1.08 and Mn of 9752 
g mol-1. 
 
 
Synthesis and characterization of mPEG-b-P(CB-co-LA-co-MAC) copolymer 
 
The synthetic procedure for mPEG-b-P(CB-co-LA-co-MAC) copolymer is shown 
in Figure 6-6. mPEG-b-P(CB-co-LA-co-MAC) copolymer was obtained by ring opening 
polymerization of CB, MAC and LA using PEO as a macroinitiator and DBU as a 
catalyst. The monomer to initiator mole ratio was set at 20:1 with MAC monomer 
constituting 8 mol%. Addition of 5 mol% DBU resulted in greater than 80% monomer 
conversion in 3 h affording copolymer with controlled molecular weights and low. 
polydispersity. 1H NMR spectrum (Figure 6-5B) of mPEG-b-P(CB-co-LA-co-MAC) 
copolymer showed the following resonance peaks at δ 3.65, 5.12, 5.28-5.8 and 7.3 
attributable to the methylene protons of mPEG, the methylene protons of lactide, the 
acryloyl protons of MAC and the phenyl protons of carbonate, respectively. Furthermore, 
the signals at 4.25-4.35 reflect the methylene protons in the carbonate main chain and 
confirm successful ring opening polymerization of the carbonate monomers. The 
molecular weight of mPEG-b-P(CB-co-LA-co-MAC) copolymer was estimated to be 
10020 g/mol using the mPEG ( δ = 3.65), LA (δ = 5.12), CB (δ = 7.3) and MAC (δ = 5.8) 
characteristic peaks. GPC revealed mPEG-b-P(CB-co-LA-co-MAC) copolymer to have a 
polydispersity of 1.08 and Mn of 10279 g/mol which was close to the theoretical 
molecular weight and that determined by 1H NMR spectroscopy. 
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Figure 6-5. 1H NMR spectra for lactic acid and carbonate-based copolymer for 
crosslinked micelles.  
 
(A) Methoxy poly (ethylene glycol)-b-poly (5-methyl-5-allyl-1,3-dioxane-2-one)-b-
poly(carbonate-co-lactide) [mPEG-b-PMAC-b-P(CB-co-LA)] copolymer in CDCl3. 
(B) Methoxy poly (ethylene glycol)-b-poly (5-methyl-5-allyl-1,3-dioxane-2-one-co-
carbonate-co-lactide) [mPEG-b-P(CB-co-LA-co-MAC)] copolymer in CDCl3.  
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Table 6-1. Characteristics of lactic acid and carbonate-based copolymers. 
 
Block copolymera
 
 Mn 
(1H NMRb) 
Mn 
(GPCc) 
Mw 
(GPCc) 
Mw/Mn 
(GPCc) 
CMC(g /L) 
      
mPEG114-b-P(CB8-co-LA35-co-MAC2.5)   10020 10279 11103 1.08 0.001 
mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) 10558 9752 10491 1.08 0.0008 
a Subscripts reflect degree of polymerization of each monomer obtained from 1H NMR spectroscopy. b Molecular weight 
calculated from 1H NMR spectroscopy in g/mol. c Molecular weight obtained from GPC in g/mol. 
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Figure 6-6. Synthesis method for preparation of lactic acid and carbonate-based crosslinked micelles. 
 
Conditions: (i) DBU, CH2Cl2, RT, 3 h. (ii) AIBN, 60°C.  
  
i
mPEG-b-P(LA-co-CB-co-MAC)
+
mPEG
LA
CB MAC
ii
 124 
 
Microstructure analysis and polymer toxicity   
 
MAC arrangement is expected to be blocky in mPEG-b-PMAC-b-P(CB-co-LA) 
and random in mPEG-b-P(CB-co-LA-co-MAC) copolymers. Since 13C NMR 
spectroscopy is sensitive to chemical shifts of the quaternary carbon in the polymer 
backbone and secondary carbon in the side group, it was used to confirm MAC 
arrangement in both copolymers. The 13C NMR spectra of mPEG-b-PMAC-b-P(CB-co-
LA) and mPEG-b-P(CB-co-LA-co-MAC) copolymers are shown in Figure 6-7A and B, 
respectively, and further confirm successful copolymer synthesis. However, to determine 
MAC monomer arrangement, the 13C NMR spectra of mPEG-b-PMAC, mPEG-b-
PMAC-b-P(CB-co-LA), mPEG-b-P(CB-co-LA-co-MAC) and mPEG-b-P(CB-co-LA) 
copolymers were analyzed by observing peaks at 65.82 ppm (secondary carbon) and 
46.48 ppm (quaternary carbon), respectively.  
From Figure 6-8, a distinctive peak can be observed at 65.82 ppm for mPEG-b-
PMAC copolymer synonymous with the secondary carbon on the allyl group. This 
characteristic peak at 65.82 ppm is also evident for mPEG-b-PMAC-b-P(CB-co-LA) 
copolymer suggesting presence of mPEG-b-PMAC block in mPEG-b-PMAC-b-P(CB-co- 
LA) copolymer. The additional peak shifted downfield is assigned as the same carbon of 
MAC unit adjacent to P(CB-co-LA) which is reasonable since PMAC is short (n = 2.5). 
In contrast, the characteristic secondary carbon peak of MAC shifts downfield for mPEG-
b- P(CB-co-LA-co-MAC) copolymer, indicating lack of MAC block sequence. This 
MAC peak is clearly absent in mPEG-b-P(CB-co-LA) copolymer. Furthermore, the 46.48 
ppm peak representing the quaternary carbon in mPEG-b-PMAC main chain is seen in 
the spectra of mPEG-b-PMAC-b-P(CB-co-LA) copolymer. The same peak is seen for 
mPEG-b-PMAC-b-P(CB-co-LA) overlapped with the broad peak which is corresponding 
to the quaternary carbon from the CB unit. Unlike mPEG-b-PMAC and mPEG-b-PMAC-
b-P(CB-co-LA), the 46.48 ppm peak is shifted downfield for mPEG-b-P(CB-co-LA-co-
MAC) demonstrating random distribution of MAC monomer. A similar broad peak can 
be observed for mPEG-b-P(CB-co-LA) reflecting contribution from the CB quaternary 
carbon. Since allyl compounds can be toxic, we evaluated the toxicity of mPEG-b-
PMAC-b-P(CB-co-LA) and mPEG-b-P(CB-co-LA-co-MAC) copolymers in LNCaP 
prostate cancer cell lines. Our data reveal both copolymers are not toxic up to 2000 
µg/mL (Figure 6-9). 
In contrast, the characteristic secondary carbon peak of MAC shifts downfield for 
mPEG-b-P(CB-co-LA-co-MAC) copolymer, indicating lack of MAC block sequence. 
This MAC peak is clearly absent in mPEG-b-P(CB-co-LA) copolymer. Furthermore, the 
46.48 ppm peak representing the quaternary carbon in mPEG-b-PMAC main chain is 
seen in the spectra of mPEG-b-PMAC-b-P(CB-co-LA) copolymer. The same peak is seen 
for mPEG-b-PMAC-b-P(CB-co-LA) overlapped with the broad peak which is 
corresponding to the quaternary carbon from the CB unit. Unlike mPEG-b-PMAC and 
mPEG-b-PMAC-b-P(CB-co-LA), the 46.48 ppm peak is shifted downfield for mPEG-b-
P(CB-co-LA-co-MAC) demonstrating random distribution of MAC monomer. A similar 
broad peak can be observed for mPEG-b-P(CB-co-LA) reflecting contribution from the 
CB quaternary carbon. Since allyl compounds can be toxic, we evaluated the toxicity of 
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Figure 6-7. 13C NMR spectra for lactic acid and carbonate-based copolymer for 
crosslinked micelles. 
 
(A) Methoxy poly (ethylene glycol)-b-poly (5-methyl-5-allyl-1,3-dioxane-2-one)-b-
poly(carbonate-co-lactide) [mPEG-b-PMAC-b-P(CB-co-LA)] copolymer in CDCl3. (B) 
Methoxy poly (ethylene glycol)-b-poly (5-methyl-5-allyl-1,3-dioxane-2-one-co-
carbonate-co-lactide) [mPEG-b-P(CB-co-LA-co-MAC)] copolymer in CDCl3. 
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Figure 6-8. 13C NMR spectra comparative plot for mPEG-b-PMAC, mPEG-b-
PMAC-b-P(CB-co-LA), mPEG-b-P(CB-co-LA-co-MAC) and mPEG-b-P(CB-co-LA) 
demonstrating differences in monomer arrangement. 
 
  
(ppm)65.865.966.066.166.266.3 (ppm)46.446.546.646.7
mPEG-b-P(CB-co-LA)
mPEG-b-P(CB-co-LA-co-MAC)
mPEG-b-PMAC-b-P(CB-co-LA)
mPEG-b-PMAC
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Figure 6-9. Cytotoxicity of mPEG-b-PMAC-b-P(CB-co-LA) and mPEG-b-P(CB-
co-LA-co-MAC) copolymers in prostate cancer cells.  
 
LNCaP cells were incubated with various concentrations of copolymers (0 – 2000 
µg/mL) for 48 h and cell viability determined by MTT assay. Data are presented as mean 
±  standard deviation (n = 3). 
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mPEG-b-PMAC-b-P(CB-co-LA) and mPEG-b-P(CB-co-LA-co-MAC) copolymers in 
LNCaP prostate cancer cell lines. Our data reveal both copolymers are not toxic up to 
2000 µg/mL (Figure 6-9). 
 
 
Effect of polymer composition and MAC location on CMC, particle size and drug 
loading  
 
Slight changes in polymer composition (e.g., monomer content and arrangement) 
can affect micelle properties. Therefore, we examined the effect of polymer composition, 
MAC location and crosslinking on CMC, size and drug loading. The CMC of mPEG-b-
P(CB-co-LA-co-MAC) was found to be 0.001 g/L. In contrast mPEG-b-PMAC-b-P(CB-
co-LA) had a CMC of 0.0008 g/L. These results when juxtaposed with our previous 
findings [170] suggests the presence of the intermediate MAC block results in 
copolymers that form more thermodynamically stable micelles compared to random 
distribution of MAC in the hydrophobic core. 
 
Subsequently, micelle size and drug-loading content were determined following 
preparation by the film sonication method. We observed the introduction of MAC 
monomer did not affect the micelle forming ability or morphology of the block 
copolymers regardless of its location. Micelle size and morphology were examined by 
dynamic light scattering (DLS) and transmission electron microscopy, respectively. 
Average hydrodynamic size was 123 ± 3.02 nm for mPEG-b-P(CB-co-LA-co-MAC) 
copolymer while that of mPEG-b-PMAC-b-P(CB-co-LA) was 128 ± 1.10 nm (Tables  
6-2 and 6-3) with both copolymers resulting in micelles possessing low PDI values (0.12-
0.15; reference Tables 6-2 and 6-3) implying a narrow micelle size distribution. 
Furthermore, our findings suggest inclusion of drug resulted in a modest increase in 
micelle size. Specifically, micelle size was 139 ± 1.05 nm for mPEG-b-P(CB-co-LA-co-
MAC) copolymer while that of mPEG-b-PMAC-b-P(CB-co-LA) was 133 ± 1.49 nm. 
However, drug-loaded micelles still exhibited low PDI values.  
 
We next quantified the amount of drug loaded into the micelles in terms of drug 
loading density (Equation 6-1) and encapsulation efficiency (Equation 6-2). From 
Table 6-2, mPEG-b-P(CB-co-LA-co-MAC) copolymer had superior drug loading 
characteristics compared to mPEG-b-PMAC-b-P(CB-co-LA). Based on a 5% theoretical 
loading, mPEG-b-P(CB-co-LA-co-MAC) had a drug loading density of 3.79% ± 0.56 
indicating an encapsulation efficiency of 78.72% ± 0.15. In contrast, drug loading density 
for mPEG-b-PMAC-b-P(CB-co-LA) was computed to be 1.01% ± 0.73 reflecting a 
20.29% ± 0.11 encapsulation efficiency. Furthermore, surface charge of the micelles 
prepared from both copolymers were observed to be slightly negative: -0.96 ± 0.05 and -
5.52 ± 0.13 mV for mPEG-b-P(CB-co-LA-co-MAC) and mPEG-b-PMAC-b-P(CB-co-
LA), respectively. 
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Table 6-2. Effect of polymer composition and MAC location on particle size and drug loading in noncrosslinked 
micelles. 
 
Block copolymer
 a Size (nm)b
 
  PDI Drug loading 
(%) ± 
SD
c 
Encapsulation 
efficiency (%) ± 
SD 
     
Before Drug Loading     
mPEG114-b-P(CB8-co-LA35-co-MAC2.5)   123.0 ± 3.02 0.15 ± 0.01 - - 
mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) 128.0 ± 1.10 0.12 ± 0.01 - - 
     
After Drug Loading     
mPEG114-b-P(CB8-co-LA35-co-MAC2.5)   139.0 ± 1.05 0.10 ± 0.02 3.79 ± 0.56 75.72 ± 0.15 
mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) 133.0 ± 1.49 0.04 ± 0.01 1.01 ± 0.73 20.29 ± 0.11 
     
 
a Subscripts reflect degree of polymerization of each monomer obtained from 1H NMR spectroscopy. b Mean particle size was 
determined by dynamic light scattering. c Percentage of drug loaded into micelles based on 5% theoretical loading. 
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Table 6-3. Effect of polymer composition and MAC location on particle size and drug loading in crosslinked micelles. 
 
Block copolymer
 a
 Size (nm)
b  PDI Drug loading 
(%) ± SD
c
 
Encapsulation 
efficiency (%) ± 
SD 
     
Before Drug Loading     
mPEG114-b-P(CB8-co-LA35-co-MAC2.5)   151.0 ± 1.69 0.12 ± 0.04 - - 
mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) 135.0 ± 1.89 0.20 ± 0.03 - - 
     
After Drug Loading     
mPEG114-b-P(CB8-co-LA35-co-MAC2.5)   118.0 ± 1.70 0.10 ± 0.01 3.21 ± 2.11 64.08 ± 0.48 
mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) 122.0 ± 0.81 0.12 ± 0.01 0.89 ± 0.10 17.77 ± 0.02 
     
 
a Subscripts reflect degree of polymerization of each monomer obtained from 1H NMR spectroscopy. b Mean particle size was 
determined by dynamic light scattering. c Percentage of drug loaded into micelles based on 5% theoretical loading. 
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Effect of crosslinking on particle size, morphology and drug loading  
 
Next, mPEG-b-P(CB-co-LA-co-MAC) and mPEG-b-PMAC-b-P(CB-co-LA) 
copolymers were suitably crosslinked in a mixture of THF and water at 70°C using AIBN 
as the initiator. Pendant allyl moieties in the core and interface of copolymers allowed 
convenient crosslinking in the presence of AIBN initiator. 1H NMR and IR spectroscopy 
was used to confirm the success of crosslinking. As shown in Figure 6-10A, a prominent 
peak at δ 5.8 ppm (acryloyl proton) can clearly be seen in the non-crosslinked micelles. 
In contrast, the signal significantly weakened for the crosslinked sample (Figure 6-10B) 
together with the methylene protons of allyl group at 4.6 ppm. Quantitative analysis from 
the 1H NMR spectra revealed 69% crosslinking efficiency. IR spectroscopy also 
confirmed successful crosslinking as indicated by the weakening of the 1650 cm-1 peak 
corresponding to the alkene group (Figure 6-11).  
 
From our studies, crosslinking of non-drug loaded micelles generally led to an 
increase in micelle size compared to their non-crosslinked counterparts (Table 6-2). This 
size change was greater for mPEG-b-P(CB-co-LA-co-MAC) which increased from 123 ± 
3.02 nm to 151 ± 1.69 nm compared to mPEG-b-PMAC-b-P(CB-co-LA) where size was 
128 ± 1.10 nm and 135 ± 1.89 nm before and after crosslinking, respectively. 
Interestingly, we observed crosslinking of drug loaded micelles resulted in a decrease in 
size compared to their non-crosslinked counterparts (Tables 6-2 and 6-3). Here again, the 
size change was greater for mPEG-b-P(CB-co-LA-co-MAC) compared to mPEG-b-
PMAC-b-P(CB-co-LA) (21 nm vs. 11 nm). Our findings also suggest crosslinking 
resulted in a modest decrease in drug loading regardless of copolymer type. Furthermore, 
TEM analysis demonstrates that crosslinking does not significantly alter micelle 
morphology (Figure 6-12). 
 
 
Effect of crosslinking on stability 
 
After confirming successful crosslinking of micelles, we next examined the effect 
of crosslinking on micelle stability in physiologically relevant and extreme micelle 
destabilization conditions. Since micelles encounter sink like conditions upon systemic 
administration, we first examined the stability of non-crosslinked and crosslinked 
micelles in PBS at micelle concentrations of 200, 20, 2 and 0.20 µg/mL. Both non-
crosslinked micelles (NCM) and crosslinked micelles (CM) remained intact up to 2 
µg/mL micelle concentration further demonstrating the thermodynamic stability of both 
micelle systems. Under these conditions, non-crosslinked micelles had an average size of 
123 ± 3.02 nm with 0.15 ±0.01 PDI while crosslinked micelles exhibited an average size 
of 127 ± 3.69 nm with 0.16 ± 0.02 PDI. However, the non-crosslinked micelles 
dissociated when micelle concentration was 0.20 µg/mL, whereas the crosslinked 
micelles maintained their nanostructure (Figure 6-13A).  
 
We next investigated the stability of micelles with or without drug in the presence 
of serum for 24 and 48 h. From Figure 6-13B, non-crosslinked micelles (NCM) appeared 
to aggregate with time as indicated by increase in particle size. For example, the di/d0  
 132 
 
 
 
Figure 6-10. 1H NMR spectra for methoxy poly (ethylene glycol)-b-poly (5-methyl-
5-allyl-1,3-dioxane-2-one-co-carbonate-co-lactide) [mPEG-b-P(MAC-co-CB-co-LA)] 
copolymer in CDCl3. 
 
(A) Before crosslinking and (B) after crosslinking.  
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Figure 6-11. FTIR spectra for lactic acid and carbonate-based copolymer. 
 
(A) Before crosslinking and (B) after crosslinking. Arrow indicates weakening of 1650 
cm-1 peak reflecting crosslinking of double bonds. (C) Peaks at 1650 cm-1 zoomed in and 
offset for clarity; Top (before crosslinking) and Bottom (after crosslinking). 
 
  
 134 
 
 
 
Figure 6-12. TEM images of (A) non-crosslinked and (B) crosslinked micelles. 
 
A B
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Figure 6-13. Stability of mPEG-b-PMAC-b-P(CB-co-LA) non-crosslinked (NCM) and crosslinked micelles (CM). 
 
(A) Micelle stability against 1000 fold dilution. (B) Micelle stability in bovine serum albumin (BSA) after 24 and 48 h. 
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(diameter at specified time to diameter at t = 0) ratio increased from approximately 1 to 4 
and 8 at 24 and 48 h, respectively. We also determined the CMC of mPEG-b-P(CB-co-
LA-co-MAC) non-crosslinked micelle and crosslinked micelles as a secondary measure 
of stability. Our results reveal uncrosslinked micelles had a CMC value of 1 mg/L based 
on where the two tangent lines intersect. In contrast, CMC of crosslinked micelles was 
determined to be 0.06 mg/L. These results demonstrate crosslinked micelles enhanced 
stability compared to uncrosslinked micelles. 
 
 
In vitro cytotoxicity of mPEG-b-PMAC-b-P(CB-co-LA) and mPEG-b-P(CB-co-LA-co-
MAC) non-crosslinked (NCM) and crosslinked micelles (CM)  
 
The inhibitory effect of bicalutamide-loaded mPEG-b-PMAC-b-P(CB-co-LA) 
and mPEG-b-P(CB-co-LA-co-MAC) non-crosslinked (NCM) and crosslinked micelles 
(CM) micelles was determined in LNCaP human prostate cancer cell line for 24 h. From 
Figure 6-14, bicalutamide-loaded crosslinked micelles more potently inhibited LNCaP 
cell growth compared to bicalutamide-loaded non-crosslinked micelles regardless of 
polymer type. For bicalutamide-loaded mPEG-b-PMAC-b-P(CB-co-LA) micelles, IC50 
for non-crosslinked micelles was ~ 47.2 µM while that of crosslinked micelles was ~ 15.0 
µM. Similarly, bicalutamide-loaded mPEG-b-P(CB-co-LA-co-MAC) non-crosslinked 
micelles had an IC50 of ~ 36.9 µM whilst crosslinked micelles had IC50 of ~ 15.4 µM. 
Bicalutamide is known to affect expression of prostate specific antigen (PSA) which is 
downstream of and regulated by the androgen-androgen receptor signaling axis. 
Therefore, we examined the effect of bicalutamide-loaded crosslinked and non-
crosslinked micelles on secreted PSA following incubation in LNCaP cells for 24 h. Our 
results suggest that bicalutamide micelles reduce secreted PSA expression by 
approximately 50% compared to control, irrespective of polymer type and presence of 
crosslinking (Figure 6-15). 
 
 
Discussion 
 
Polymeric micelles are promising drug delivery platforms [11, 170, 247, 279-
281]. Insight accruing from micelle research particularly in oncology has led to the 
strategic design and synthesis of novel polymers to address the key issues of adequate 
drug loading, targetability, sustained drug release and degradation. Despite significant 
advances made in these areas, one reason the pharmaceutical industry has not fully 
adopted micelle formulations is their perceived instability especially in biological 
environments. The purpose of our study is to address this pertinent issue through the 
synthesis, characterization and in vitro evaluation of innovative lactic acid and carbonate 
based crosslinked micelles for enhanced drug delivery. 
 
We have successfully synthesized mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and 
mPEG114-b-P(CB8-co-LA35-co-MAC2.5) copolymers for core-corona interface 
crosslinked and core crosslinked micelles, respectively (Figure 6-3). The design of these 
copolymers was guided by our desire to improve upon the existing micelle properties
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  mPEG-b-PMAC-b-P(CB-co-LA) mPEG-b-P(CB-co-LA-co-MAC) 
NCM CM NCM CM 
 
Figure 6-14. Anticancer effect of mPEG-b-PMAC-b-P(CB-co-LA) and mPeg-b-P(CB-so-LA-co-MAC) 
non-crosslinked (NCM) and crosslinked micelles (CM). 
 
3 x 103 LNCaP cells were incubated with bicalutamide-loaded micelle formulations (0, 25 and 50 µM of 
drug) for 24 h. Cell viability was determined using MTT assay and results represented as the mean ± SD of 
triplicates. *p < 0.05; **p < 0.01 using student’s unpaired t-test. 
 138 
 
 
Figure 6-15. Effect of bicalutamide-loaded mPEG-b-PMAC-b-P(CB-co-LA) and mPEG-b-P(CB-co-LA-co-MAC) 
non-crosslinked (NCM) and crosslinked micelles (CM) (50 µM of drug) on secreted prostate specific antigen (PSA) 
following 24 h incubation. 
 
* p < .05 using student’s unpaired t-test. 
PEG-b-PMAC-b-P(CB-co-LA) PEG-b-P(CB-co-LA-co-MAC) 
  
* 
* * * 
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obtained using our previously synthesized mPEG-b-P(CB-co-LA) copolymers, especially 
with regards to sub CMC and serum stability. Therefore, we decided to strategically 
introduce chemical crosslinks at the core-corona interface with the goal of creating a 
molecular fence to improve micelle integrity and sustained release. We also introduced 
crosslinks in the core as a complimentary approach and to demonstrate the flexibility of 
our crosslinking approach. Although a variety of chemistries (e.g., click chemistry, 
disulfide bond) can be used for crosslinking, we judiciously selected the MAC monomer 
as our crosslinking moiety since we did not want to dramatically alter the superior 
attributes of mPEG-b-P(CB-co-LA) copolymer (e.g., drug loading, thermodynamic 
stability, micelle architecture and biodegradability). MAC has close structural similarity 
to our well-studied cyclic carbonate (CB) monomer except it has an allyl pendant group 
in contrast to the phenyl pendant of CB. Therefore, we were confident that the 
introduction of MAC will not significantly change the backbone or hydrophilic lipophilic 
balance (HLB) of the polymer. We synthesized MAC monomer using two approaches 
(Figure 6-1) and used 1H NMR and FT-IR spectrometry to confirm its structure. No FT-
IR data was found in the literature, however, our 1H NMR spectrum matched the 
literature [274]. While the first approach had a shorter overall reaction time, the second 
approach was preferred since it resulted in higher MAC yields (70% vs. 30%) and had 
fewer steps (2 vs. 4). Our MAC yield of 70% was comparable to that reported by Hu and 
coworkers [274]. Furthermore, unlike the first approach, which required column 
chromatography, pure compounds could be obtained with recrystallization in the second 
approach, making it less labor intensive. Recently, Chen et al. also synthesized a couple 
of cyclic carbonate monomers similar to MAC [282]. However, their synthetic scheme 
required four steps, with overall yields of 40%, which is lower than our preferred second 
approach. 
 
mPEG-b-P(CB-co-LA) copolymers previously synthesized using Sn(Oct)2 
catalyzed ring-opening polymerization (ROP) exhibited relatively high PDIs (around 1.4) 
possibly due to undesired transesterification [170]. Furthermore, increasing CB content 
affected lactide reactivity. Therefore, we used the organic base catalyst DBU (pKa = 
24.3)[283] for synthesizing mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and mPEG114-b-
P(CB8-co-LA35-co-MAC2.5) copolymers. DBU is known to mitigate unwanted 
transesterification resulting in polymers with well controlled molecular weights and low 
PDIs. In synthesizing mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) we first sought to 
understand how the reactivity of MAC compares with CB using mPEG as a macro 
initiator. Our findings suggest the reactivity of MAC (80% conversion in 2 h (Figure  
6-4) to be similar to that of CB (data not shown) indicating the pendant group does not 
significantly impact the reactivity of the cyclic carbonate monomers. The DBU catalyzed 
conversion of our cyclic carbonates is higher than that of trimethyl carbonate (TMC) 
(80% vs 70%) reported by Watanabe and coworkers; however, they used 4-
(Chloromethyl)benzyl alcohol as an initiator [284]. Our kinetic study suggests MAC 
polymerization with mPEG to be first-order as demonstrated by the linear nature of the 
ln(1/(1-x)) vs. time plot (Figure 6-4B). This result is not surprising since DBU and 
mPEG concentrations do not change during polymerization. Qian et al. have reported 
similar first-order dependency with respect to monomer, DBU and macro initiator 
concentrations for ring opening polymerization (ROP) of lactide and glycolide [285]. 
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Furthermore, ROP of valerolactone using similar amidine catalysts have been shown to 
follow first-order kinetics with respect to catalyst, alcohol initiator and monomer  
concentration [286]. Although we did not systematically study the polymerization 
kinetics upon addition of CB and LA, a time of 3h was sufficient to obtain polymers with 
targeted mass ratios of MAC, CB and LA for both mPEG114-b-PMAC2.5-b-P(CB9-co-
LA39) and mPEG114-b-P(CB8-co-LA35-co-MAC2.5) copolymers (inferred from 1H NMR 
spectra). Furthermore, DBU catalyzed polymerization allowed us to obtain polymers in a 
relatively short time and avoided MAC crosslinking observed during initial 
polymerization studies attempted using Sn(Oct)2 at 120°C. 
 
Monomer arrangement in a copolymer significantly impacts its physico-chemical 
properties and consequently key micelle properties. Consequently, we performed 
microstructure analysis on mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and mPEG114-b-
P(CB8-co-LA35-co-MAC2.5) copolymers to confirm MAC arrangement in the 
copolymers. By systematically observing the shift in 65.82 ppm (secondary carbon) and 
46.48 ppm (quaternary carbon) peaks in the 13C NMR spectra of mPEG-b-PMAC, 
mPEG-b-PMAC-b-P(CB-co-LA), mPEG-b-P(CB-co-LA-co-MAC) and mPEG-b-P(CB-
co-LA) copolymers, we were able to show MAC arrangement to be block in mPEG-b-
PMAC-b-P(CB-co-LA) and random in mPEG-b-P(CB-co-LA-co-MAC). Typically, 
reported microstructure analyses of ester based copolymers utilize the carbonyl group in 
the polymer main chain. However, the close similarity between the contribution of MAC 
and CB to copolymer backbone complicates such analysis and it is not feasible to use 
carbonyl groups in the polymer backbone for microstructure analysis in the current study. 
 
Although inclusion of MAC monomer added a layer of complexity in terms of 
microstructure analysis, our results suggest that it does not detrimentally affect micelle 
forming ability or key properties. Both mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and 
mPEG114-b-P(CB8-co-LA35-co-MAC2.5) micelles exhibited similar size (with or without 
drug) which was slightly larger than mPEG-b-P(CB-co-LA) micelles prepared in our 
previous study [170]. Since micelle size is dependent on core composition and length 
(molecular weight), it appears this increase may be due to the contribution of the MAC 
monomer and relatively larger quantities of lactide present in mPEG114-b-PMAC2.5-b-
P(CB9-co-LA39) and mPEG114-b-P(CB8-co-LA35-co-MAC2.5) copolymers compared to  
mPEG114-b-P(CB8-co-LA24) and mPEG114-b-P(CB9-co-LA5) copolymers. Our results are 
consistent with the fact that hydrophobic blocks with higher molecular weight have 
generally been shown to have larger sizes. Notwithstanding, drug loading and 
encapsulation efficiency in crosslinked micelles were comparable to mPEG114-b-P(CB8-
co-LA24) and mPEG114-b-P(CB9-co-LA5) micelles possessing similar CB content. The 
difference in bicalutamide loading between mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and 
mPEG114-b-P(CB8-co-LA35-co-MAC2.5) micelles may be attributed to CB content. Our 
previous studies clearly showed that CB degree of polymerization (DP) of nine resulted 
in a precipitous decrease in bicalutamide loading compared to DP of 8 [170]. 
Furthermore, our results provide indirect evidence supporting our hypothesis that the 
structure and quantities of MAC present in the copolymer do not significantly alter drug 
loading characteristics.  
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Interestingly, mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and mPEG114-b-P(CB8-co-
LA35-co-MAC2.5) micelles exhibited CMCs better than or comparable to mPEG-b-P(CB-
co-LA) micelles with similar CB content suggesting equivalent if not better 
thermodynamic stability. Specifically, mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) micelles 
had a CMC of 0.0008 g/L while previously reported CMC of mPEG114-b-P(CB9-co-LA5) 
micelles was 0.004 g/L. Since CB content is the same in both copolymers, this five-fold 
improvement in CMC value is due to the presence of MAC and LA. However, CMC 
depends on both composition and molecular mass of the hydrophobic core [287, 288].  
Therefore, it is difficult to clearly ascertain the individual contribution of MAC due to 
considerable difference in overall core length between mPEG114-b-PMAC2.5-b-P(CB9-co-
LA39) (Mn = 9992 g/mol) and mPEG114-b-P(CB9-co-LA5) (Mn = 7510 g/mol). 
Additionally, mPEG114-b-P(CB8-co-LA35-co-MAC2.5) micelles had a CMC of 0.001 g/L 
compared to 0.002 g/L for mPEG114-b-P(CB8-co-LA24) micelles reported previously. 
Here, the modest improvement is most likely due to the presence of MAC since CB 
content is the same and the LA amounts are relatively close. Our results demonstrate that 
the CMC of mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) and mPEG114-b-P(CB8-co-LA35-co-
MAC2.5) micelles is sensitive to the presence of MAC but more importantly to its location 
and arrangement: block versus random distribution among CB and LA. 
 
Crosslinking based on double bonds requires a radical initiator and exposure to 
heat or ultraviolet (UV) light. Our copolymers were successfully crosslinked using AIBN 
as radical initiator at a temperature of 70°C for 24 h. We observed crosslinking efficiency 
of approximately 70% which was slightly lower than the 80% value reported in the 
literature [277]. Complete crosslinking may not be possible since all the allyl moieties 
present will have to be in close proximity for this to occur. However, it is unlikely that 
micelle architecture would permit all the double bonds to be within the effective distance 
required for crosslinking. Theoretically, a few rightly positioned crosslinks would be 
sufficient to improve micelle mechanical integrity and 100% crosslinking efficiency is 
not required. We found crosslinking of blank micelles caused a modest increase in size. 
This we believe may be an artifact of the crosslinking process since THF used in the 
process is known to cause micelles to swell. Unexpectedly, crosslinking of drug loaded 
micelles resulted in a decrease in micelle size regardless of MAC location. This was 
accompanied by a small loss in drug loading and encapsulation efficiency post 
crosslinking. The reduction in drug loading and encapsulation efficiency may be due to 
leakage during the crosslinking process and may account for the modest size decrease 
observed after crosslinking. 
 
Polymeric micelles are dynamic in nature and gradually disintegrate under sub 
CMC conditions. Therefore, monitoring changes in micelle size (using DLS) at different 
dilutions is an elegant way to determine micelle stability. Our results reveal crosslinked 
micelles remain intact even below the CMC (Figure 6-13A) while non-crosslinked 
micelles disintegrated. CMC for crosslinked micelles was found to be 20-fold lower 
compared to non-crosslinked micelles confirming the fact that crosslinked micelles were 
several times more stable than their non-crosslinked counterparts. It is worth mentioning 
that, although CMC of crosslinked micelles has little practical meaning it still provides a 
reasonable measure of the extent in improvement in micelle mechanical integrity. 
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Micelles have also been shown to become unstable once they encounter blood 
components [266, 287, 289]. Instability may result from protein adsorption, protein 
penetration or drug extraction [287]. Since the most abundant protein in blood plasma is 
serum albumin, we investigated the effect of physiological simulating concentrations of 
BSA (45 mg/mL) on crosslinked and non-crosslinked micelle stability using DLS to 
observe time dependent changes in micelle size. Our results showed significant increase 
in size of non-crosslinked micelles with time and reflect aggregation of micelles in BSA. 
This phenomenon may be due to protein adsorption which is undesirable since it can 
result in fast clearance by the mononuclear phagocyte system (MPS) [290]. It has been 
shown that BSA-micelle interaction is typically driven by hydrophobic aggregation. For 
instance, micelles with high density hydrophilic corona experience greater steric 
stabilization and encounter less BSA interaction [291]. Other instances of polymeric 
micelle aggregation and interaction with BSA have been reported in the literature [291, 
292]. In contrast, there was no appreciable increase in the size of crosslinked micelles 
following incubation with BSA. One reason may be the less dynamic nature of 
crosslinked micelles which limits the continuous interchange of unimers thereby reducing 
the possibility of BSA interacting with the hydrophobic core. It is also likely that the 
presence of covalent crosslinks make it difficult for BSA to disrupt micelle architecture 
thus preventing BSA-micelle aggregates.  
 
 
Conclusions 
 
To address the current need for biodegradable, biocompatible and stable 
polymeric micelle delivery systems, we report on the synthesis, characterization and 
evaluation of lactic-acid and carbonate-based copolymers containing an allyl moiety for 
preparing interface and core crosslinked micelles. A series of complimentary 
spectroscopic techniques was used to confirm successful synthesis by ring opening 
polymerization, elucidate polymer microstructure and confirm crosslinking. mPEG114-b-
PMAC2.5-b-P(CB9-co-LA39) and mPEG114-b-P(CB8-co-LA35-co-MAC2.5) copolymers for 
interface and core crosslinking, respectively, displayed low polydispersity (1.08) and 
CMC values (0.8-1 mg/L). Inclusion of MAC monomer did not significantly alter micelle 
size or morphology irrespective of polymer composition or MAC location. Importantly, 
mPEG114-b-P(CB8-co-LA35-co-MAC2.5) had a higher drug encapsulation efficiency 
(78.72%  ± 0.15) compared to mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) (20.29% ± 0.11). 
Subsequent micelle crosslinking did not dramatically change drug loading or micelle 
morphology. However, there was strong link between micelle crosslinking and improved 
stability when incubated in aqueous media under extensive dilution and physiological 
simulating serum (BSA ~ 45 mg/mL). Crosslinked micelle size remained unchanged 
while non-crosslinked micelles disintegrated at a thousand fold dilution. Besides, 
crosslinked micelle size remained unchanged in BSA whereas there was a time-
dependent increase in the size of non-crosslinked micelles. These results showed 
crosslinked micelles to be more stable compared to their non-crosslinked counterparts. 
Additionally, bicalutamide-loaded crosslinked micelles were found to be more potent in 
inhibiting proliferation of LNCaP prostate cancer cells compared to non-crosslinked 
micelles regardless of polymer type. In all, we have demonstrated that these new 
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biodegradable copolymer systems are potentially useful for cancer therapy. Future studies 
on influence of MAC block length, extent of crosslinking efficiency and ratio of MAC to 
CB and LA on key micelle properties are required to generate material design rules which 
can be utilized for customized fabrication of improved micelle delivery platforms.   
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CHAPTER 7.    ANDROGEN RECEPTOR AND XIAP GENE SILENCING 
INHIBITS CELL PROLIFERATION AND INDUCES APOPTOSIS IN 
HORMONE REFRACTORY PROSTATE CANCER 
 
 
Introduction 
 
To date, therapeutic options for advanced prostate cancer are typically palliative 
and largely ineffective in the long term. Profound gaps in our understanding regarding 
mechanisms leading to progression of prostate cancer coupled with multidrug resistance 
(MDR) associated with small molecule based therapies and lack of enabling delivery 
technologies has hindered the emergence of potent therapies against advanced prostate 
cancer. Presently, the key role of the androgen receptor (AR) in prostate cancer 
progression has widely been accepted. For instance, it has been reported that all prostate 
cancers express the AR regardless of stage [293]. However, AR undergoes some 
characteristic mechanistic changes during progression to its advanced stage which render 
present anti-androgens (e.g., bicalutamide) ineffective. First, there is an altering of ligand 
specificity due to mutations in the AR leading to aberrant activation by non-androgenic 
molecules including anti-androgens [294]. Secondly, approximately a third of prostate 
cancers that recur due to failing endocrine therapy contain an AR gene amplification 
[295, 296]. In such cases, AR is overexpressed and causes prostate cancer cells to be 
hypersensitive to low levels of androgens resulting in continual androgen-dependent 
growth [296, 297]. These evidences suggest that AR signaling indeed plays a pivotal role 
in development and progression of prostate cancer. Therefore, emerging therapeutic 
strategies should include effectual approaches of down-regulating AR gene expression in 
cancerous cells rather than mere inactivation. 
 
Resistance to apoptosis is a hallmark of progression to advanced prostate cancer. 
This acquired defect in the apoptotic machinery arises from incapacitating mutations 
which provides cancer cells with an undesirable proliferation edge [298, 299]. 
Consequently, regulators of apoptosis such as Bcl-2 and inhibitors of apoptosis protein 
(IAPs) have attracted attention as potential therapeutic targets. IAPs prevent cell death in 
response to external stimuli by inhibiting downstream portions of the apoptotic pathway 
through endogenous suppression of caspase activity [182-184]. Among the various IAPs, 
X chromosome-linked IAP (XIAP) is the most potent and thoroughly characterized [184]. 
XIAP protein binds and inhibits the initiator caspase-9 and effector caspase-3 and 
caspase-7 through the binding of its BIR3 domain and the linker region between BIR1 
and BIR2, respectively; consequently inhibiting both intrinsic and extrinsic apoptotic 
pathways [185-188, 300]. The importance of XIAP as a therapeutic target has been 
supported by several lines of evidence. For example, expression levels of XIAP in human 
prostate cancer cells were found to correlate with apoptotic resistance [189, 190]. Also, in 
vitro studies showed XIAP overexpression to confer multiagent chemoresistance. 
Consistent with this hypothesis, down-regulation of XIAP using RNA interference 
(RNAi) technology and antisense oligonucleotides was found to sensitize malignant cell 
lines to chemotherapy [301-304].  
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We have previously shown that combination therapy targeting AR and XIAP 
using small molecules, such as bicalutamide and embelin is a promising approach to treat 
prostate cancer [11]. However, prolonged treatment results in bicalutamide functioning as 
agonists rather than antagonists due to AR mutations and amplification. Furthermore, 
most chemotherapeutics including embelin eventually succumb to multidrug resistance 
(MDR) due to the presence of ATP-Binding Cassette (ABC) transporters in cancer cells. 
Since RNA interference (RNAi) technology can overcome these major obstacles, we 
hypothesize that AR and XIAP gene silencing using RNAi technology will be more 
potent in treating advanced prostate cancer (Figure 7-1).  
 
RNAi is a double-stranded RNA-dependent endogenous gene silencing 
mechanism resulting in sequence-specific mRNA degradation [305]. Application of 
RNAi is gaining popularity in oncology as a therapeutic approach since theoretically any 
oncogene can be silenced. RNAi may be achieved using chemically synthesized small 
interefering RNA (siRNA) or vector based short hairpin RNA (shRNA). Synthesized 
siRNAs typically elicit quick gene silencing, however they are costly and the duration of 
silencing is short. In contrast, vector based shRNA results in longer gene silencing and is 
relatively cheaper [306]. Despite their potential benefits, clinical translation of siRNA 
and shRNAs has been limited by their low cellular uptake and susceptibility to enzymatic 
degradation in vivo due to their large molecular weight and negative charge. Hence, there 
is an urgent need to develop carriers for siRNA delivery. Polymeric carriers for RNAi 
have garnered interest since they can be engineered to possess moieties that can 
effectively bind and condense siRNA, enhance cellular uptake and reduce enzymatic 
degradation. 
 
In this work, we designed and screened six chemically synthesized siRNAs: three 
siRNAs targeting distinct regions of AR and XIAP mRNA, respectively. The most potent 
siRNA sequences for both genes were then selected and their effect on inducing 
apoptosis and inhibiting cell proliferation in prostate cancer cells as monotherapy or 
combination therapy examined. Synthetic siRNAs are prone to in vivo instability and 
tend to be exhorbitant. Therefore, we converted potent siRNA sequences against AR and 
XIAP into shRNAs and constructed a bipartite plasmid using psiRNA-DUO vector. We 
demonstrate that our bipartite plasmid effectively silences AR and XIAP gene expression 
and can lead to longer silencing effect compared to synthetic siRNA. Finally, we also 
synthesized and characterized a novel biodegradable and non-toxic N-(2-hydroxypropyl) 
methacrylamide (HPMA) based copolymer composed of polycationic, lipid and pka 
modulator moieties and report on its potential for efficient delivery of siRNA and shRNA 
plasmid vectors.  
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Figure 7-1.  Schematic diagram showing the combined effect of androgen 
receptor and XIAP gene silencing on apoptosis and tumor regression.  
 
Down-regulation of AR results in the inhibition of proliferation and invasion while down-
regulation of XIAP facilitates apoptotic mechanism. Hence, down-regulation of both AR 
and XIAP pathways results in potential synergistic effect in regressing tumors. 
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Materials and Methods  
 
 
Materials 
 
Human prostate cancer cell lines (LNCaP and C4-2) were cultured in Roswell 
Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA), with 10% 
fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic (100 x) (Invitrogen, Carlsbad, 
CA) in a 5% CO2 atmosphere at 37°C. TrypLETM Express and Lipofectamine 2000 were 
procured from Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA) (purity > 96%) 
was obtained from Sigma-Aldrich (St. Louis, MO). SYBR Green real time PCR master 
mix and reverse transcription reagents were purchased from Applied Biosystems (Foster 
city, CA). Human Total XIAP ELISA kit was purchased from R&D Systems 
(Minneapolis, MN). Primary and secondary antibodies were purchased from Abcam 
(Cambridge, MA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO) 
unless otherwise stated and were used as received.   
 
 
Design and synthesis of siRNA 
 
Three synthetic siRNAs targeting androgen receptor (AR) mRNA (Accension no.: 
NM_000044) and XIAP mRNA (Accension no.: NM_001167) were designed using 
BLOCK-iTTM RNAi Designer and obtained from Invitrogen (Carlsbad, CA). siRNA 
sequences and their start sites are listed in Table 7-1. The designed siRNA sequences 
were blasted against the human genome database to eliminate cross-silencing of 
nontarget genes.  
 
 
Synthesis of HPMA-g-APMA-g-MM-g-HM copolymers 
 
Copolymers were synthesized by free radical copolymerization of N-(2-
hydroxypropyl)methacrylamide (HPMA), N-(3-aminopropyl)methacrylamide 
hydrochloride (APMA), morpholinoethyl methacrylate (MM), and n-hexyl methacrylate 
(HM) in DMSO at 60 °C for 24 h using 2,2’-azobisisobutyronitrile (AIBN) as an initiator 
and mercaptopropanol as a chain transfer agent. Typically, HPMA (200 mg, 1.4 mmol), 
APMA (21 mg, 0.12 mmol), MM (46.3 mg, 0.23 mmol), and HM (138 mg, 0.70 mmol), 
AIBN (15 mg, 3 mol%) and Mercaptopropanol (12 µL, 6 mol%) were dissolved in 
DMSO (2.45 ml, 15 wt %), placed in an ampoule, purged with nitrogen for 5 min, and 
sealed. After the reaction the polymer was dissolved in water and dialyzed for 48 h using 
a 5000 MWCO membrane to remove unreacted monomer. The polymers were isolated by 
freeze drying with a yield of 70% and characterized using 1H-NMR using d-Methanol as 
solvent (Table 7-2).  
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Table 7-1. Small interfering RNA (siRNA) against human androgen receptor and X-linked inhibitor of apoptosis. 
 
Gene Sequence Start site 
AR (NM_000044)  
 CCGAGGAGCUUUCCAGAAU     1172 
 CCGCUGACCUUAAAGACAU     1648 
 CCACUUCCUCCAAGGACAA     1768 
   
XIAP (NM_001167)  
 ACACUGGCAGAGCAGGGUUUCUUU     264 
 GAAGGAGAUACCGUGCGGUGCUUA     297 
 CCAGAAUGGUCAGUACAAAGUUGAA     458 
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Table 7-2. Characterization of HPMA-g-APMA-g-MM-g-HM copolymers. 
 
Polymer HPMAa  HPMAb HMa  HMb  MMa  MMb  APMAa  APMAb 
MWc 
(kDa) PDId 
           
HPMA16-g-APMA1-g-
MM33-g-HM50 18.2 15.7 41.8 49.5 30 33.4 10 1.4 8.7 1.3 
           
HPMA32-g-APMA3-g-
MM22-g-HM43  26.6 32.1 33.4 42.9 20 22.3 20 2.7 8.3 1.2 
           
 
 
 
a 
Feed Ratio of Monomer; 
b
 determined by 
1
H NMR using d-MeOH as solvent;
 c 
determined by SEC using the MALS 
system on Superose 6 columns; 
d
 polydispersity (Mw/Mn). 
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Construction of shRNA expression plasmids 
 
Two potent siRNAs targeting AR (start site 3008) and XIAP (start site 297) were 
converted into shRNA (Table 7-3) and utilized for plasmid construction. pshRNA-3008, 
pshRNA-297 and pshRNA-3008-297 vectors were constructed using psiRNA-DUO 
vector, which contains two shRNA expression cassettes controlled by a human 7SK RNA 
polymerase III promoter and contains a green fluorescence protein (GFP) reported gene 
(InvivoGen, San Diego, CA). shRNAs were obtained by annealing two complementary 
oligonucleotides and ligated into psiRNA-DUO vector at 27°C for 2 h using T4 DNA 
ligase. Subsequently, the ligation mixture was transformed into XL2-blue ultracompetent 
cells (Agilent Technologies Inc, Santa Clara, CA), positive clones identified using 
white/blue selection, amplified in LB media and plasmids purified using Promega 
PureYieldTM Plasmid Miniprep Kit (Promega, Madison, WI). Four positive clones were 
sequenced to verify the shRNA insert sequence. 
 
 
Transfection of siRNA and shRNA 
 
LNCaP and C4-2 cells were seeded in 24-well plates at a density of 4 × 104 
cells/well and maintained in 0.5 mL of RPMI 1640 medium containing 10% fetal bovine 
serum (FBS) at 37°C and 5% overnight for attachment. siRNA duplexes (40 and 100 nM) 
and plasmid (1µg) were complexed with HPMA16-g-APMA1-g-MM33-g-HM50 and 
HPMA32-g-APMA3-g-MM22-g-HM43 at a charge ratio of 4:1 and 8:1 (polymer:siRNA). 
The formulated polyplexes were added and incubated with cells for 48 or 72 h at 37°C. 
siRNA and shRNA effectiveness was assayed using real time RT-PCR, ELISA and 
Western blot. 
 
 
Real-time reverse transcription-PCR 
 
Total RNA was isolated using RNeasy Mini kit (Qiagen, Valencia, CA) and 1 μg 
from each sample was converted to cDNA using MultiScribe Reverse Transcriptase 
Reagent and random hexamers (Applied Biosystems Inc., Branchburg, NJ).  One hundred 
nanograms of the cDNA was amplified by real time PCR using SYBR Green-1 dye 
universal master mix on ABI Prism 7700 Sequence Detection System (Applied 
Biosystems, Inc., Foster City, CA). The primers used were as follows: AR: forward, 5’-
AGC CAT TGA GCC AGG TGT AG-3’; reverse, 5’-CGT GTA AGT TGC GGA AGC 
C-3’. PSA: forward, 5’-GTG GGT CCC GGT TGT CT-3’; reverse, 5’-
AGCCCAGCTCCCTGTCT-3’.XIAP: forward, 5′-TGT TTC AGC ATC AAC ACT 
GGC ACG-3′; reverse, 5′- GCA TGA CAA CTA AAG CAC CGG AC-3′. PCR products 
were subjected to melting-curve analysis to confirm PCR specificity. The comparative 
threshold (Ct) method was used for data analysis and normalized with β-actin. 
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Table 7-3. shRNA sequences targeting specific regions of androgen receptor (AR) and XIAP genes. 
 
 
Blue color signifies restriction site. Red color indicates loop sequence. 
 
 
Vector shRNA sequence 
pshRNA-1172 
 
Sense: 5' 
ACCTCCCGAGGAGCTTTCCAGAATTCAAGAGATTCTGGAAAGCTCCTCGGTT 3‘ 
Antisense: 5' 
CAAAAACCGAGGAGCTTTCCAGAATCTCTTGAATTCTGGAAAGCTCCTCGGG 3' 
pshRNA-1648 Sense: 5' 
ACCTCCCGCTGACCTTAAAGACATTCAAGAGATGTCTTTAAGGTCAGCGGTT 3‘ 
Antisense: 5' 
CAAAAACCGCTGACCTTAAAGACATCTCTTGAATGTCTTTAAGGTCAGCGGG 3' 
pshRNA-3008 Sense: 5' 
ACCTCGCTGAAGAAACTTGGTAATTCAAGAGATTACCAAGTTTCTTCAGCTT 3‘ 
Antisense: 5' 
CAAAAAGCTGAAGAAACTTGGTAATCTCTTGAATTACCAAGTTTCTTCAGCG 3' 
pshRNA-297 Sense: 5' 
GTACCTCGAAGGAGATACCGTGCGGTGCTTATCAAGAGTAAGCACCGCACGGT
ATCTCCTTCTTTTTGGAAA 3‘ 
Antisense: 5' 
AGCTTTTCCAAAAAGAAGGAGATACCGTGCGGTGCTTACTCTTGATAAGCACC
GCACGGTATCTCCTTCGAG 3' 
 152 
 
Western blot analysis 
 
Cells were transfected with 40 nM of 1172, 1648 and 1768 (Table 7-1) for 72 h. 
Post treatement, cells were lysed using RIPA buffer (Sigma-Aldrich, St. Louis, MO) and 
protein concentration measured with bicinchoninic acid (BCA) protein assay kit (Pierece, 
Rockford, IL). The lysate was boiled for 5 mins and subjected to a 15% SDS-PAGE and 
transferred to a PVDF membrane using iBlotTM system (Invitrogen, Carlsbad, CA). The 
membranes were then blocked with 3% bovine serum albumin in 1x tris buffered saline 
tween (TBST) at room temperature for an hour. Membranes were blocked with 3% BSA 
in 1x tris buffered saline Tween (TBST) at room temperature for 1 h and then incubated 
with primary antibodies at 4°C overnight, followed by incubation with secondary 
antibody conjugated with horseradish peroxidase (HRP) at room temperature for 1 h. The 
signal of target proteins was detected using Immun-Star HRP chemiluminescent kit 
(BioRad, Hercules, CA). 
 
 
XIAP concentration detection using ELISA 
 
Cells were transfected with XIAP siRNA at a dose of 40 nM using Lipofectamine 
2000 at 3:1 N/P ratio. Seventy-two hours post transfection, cells were lysed and XIAP 
concentration detected using Human XIAP ELISA kit as described in the manufacturer’s 
protocol. 
 
 
siRNA uptake and cellular distribution study by flow cytometry and confocal microscopy 
 
The ability of copolymers to transfect siRNA into C4-2 cells was assessed using 
FAM-labeled siRNA (160 nM) formulated into polyplexes at an N/P ratio of 8 
(copolymers). C4-2 cells were plated in 6 well plates (5 x 104 cells/well) and incubated 
with polyplex for 3 h. Cells were then washed with 1x cold PBS, trypsinized and FAM-
labeled siRNA uptake detected by a Becton–Dickinson FACSortTM flow cytometer 
(Franklin Lakes, NJ). The data was analyzed with ModFitTM software (Becton–
Dickinson).  
 
Intracellular trafficking of FAM-labeled siRNA was also evaluated using confocal 
fluorescent microscopy. Polyplexes were formulated using copolymer at N/P ratio of 8. 
Cells were cultured in 8 well chamber plates and incubated with polyplexes for 3 h. 
Afterward, cells were washed thrice with 1x PBS, fixed in paraformaldehyde in PBS for 
10 min. For nucleus labeling, fixed cells were washed with PBS and then incubated with 
4’,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen Co., OR, USA) for 
15 min. Localization of complexes in cells was visualized by a Zeiss 510 LSMNLO 
confocal microscope (Carl Zeiss Microscope systems, Jena, Germany) with identical 
settings for each confocal study. 
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In vitro cell viability assays 
 
LNCaP and C4-2 cells (American Type Culture Collection) were incubated in 
RPMI 1640 media, 10% fetal bovine serum and 1% antibiotic-antimycotic at 37°C in 
humidified environment of 5% CO2 and subcultured every 3-4 days to maintain 
exponential growth. Cells were seeded in 96-well plates at a density of 1 x 104 viable 
cells/well and incubated for 48 h. The cells were exposed to siRNA targeting AR and 
XIAP for 96 h. At the end of treatment, 20 µl of MTT (5 mg/ml) was added to each well 
and incubated for 3-4 h and analyzed at a test wavelength of 560 nm. Cell viability was 
expressed as a percentage of the intensity of controls. 
 
 
Apoptosis and cell cycle analysis 
 
Following treatment with siRNA targeting AR and XIAP for 96 h, cells were 
trypsinized and fixed in 70% ice-cold ethanol and washed with PBS. Samples were 
resuspended in 500 µl of propidium iodide solution containing RNAse A (BD 
Pharmingen, San Diego, CA) for 15 min at room temperature. Relative DNA content per 
cell was acquired by measuring DNA fluorescence using flow cytometry and subsequent 
analysis performed with Modfit program. 
 
 
In vivo efficacy assessment of siRNA/shRNA polyplex in xenografts 
 
All animal experiments were performed in accordance with NIH animal use 
guidelines and the protocol approved by the Animal Care and Use Committee at the 
University of Tennessee Health Science Center. Xenograft flank tumors were induced in 
8 week old male athymic nu/nu mice purchased from The Jackson Laboratory (Bar 
Harbor, ME) by subcutaneous injection of 3 million C4-2 cells suspended in 1:1 media 
and matrigel. When tumors reached approximately 50 mm3, mice were randomized into 
five groups of 5 mice, minimizing weight and tumor size differences. Each group was 
treated with three consecutive intratumoral injection of blank polyplex, polyplex 
formulated with AR, XIAP and pshRNA-3008-297 (2 mg/kg). Tumors were then 
isolated, RNA extracted and gene silencing determined using real-time RT-PCR.  
 
 
Results 
 
 
AR and XIAP gene silencing  
 
To determine the ability of siRNA to specifically silence AR and XIAP gene 
expression, we designed and selected three siRNAs targeting different regions of each 
gene (Table 7-1). These siRNAs were screened for potency by transient transfection into 
LNCaP and C4-2 cells upon complex formation with LipofectamineTM 2000 (transfection 
efficiency was 90 ± 7% as determined by BLOCK-iTTM Alexa Fluor® red fluorescent 
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oligo). Real time RT-PCR was used to quantitatively determine AR and XIAP silencing 
at mRNA levels. All siRNAs targeting AR (1172, 1648 and 1768) used in this study 
silenced AR mRNA expression in both cells. Furthermore, 1172 was identified as the 
most potent sequence resulting in approximately 75% knockdown regardless of cell type. 
In contrast, 1648 and 1768 decreased AR mRNA levels to 26% and 44%, respectively, in 
LNCaP cells compared to 53% and 67% in C4-2 cells (Figure 7-2A). Also, the three 
XIAP siRNAs (264, 297 and 458) tested down-regulated XIAP mRNA levels in both 
cells and were generally more potent in C4-2 cells compared to LNCaP cells (Figure  
7-2B). XIAP mRNA expression in C4-2 cells was reduced to approximately 20% 
irrespective of siRNA sequence used. In contrast, 264 and 297 led to approximately 50% 
knockdown while 458 resulted in 32% knockdown in LNCaP cells. 
 
Western blot analysis revealed 1172, 1648 and 1768 to significantly decrease 
expression levels of AR protein in C4-2 cells (Figure 7-2C). We also determined the 
effect of AR silencing on expression of prostate specific antigen (PSA) gene which is 
downstream of AR. We found 1172, 1648 and 1768 to decrease PSA protein expression 
compared to control. ELISA was used to determine the potency of XIAP siRNAs in 
decreasing C4-2 XIAP protein expression. From Figure 7-2D, all XIAP siRNA 
sequences significantly decreased XIAP protein expression (~ five fold). Consequently, 
1172 and 264 were used for further studies on effects associated with dual knockdown of 
AR and XIAP genes.  
 
 
Synthesis and characterization of HPMA-g-APMA-g-MM-g-HM copolymers 
 
HPMA-g-APMA-g-MM-g-HM copolymers (HPMA16-g-APMA1-g-MM33-g-
HM50 and HPMA32-g-APMA3-g-MM22-g-HM43) were synthesized from N-(2-
hydroxypropyl)methacrylamide, N-(3-aminopropyl)methacrylamide hydrochloride, 
morpholinoethyl methacrylate, and n-hexyl methacrylate by free radical 
copolymerization. The reaction was performed in DMSO at 60°C for 24 h using AIBN as 
the initiator and mercaptopropanol as a chain transfer agent (Figure 7-3). Following 
polymerization and purification, the structure of copolymers was confirmed by 1H NMR 
and size exclusion chromatography (SEC) using multi angle light scattering (MALS) 
system on Superose 6 column (Table 7-2). The molecular weights (MW) of both 
copolymers were calculated from 1H NMR spectra and compared to the theoretical MW 
based on feed ratio and degree of polymerization (dp). We found the estimated MW to be 
in close agreement with the theoretical molecular weight. Specifically, the actual MW of 
HPMA16-g-APMA1-g-MM33-g-HM50 was computed to be 17,580.75 g/mol for a 
theoretical MW of 17,487.19 g/mol. Also, the calculated MW of HPMA32-g-APMA3-g-
MM22-g-HM43 was 16,826.22 g/mol while the theoretical MW was 17,054.47 g/mol. For 
both copolymers HPMA, HM and MM monomers were essentially 100% converted in 24 
h using our reaction conditions (ref. Materials and Methods). Interestingly, we found 
APMA monomer to be only 14% converted for both copolymers. Further characterization 
using SEC revealed HPMA32-g-APMA3-g-MM22-g-HM43 had a molecular weight of 
8,300 g/mol and polydispersity (PDI) of 1.2 while HPMA16-g-APMA1-g-MM33-g-HM50 
had molecular weight of 8,700 g/mol and PDI of 1.3.  
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Figure 7-2. Effect of siRNA sequence on AR and XIAP gene silencing after 
complex formation with Lipofectamine 2000. 
 
Three different siRNAs targeting different regions of AR and XIAP mRNA were 
transfected into LNCaP and C4-2 cells at a concentration of 40 nM for 48 h. (A) AR gene 
silencing determined by real time RT-PCR. (B) XIAP gene silencing determined by real 
time RT-PCR. (c) Western blot analysis of AR and PSA protein expression in C4-2 cells 
96 h post transfection  with 40 nM and (D) ELISA analysis of XIAP protein expression in 
C4-2 cells 96 h post transfection  with 40 nM. Results were represented as the mean ± SD 
(n = 3). *p < 0.05, **p < 0.01 compared to control.  
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Figure 7-3. Synthesis of HPMA-g-APMA-g-MM-g-HM copolymers.  
xw y z
DMSO, AIBN
50°C, 24 h
 157 
 
Effect of HPMA-g-APMA-g-MM-g-HM copolymers on nucleic acid condensation and 
polyplex size 
 
Since charge (N/P) ratio affects the electrostatic interaction between polymer and 
siRNA, we determined the siRNA condensing ability of HPMA32-g-APMA3-g-MM22-g-
HM43and HPMA16-g-APMA1-g-MM33-g-HM50 copolymers at specified charge (N/P) 
ratios using the ethidium bromide (EB) fluorescence quenching assay. From Figure 
7-4A, both copolymers were able to effectively bind siRNA. However, HPMA32-g-
APMA3-g-MM22-g-HM43 showed superior fluorescence quenching compared to 
HPMA16-g-APMA1-g-MM33-g-HM50 at N/P ratio above 4.  
 
We next examined the effect of N/P ratio on the size of HPMA32-g-APMA3-g-
MM22-g-HM43 and HPMA16-g-APMA1-g-MM33-g-HM50 polyplexes. In general, increase 
in N/P ratio led to a decrease in polyplex size (Figure 7-4B). HPMA16-g-APMA1-g-
MM33-g-HM50 polyplex size decreased from 368 ± 3.24 nm (N/P = 1) to ~ 270 nm (N/P = 
4 and 8). In contrast, polyplexes formulated using HPMA32-g-APMA3-g-MM22-g-
HM43copolymer decreased from 251 ± 9.3 nm (N/P = 1) to ~ 131 nm (N/P = 4 and 8) and 
were in general smaller than HPMA16-g-APMA1-g-MM33-g-HM50 polyplexes at each 
N/P ratio. 
 
 
Effect of charge ratio on cellular uptake of polymer/siRNA complexes 
 
The effect of charge ratio on cellular uptake of HPMA32-g-APMA3-g-MM22-g-
HM43/siRNA complexes in C4-2 prostate cancer cells was determined using FAM-
labeled siRNA and flow cytometry. As shown in Figure 7-4C, increasing N/P ratio led to 
increase in the uptake of polyplexes in C4-2 cells. Specifically, cellular uptake of 
HPMA32-g-APMA3-g-MM22-g-HM43 /siRNA polyplexes was five-fold higher compared 
to the control (free siRNA) at N/P ratio of 4, while at N/P ratio of 8 cell uptake of 
polyplex was 11-fold greater compared to control. Confocal microscopy was used to 
confirm cellular uptake (Figure 7-4D). No detectable siRNA fluorescence was observed 
in control (free siRNA). In contrast, siRNA fluorescence was clearly seen in the 
cytoplasm when siRNA was formulated in polymer at N/P ratio of 4 and 8. The amount 
of fluorescence was slightly greater at N/P = 8 compared to N/P = 4.  
 
 
Effect of HPMA32-g-APMA3-g-MM22-g-HM43 and Lipofectamine 2000 on AR and XIAP 
gene silencing 
 
We next examined the effect of charge ratio on AR and XIAP gene silencing in 
C4-2 cells using HPMA32-g-APMA3-g-MM22-g-HM43 copolymer. We found AR gene 
silencing to be dependent on charge ratio. Compared to control, AR gene expression 
decreased to 84.6 ± 6.7 and 49.7 ± 1.9 at N/P = 4 and N/P = 8, respectively. Contrarily, 
XIAP expression decreased by more than 95% compared to the control regardless of N/P 
ratio (Figure 7-5). We also compared AR and XIAP gene silencing using HPMA32-g-  
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Figure 7-4. Effect of charge (N/P) ratio on siRNA condensation, polyplex size and 
cellular uptake. 
 
(A) siRNA condensation  by HPMA-g-APMA-g-MM-g-HM copolymers in HEPES 
buffer monitored by ethidium bromide fluorescence quenching assay; (B) size of 
polyplex and (C and D) cellular uptake of FAM-siRNA HPMA-g-APMA-g-MM-g-HM 
complexes by C4-2 cells. siRNA positive cells determined using flow cytometry. Cells 
treated with naked siRNA served as control. *P < 0.01. Confocal microscopy images of 
cells post treatment with FAM-siRNA formulated with HPMA32-g-APMA3-g-MM22-g-
HM43 at N/P ratio of 4 and 8. Nuclei (blue) are stained with DAPI and siRNA polyplex 
fluoresce green. Results were represented as the mean ± SD (n = 3).  
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Figure 7-5. Comparison of HPMA32-g-APMA3-g-MM22-g-HM43 and lipofectamine 
2000 on AR and XIAP gene silencing. 
 
HPMA32-g-APMA3-g-MM22-g-HM43 (N/P ratio = 4 and 8) and lipofectamine 2000 were 
used to complex siRNA (100 nM). 3 x 103 C4-2 cells were treated with complexes for 72 
h and extent of gene silencing determined using real-time RT PCR. Results were 
represented as the mean ± SD (n=3). * p < 0.01, ** p < 0.001.  
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observed when siRNA was formulated with HPMA32-g-APMA3-g-MM22-g-HM43 
copolymer at N/P = 8 was comparable to that using Lipofectamine 2000. 
 
 
AR and XIAP gene silencing induces apoptosis and inhibits C4-2 cell proliferation  
  
We hypothesized that simultaneous silencing of AR and XIAP should translate 
into increased apoptosis. Therefore, we examined the effect of AR (1172) and XIAP 
(264) siRNA, alone or in combination, on apoptotic induction in C4-2 cells after 96 h. 
From Figure 7-6A, 1172 was more potent than 264 in inducing apoptosis (43% vs. 23%). 
Also, treatment of C4-2 cells with 1172 and 264 combination resulted in significant 
increase in percent of cells undergoing apoptosis (85%) compared to control or 
monotherapy.  
 
We postulated that the increased apoptosis observed from simultaneously 
silencing AR and XIAP should result from increase in caspase 3 expression. Therefore, 
we examined the effect of 1172 and 264, alone or in combination, on caspase 3 mRNA 
and protein levels. Treatment with 1172 was more potent than 264 in increasing caspase 
3 mRNA expression (~1.3 fold vs. 1.9 fold). However, dual silencing of AR and XIAP 
led to approximately 7-fold increase in caspase 3 mRNA expression (Figure 7-6C). 
Western blotting was used to determine effect of 1172 and 264 on caspase 3 protein 
levels. Consistent with our real time RT-PCR results, 1172 and 264 combination was 
most effective in inducing apoptosis based on increase in procaspase 3 expression levels 
compared to control or monotherapy . Treatment with 264 and 1172 silencing resulted in 
1.1 and 1.6 fold increase in procaspase 3 levels compared to control. In contrast, 
simultaneous silencing of AR and XIAP was at least 3.7-fold more potent in increasing 
caspase 3 protein levels compared to monotherapy (Figure 7-6D).  
 
To examine the effects of AR and XIAP inhibition on cell proliferation, C4-2 
cells were transfected with 1172 and 264 alone or in combination and assayed after 96 
hours. XIAP and AR down-regulation resulted in approximately 20% and 50% growth 
inhibition in C4-2 cells, respectively, compared to control (Figure 7-6E). However, 
combined silencing of XIAP and AR genes decreased cell growth to approximately 38% 
and was more potent in inhibiting cell proliferation compared to monotherapy. 
 
 
Construction of shRNA plasmids 
 
Following the encouraging results obtained using AR and XIAP siRNA, we 
selected potent siRNA sequences targeting AR and XIAP genes, converted them into 
shRNA and constructed three shRNA expressing vectors so as to obtain longer silencing 
and hence better therapeutic effect. pshRNA-297, pshRNA-3008 and pshRNA-3008+297 
vectors were obtained by inserting the respective sequences (Table 7-3) into psiRNA-
DUO vector (InvivoGen, San Diego, CA) and plasmids confirmed by DNA sequencing. 
A schematic representation of the constructed shRNA expression vectors is shown in 
Figure 7-7.  
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Figure 7-6. Effect of AR and XIAP gene silencing on apoptosis and proliferation 
in C4-2 cells. 
 
Cells were transfected with siRNA targeting AR(1172) and XIAP (264) alone or in 
combination for 96 h. Cells were then stained with propidium iodide and analyzed on a 
flow cytometer. (A) Quantitative analysis of cell cycle distribution. (B) Graphical 
depiction of apoptotic index. (C) 1 x 105 cells were transfected with siRNA targeting 
AR(1172) and XIAP (264) alone or in combination for 48 h, total RNA extracted and 
caspase 3 expression at mRNA level determined using real-time RT-PCR. (D) Western 
blot analysis of pro-caspase 3 protein expression in C4-2 cells post transfection with 
siRNA targeting AR(1172) and XIAP (264) alone or in combination for 96 h. (E) Cell 
viability was determined by MTT assay and expressed as% of control. Results were 
represented as the mean ± SD (n = 3). *p < 0.01 compared to control. 
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Figure 7-7. Schematic representation of shRNA expression vectors encoding single shRNAs targeting AR or XIAP or 
bipartite vector encoding shRNA simultaneously targeting AR and XIAP driven by two 7SK promoters. 
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Effect of HPMA32-g-APMA3-g-MM22-g-HM43 copolymer on plasmid transfection 
efficiency and condensation 
 
Following construction of shRNA plasmids, we determined the ability of 
HPMA32-g-APMA3-g-MM22-g-HM43 to transfect these vectors into C4-2 cells using 
fluorescent microscopy. For this study, C4-2 cells were engineered to express red 
fluorescent protein (RFP) while the shRNA vector express green fluorescent protein 
(GFP). Using our optimized conditions, we were able to obtain ~70% transfection 
efficiency with HPMA32-g-APMA3-g-MM22-g-HM43 (N/P = 8) copolymer as depicted by 
the presence of green and orange cells (Figure 7-8A).  
 
We also determined the ability of HPMA32-g-APMA3-g-MM22-g-HM43 
copolymer to condense our shRNA vector using the ethidium bromide assay. As shown 
in Figure 7-8B, HPMA32-g-APMA3-g-MM22-g-HM43 copolymer effectively condensed 
our shRNA vector as demonstrated by significant ethidium bromide fluorescence 
quenching even at N/P ratio of 1. 
 
 
Effect of shRNA sequence on AR gene silencing 
 
We next examined the effect of shRNA sequence (Table 7-3) on AR gene 
silencing. In particular, we were interested in the effect of the first nucleotide on gene 
silencing under the 7SK promoter. From Figure 7-9A, pshRNA-1172 and pshRNA-1648 
did not result in any detectable AR silencing in C4-2 cells even at 72 h post transfection. 
In contrast, pshRNA-3008 resulted in approximately 60% decrease in AR mRNA 
expression. This difference is largely due to fact that both pshRNA-1172 and pshRNA-
1648 have a pyrimidine (cytosine) as the first nucleotide while pshRNA-3008 has a 
purine (guanine) as the first nucleotide. We also found AR silencing using pshRNA-3008 
to be time-dependent. Compared to control, pshRNA-3008 resulted in approximately 
25% silencing after 24 h compared to approximately 60% at 72 h (Figure 7-9B). 
 
 
Effect of shRNA expression on AR and XIAP gene silencing  
 
To assess the effectiveness of our bipartite plasmid (pshRNA-3008-297), we 
employed the psiRNA-DUO vector to direct synthesis of AR and XIAP siRNAs in C4-2 
prostate cancer cells. Subsequent to pshRNA-3008-297 cloning, amplification and 
purification, HPMA32-g-APMA3-g-MM22-g-HM43/plasmid polyplexes were formulated 
and particle size and zeta potential determined using dynamic light scattering. Polyplexes 
had a mean particle size of 111 ± 2.43 nm and zeta potential of -2.94 ± 0.03 mV. 
Compared to the control, XIAP gene silencing in C4-2 cells was ~ 60% post transfection 
of pshRNA-3008-297. This level of silencing was similar to that of pshRNA-297 which 
silences XIAP alone, while pshRNA-3008 has no effect on XIAP expression (Figure  
7-10A). Also, both pshRNA-3008 and pshRNA-3008-297 resulted in ~ 60% AR 
silencing whereas pshRNA-297 had no effect (Figure 7-10B). 
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Figure 7-8. Effect of HPMA32-g-APMA3-g-MM22-g-HM43 on transfection 
efficiency and condensation. 
 
(A) HPMA32-g-APMA3-g-MM22-g-HM43 (N/P ratio = 8) was used to complex pshRNA-
GFP (1 µg). C4-2 cells were treated with complexes for 72 h and extent of extent of 
transfection determined fluorescent microscopy. (B) Effect of charge (N/P) ratio on 
plasmid condensation by HPMA-APMA-lipid copolymers in HEPES buffer monitored 
by ethidium bromide fluorescence quenching assay.  
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Figure 7-9.  Effect of shRNA sequence and time on androgen receptor (AR) gene 
silencing. 
 
(A) Effect of shRNA sequence on androgen receptor (AR) gene silencing. Three different 
siRNA sequences targeting specified regions of the AR were converted into shRNA 
expression vectors and their ability to silence AR gene was examined in C4-2 prostate 
cancer 72 h post transfection. (B) Time dependent effect of pshRNA-3008 on AR gene 
silencing in C4-2 cells. Results were represented as the mean  ±  SD (n = 3). * p < 0.01 
using student’s unpaired t- test.  
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Figure 7-10. Effect of shRNA expression on AR and XIAP gene silencing.  
 
(A) Effect of control plasmid, pshRNA-3008, pshRNA-297 and pshRNA-3008-297 
vectors on XIAP gene expression. (B) Effect of control plasmid, pshRNA-3008, 
pshRNA-297 and pshRNA-3008-297 vectors on AR gene expression. C4-2 cells were 
treated with complexes for 72 h and extent of gene silencing determined using real-time 
RT PCR. Results were represented as the mean ± SD (n = 3). * p < 0.01 using student’s 
unpaired t- test. 
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Discussion 
 
Prostate cancer is a highly prevalent and lethal disease affecting men in the 
United States, with one in six men likely to be diagnosed with the disease in their life 
time. The predominant nature of prostate cancer requires the development of new 
therapeutic paradigms due to the limitations of existing treatments. Current anticancer 
drugs are limited to certain groups of receptors, enzymes and ion channels and are 
typically susceptible to chemoresistance. However, the genetic disposition of prostate 
cancer makes it amenable to RNAi-mediated therapy. RNAi molecules (e.g., siRNA, 
shRNA) interfere with translation, do not interact with chromosomal DNA and are not 
subject to chemoresistance. Among all genes, AR and XIAP are pivotal mediators of 
prostate cancer and targeting these genes has attracted much attention. Therefore, the goal 
of this study was to determine whether simultaneously targeting AR and XIAP using 
chemical synthesized siRNAs and vector based shRNAs encapsulated within polymeric 
nano vehicles can be effective in treating prostate cancer.  
Silencing potency of siRNA sequences heavily influences their therapeutic 
efficacy. Unlike antisense technology, functionality of siRNAs strongly depends on 
siRNA-specific features rather than local mRNA target characteristics; therefore, we 
designed siRNA sequences using BLOCK-iT RNAi Designer from Life Technologies 
and selected three sequences targeting the mRNA of AR and XIAP genes (Table 7-1). 
Our findings suggest siRNA targeting 1172 coding site for AR exhibited the best 
silencing effect regardless of cell type. Also, all siRNAs targeting XIAP mRNA (264, 
297 and 458 coding sites) resulted in strong gene silencing in C4-2 cells. The excellent 
gene silencing observed suggest these siRNAs have good assembly with the RNA 
induces silencing complex (RISC), adequately activate RISC and exhibit strong target 
recognition and cleavage [307]. 
Although we used Lipofectamine 2000 for screening siRNA sequences, one major 
goal of this work was to develop a comparatively less toxic delivery system for RNAi 
molecules. Therefore, we synthesized and evaluated a biodegradable non-toxic HPMA 
based multi component copolymer for nucleic acid delivery capable of overcoming the 
barriers (e.g., poor cellular uptake) limiting siRNA delivery to mRNA target sites. To 
achieve this, three distinct moieties: polycationic (APMA), lipid (HM) and pka modulator 
(MM) were grafted onto the HPMA backbone. The presence of primary amines in the 
APMA group allows electrostatic interaction with siRNA and vector based shRNAs 
thereby neutralizing the negative charge and facilitating condensation. Since cell 
membranes are composed of lipids, it is hypothesized that inclusion of lipid chains such 
as HM can facilitate transfection efficiency and cellular uptake. Furthermore, inclusion of 
the pka modulator is expected to aid siRNA release in the endosome. This is important 
since siRNA therapy can only be effective if it is released in a timely fashion when 
delivered. 
Our findings reveal this polymeric carrier effectively condensed siRNA and 
vector based shRNA into stable complexes. Also, polyplexes resulted in enhanced 
cellular uptake, transfection efficiency and gene silencing at optimum charge (N/P) 
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ratios. Biophysical characterization indicated formation of HPMA32-g-APMA3-g-MM22-
g-HM43 polyplexes was influenced by N/P ratio. Specifically, polyplex size decreased 
with increasing N/P ratio. This is likely due to stronger electrostatic interaction between 
copolymer and siRNA as N/P increases [308]. Furthermore, there was a positive 
correlation between N/P ratio and gene silencing. This may result from the formation of 
more stable complexes and the improved cellular uptake of polyplexes. 
 
Our previous studies suggest combination therapy targeting AR and XIAP to be a 
promising approach for treating prostate cancer. Therefore, we were interested in 
determining whether AR and XIAP combination therapy using RNA interference would 
result in a similar phenomenon. To test our combination therapy we selected siRNAs 
targeting 1172 and 297 coding sites. Indeed, we found simultaneous silencing of AR and 
XIAP genes translated into supra-additive induction of apoptosis and increased inhibition 
of cell proliferation compared to monotherapy or control. Interestingly, silencing of 
XIAP alone resulted in comparatively lower apoptosis compared to AR silencing. Hence, 
it is possible that AR gene silencing serves as an apoptotic trigger whereas XIAP gene 
silencing relieves an apoptotic molecular brake. This result is therefore consistent with 
previously reported work where we observed similar supra additive effects using small 
molecule anticancer agents [11, 279]. 
 
Vector-based shRNAs are a promising means of achieving gene silencing since 
they are comparatively cheaper than siRNAs and more stable in vivo. Therefore, to 
demonstrate the utility of our delivery system and to confirm our combination therapy 
hypothesis, we successfully constructed a bipartite plasmid simultaneously targeting AR 
and XIAP genes using the most potent sequences identified in the siRNA screening 
process. Interestingly, we observed shRNA targeting AR mRNA had poor silencing 
effect which is likely due to the first nucleotide being a pyrimidine (cytosine). 
Subsequent change to a sequence targeting the 3008 coding site possessing a purine 
(guanine) resulted in approximately 60% silencing of AR after 72 h. Furthermore, gene 
silencing using our bipartite system was specific and comparable to that obtained with the 
single insert (Figure 7-9). Our HPMA32-g-APMA3-g-MM22-g-HM43 carrier was also 
observed to effectively condense vector based shRNAs.  
In summary, we have described the synthesis, characterization and in vitro 
assessment of biodegradable HPMA based copolymer consisting of polycationic, lipid 
and pka modulator moieties for efficient siRNA and vector based shRNA delivery. We 
showed that this copolymer efficiently condensed siRNA and plasmid, enhanced cellular 
uptake of siRNA and AR and XIAP gene silencing. Additionally, we have demonstrated 
that simultaneous targeting of AR and XIAP using RNA interference is potent in 
inhibiting cell proliferation and inducing apoptosis in hormone refractory prostate cancer 
compared to monotherapy or control. Our findings suggest HPMA32-g-APMA3-g-MM22-
g-HM43 polyplexes are a promising approach for delivering siRNA or vector based 
shRNA for treating prostate cancer. However, further in vivo studies are needed to fully 
demonstrate proof-of-concept and ultimate clinical translation. 
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CHAPTER 8.    CONCLUSIONS AND FUTURE RESEARCH 
 
 
Since the seminal work of Huggins and Hodges [309, 310] regarding the key role 
of androgen in prostate cancer, therapeutic approaches revolving around decreasing 
circulating androgen (e.g., use of antiandrogens) have been adopted as the primary mode 
of treatment. However, it is clear that this treatment strategy is at best palliative. Even 
recent application of chemotherapy appears to offer little hope to prostate cancer patients. 
Therefore, there is an urgent need for a paradigm shift concerning efficient and effective 
treatment modalities for prostate cancer. This dissertation focused on developing and 
investigating an AR and XIAP pathway-based combination therapy approach for treating 
prostate cancer and the engineering of polymeric nano vehicles to facilitate delivery of 
drug and nucleic acid utilized in the therapeutic strategy. The specific conclusions of this 
study are presented below. 
 
 
Cancer Therapeutics 
 
The potential of combination therapy simultaneously targeting the androgen 
receptor and XIAP pathways has been investigated through a series of in vitro and in vivo 
studies. Combination therapy using bicalutamide (antiandrogen) and embelin (XIAP 
inhibitor) was more potent in treating prostate cancer compared to monotherapy or 
control. Effectiveness of bicalutamide and embelin combination therapy was found to be 
cell line and schedule dependent. Combination was synergistic in C4-2 cells and for 
simultaneous and sequential treatment (bicalutamide followed by embelin). Second 
generation antiandrogen ((S)-N-(4-cyano-3-(trifluoromethyl) phenyl)-3-((4-
cyanophenyl)(methyl)amino)-2-hydroxy-2-methylpropanamide) (CBDIV17)) was more 
potent than bicalutamide in inhibiting proliferation of C4-2 and LNCaP cells and in 
inducing apoptosis. Combination of CBDIV17 and embelin led to supra-additive 
antiproliferative and apoptotic effects. Embelin was observed to downregulate AR 
expression and decrease androgen-mediated AR phosphorylation at Ser81. Simultaneously 
targeting AR and XIAP using siRNAs was also more effective in treating prostate cancer 
compared to monotherapy or control. 
 
 
Biomaterials and NanoBio Technology 
 
A series of biocompatible materials with varying chemical and structural 
properties have been designed and synthesized to improve micelle drug loading, stability 
and controlled drug release. Specifically, it was established that chemical tailoring of the 
PEG-b-PLLA micelle core through the introduction of carbonate moieties enhanced the 
solubilization of the highly lipophilic drug bicalutamide.  This result was consistent with 
predictions made based on the Flory-Huggins interaction parameters computed for 
polymer/bicalutamide pairs using the group contribution method. Bicalutamide loading in 
PEG-b-P(CB-co-LA) micelles was four times better than in PEG-b-PLLA. PEG-b-P(CB-
co-LA) copolymers were also shown to significantly solubilize bicalutamide as aqueous 
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micellar solutions had drug concentrations approximately 800-fold higher than the 
saturated solubility of bicalutamide in water. In water, PEG-b-P(CB-co-LA) copolymers 
formed spherical micelles with CMC values up to 10 times lower than PEG-b-PLLA 
copolymers (i.e., 0.31 µM for 20 mol% carbonate and 3.3 µM for 0 mol% carbonate), 
indicating that introduction of carbonate monomer results in copolymers which are more 
thermodynamically favored for self-assembly and exhibit better thermodynamic stability. 
Finally, PEG-b-P(CB-co-LA) copolymers was found to result in slower bicalutamide 
release compared to PEG-b-PLLA copolymers. Even though the inhibitory effect of 
bicalutamide-loaded PEG-b-P(CB-co-LA) micelles on LNCaP cell proliferation was 
similar to free drug these results are quite significant since drug dissolved in methanol 
would not be suitable for clinical application. In conclusion, these studies highlight the 
effect of chemically modifying the PEG-b-PLLA micelle core with a carbonate monomer 
on drug loading, release and stability and demonstrate their potential use as drug delivery 
vehicles.  
 
Further modifications were made to the existing PEG-b-P(CB-co-LA) copolymer 
by strategically introducing crosslinkable groups in the core and core-corona interface to 
further enhance micelle stability [311]. A series of complimentary spectroscopic 
techniques was used to confirm successful synthesis by ring opening polymerization, 
elucidate polymer microstructure and confirm crosslinking. mPEG114-b-PMAC2.5-b-
P(CB9-co-LA39) and mPEG114-b-P(CB8-co-LA35-co-MAC2.5) copolymers for interface 
and core crosslinking, respectively, displayed low polydispersity (1.08) and CMC values 
(0.8-1 mg/L). Inclusion of MAC monomer did not significantly alter micelle size or 
morphology irrespective of polymer composition or MAC location. Importantly, 
mPEG114-b-P(CB8-co-LA35-co-MAC2.5) had a higher drug encapsulation efficiency 
(78.72% ± 0.15) compared to mPEG114-b-PMAC2.5-b-P(CB9-co-LA39) (20.29% ± 0.11). 
Subsequent micelle crosslinking did not dramatically change drug loading or micelle 
morphology. However, there was strong link between micelle crosslinking and improved 
stability when incubated in aqueous media under extensive dilution and physiological 
simulating serum (BSA ~ 45 mg/mL). Crosslinked micelle size remained unchanged 
while non-crosslinked micelles disintegrated at a thousand fold dilution. Besides, 
crosslinked micelle size remained unchanged in BSA whereas there was a time-
dependent increase in the size of non-crosslinked micelles. These results showed 
crosslinked micelles to be more stable compared to their non-crosslinked counterparts. 
Additionally, bicalutamide-loaded crosslinked micelles were found to be more potent in 
inhibiting proliferation of LNCaP prostate cancer cells compared to non-crosslinked 
micelles regardless of polymer type. In all, we have demonstrated that these new 
biodegradable copolymer systems are potentially useful for cancer therapy.  
 
 
Future Research 
 
The findings presented in the study demonstrate proof of principle that 
combination therapy targeting the androgen receptor and XIAP pathways is capable of 
regressing prostate cancer tumors. It is also evident that rationally designed polymers 
chemically tailored to solubilize hydrophobic drugs not only enhance drug loading but 
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improve overall cancer therapy. Nonetheless, this work is but a modest step towards 
future polymeric nanomedicine based prostate cancer therapy. Some natural extensions of 
this work worth consideration are as follows. Future in depth studies elucidating the 
molecular mechanism governing combination therapy targeting AR and XIAP at the 
genomic and proteome levels is required. Additionally, investigating the mode of action 
by which embelin down-regulates AR gene expression is necessary. Such mechanistic 
insight will not only enhance our understanding but also lead to the design of highly 
potent molecules.  
 
Micellar delivery platforms envisaged for antiandrogen and XIAP inhibitor 
combinations should have high drug loading, be crosslinked to ensure excellent in vivo 
stability and made site-specific to enhance delivery after systemic administration. 
Regarding polymers for crosslinked micelles, future studies on influence of MAC block 
length, extent of crosslinking efficiency and ratio of MAC to CB and LA on key micelle 
properties are required to generate material design rules which can be utilized for 
customized fabrication of improved micelle delivery platforms. Also, conjugating 
targeting ligands (e.g., Leutenizing hormone-releasing hormone (LHRH)) to the 
polymeric micelles to enhance site-specificity is key to obtaining the desired 
multicomponent micelles for antiandrogen and XIAP inhibitor based combination 
therapy. Additionally, creating and testing polymers for nucleic acids delivery is required. 
Possible synthetic approaches include using the lactic acid and carbonate-based 
chemistries established in this work and systematically grafting polycationic, lipid and 
pka modulator moieties to facilitate siRNA condensation, transfection efficiency and 
release, respectively. Finally, futher in vivo testing is necessary to authenticate these 
findings and facilitate clinical translation. 
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